var title_f7_21_7504="Selective media GI pathogens";
var content_f7_21_7504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Isolation of enteric pathogens from stool using selective media",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 172px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Selective media used in the isolation of enteric pathogens from stool. On each plate, Shigella is indicated by the arrowhead and Escherichia coli by the arrow; all three media differentiate lactose fermenting from nonlactose fermenting organisms by pH sensitive dyes. Panel A: MacConkey agar; panel B: Hektoen enteric agar; and panel C: Xylose lysine deoxycholate agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Glickman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7504=[""].join("\n");
var outline_f7_21_7504=null;
var title_f7_21_7505="Knee-to-knee position";
var content_f7_21_7505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knee-to-knee position for oral health examination of young children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 266px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEKAU0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0f4sfF2XwB4mttKj0eK/jls1ut73RjYZkZdv3W/u1w7/tM3CsynwpF8v/AE/n/wCNVhftZcfEPTDjdjS0+X/ttJXhzhY9wUI392gGvM+iz+05OW2r4Ti3bf8AoIf/AGqoz+1BME3HwlGI/wC82pf/AGqvnWST951+b+7UDybjlD/3xQKz7n0r/wANN3JGV8Iw/wDgy/8AtVRj9qCUhseEo93/AGEv/tVfN8hKFSp+77U2TaVYMqbv7tAWfc+k1/aflLqv/CIKob/qJf8A2qn/APDTsny/8UlH/wCDL/7VXzWpVtrL8y1IqZXb/ElAWfc+kT+064Te3hNP/Bj/APaqrJ+1OWVf+KPVc/8AUU/+1V88yOPsrY+Vt2xaoSEMPlP3m+b5KAs+59Mx/tSMxXHg9drd/wC0v/tVN/4allDn/ik4sZ6f2gc4+vlV80uQfvFGX+H5qVfKebO9trfxKu7/AMdoGro+lP8Ahqhs/wDInD/waf8A2qn/APDUxDMT4RiKgdBqRz+fk18wlSxHzo1Kq7mXlN33fuUBqfZOmfHCe/sba6j8PQKs8e7ab5vl/wDIdX0+Lt1t/wCQDBt/6/m/+N188/Du5M3h+KPdueCRo1WuxidUXgrQB6v/AMLfuNv/ACAIv/A5v/jdJ/wt+53Ef2BD8px/x/N/8bry3zCV+U1S1HUIbOB5ZZFVEDfxUAdNf/tOyW15cW48KRP5TtGWGoMASp7fuqgb9qWRfveEkxt3f8hA/wDxqvm2R2kmd8cks1RA7VXc7bWoHd/1Y+mf+GpJB/zKUWf+wgf/AI1Sf8NRy8/8Uiny9f8AiYH/AONV80LH8yljt/u/9901Pm3Llm/2qAu/6sfTf/DUUu3P/CIpt/7CDf8AxqkH7U0hH/Inx/8Agx/+118zLJ91vmY0Mecof4aBXf8AVj6a/wCGo5c8+DkHGedR/wDtdB/akkx/yJyf+DEf/G6+ZWdd21S3zf3vkpEG4ZyzNu+7QF3/AFY+ufDH7QM+uSSInheKAqNw3agSfy8utXwj8bZfEDeJUbw6tsNFs57sn7buEvlHlBmNcf549Pmb4XFV1tFYMzMjJ8o+78ldL8LXWPw/8ULo5IGnSxDB27t7NQNanr2h/tAXmqRzn/hE4oTCVUg6juyT/wBs6y5P2mJUbY/g8FgdpK6lgfmYhXhvhzWbTSrK5Mpbe9wPLVf7myubmmDsXUfKX3feoE2z6z8O/Hi71eGZn8LwWxjbbtbUi27/AMhVqt8Y7lRx4ftj/wBv5/8AjVfLela9Dplhcxwtuldt25m+7VbU/EMt39xgqr70DufUk3xxeJiraFa7l/6fz/8AGqm/4XPNjjw/C3/b8f8A41XyI12S+ZJDu/u5q9b63NAVWNw3y7PmagLn1cvxluC23/hH4P8AwPP/AMap3/C5Lrt4dgP/AG/n/wCNV81WPivYVFwqt/wKujstRtriIOs8Bx95d6UBc9wPxnucfL4dgP8A2/n/AONUg+NFz8v/ABTtv83/AFET/wDG68caZHZVV4W/4GlOB3H5FG5v4UKUBc9g/wCF1XAUn/hHIuP+n8//ABus+3+PU0sYb/hGIlz8v/IRP/xqvMrON55oVjQHzHCda56AZRhGn3XoC57m/wAdbhYZJB4bgITJx/aR7f8AbKvcoTn2+UcfnXxK53Wc33m/dhvve1fbFsfl/AUCPkn9rT/koum7du7+yE/9HSV4dI2MqnzBfusvybq9y/a0Df8ACwtPZP4dJT+L/ptJXhJ6/doGyIM52L8ysrfNupYkXYFU8tTHJyFz8tPgbcvJTd/DQIk2LFCsWWRvkdkZKZIFV5FVvMVfk8xv4qeJfLaT503N/eT5qTdkbfM+b7jbKAEj2yN825/9nZ96pYTvVDja23+JKhJIp5Of3eaAEnU/Zo/l3fxVSBGGVF2rVq53bY1x8q/J9yoJV3x/Of8A7KgAY/LtTdt27KVo8lV+Xc3/AI5SS7WV+f8AvqlK+ZNn5vmoAaMsV5Vm/iWn7N0WWX5t2xvkqI9P7zfw1L5RA5DbfM+VaAOg8N+Iv7Gspo47RJnZvNXc2xaur49vt+ZoIGj/AIVi+SuQlCsV/d/L9xfmpkpLbRIvzfe+X+GgDuU8fXK3HzW0TW6t93+KszWtYfWV3tJtj2ttjx8tcupOc5b7tK3C9fvUAChX2HP/AI5SiTMartRvloYjK7V2/wCzRu3r8q/Kv8W6gBSSQrf8DpCQkP8AtfepG+b/AHv7tKy/Mfl+VmoAdlXDqh27qY231+ZadtaQso2t8vyrSCT5mO35qAEzmRz97/4qlKqfvbNzf3abGrY2rn7v9yrcMbbFxt3fPtoAvaNeTaRcR3Vm+2YBl3bN9VopHClY2YGVBuRR8p/3qQhmKqyptVv4qj2zd1/4BuoAcXVkVNu3bu3fJUawrKkj7Rtj+dquw2Mtw9vBbQhpnk2Jtq9rtnBptl9hLLJdeZunb+BW/upQBzzFdrMq/MjVKBEF2jZxURchtu1G+apQCyRhXjZtrfL/AHf9igB8kKRna4x8tN2RqflVt336jhPl8/Lt25/3amI8t9jH/eoAasUe3awLN/F/s05Ylj+VRlfpS53Hr/45S9e+5aANnSbbTrhhE6Mp3fez96tdtEtCuR5m37nWuVjYxuhU/d+7xXfWUiy2cDs6fMvzLsoAzYNJSOaN4Lm5iK/dKSVqqihGXYxG7Zj0oMYAZ88/c/4FSn7vlxFG3fcoAuSFfsUi7dvyt976V9tW3T8BXxI3y2c6DZ/q2b7nsa+3IfvN+FAHyF+1ztHxH0wFN3/EoT/0dJXhW4l/lO2vef2qLO7vPilZLYwiZotCE7glVAjR52c/N/s5r5+kdNyc0DZMhVdvy7vmpJGIilG3lahaX5dqj7zfcakndcyKh+Vduzc1Ai9K0Ek3yQNDCAqbd27/AHvmqBSzDZ82f7yVAJfLmTeX8pl24Vvm2f3ahMm0rtxuX+KgDRX5l2gfL/DUiny/LZeP46zhNH92RW2VYWTbt/dsu7/a+7QAt3vUqqH5Qv8AFUS/KdsQ2L/vfNUE8pcxMw52UwOibfLG713LQBcUd87v+AUFuV2hG/3qrtIu5lUUROjuvybv9mgC5EhR8eWjN/tfdWnsUKeYzrJMzfdqozmSTYpZV+/T2ZVj2qqNtb/WbqAHyo8DYbmT/d+7TcAhgi/Nt+633qfNcyLE6Rr87fe+T71RFmUyL/G38NACsSqMrbP++KYxUqvzLtVf7lQ72Xfg7fu/ep0jMq5yqqy/LtagB4K7lKlGpmNoHP8Atf3aCy7eqbv9yoyT8pK7v4VoAsCT+FV3Mqp/FURkJIVfvL/epmCw2qrbmb+7SZJO1VX5aAJd6+nzbaA4JVfm/wC+KrMxZs5+9T42Ksp/iH/jtAF6FFlkY7R/wKr9rB5zxxIgM0n8K1V02Fru+gt03bnZVVd1e2+DfBMOnqXmJeWRfmYLQB5LPYOiZlVf9lWP3Ku+H9Hlv3h8i1Mh3bGG35f+BPXvg8MWt3CXe1hZY1+VWjSpIdBgstOVYoViDFtyRrt+TZQB5Tcy2/hmweG3dTqTL8xVvu/7C15te/vZA/AJO5uPvV6Hr+hRm8eO3lYM7MN0ife/3a4SGyN24iiw0zH5aAM13GNv8X97/wCKp0hDP/0y2/erbfwzdtG7xoW+V6oXlhJCyiRSsjfdbLUAUtv7puUX/a3feqQFVjK/e+X+9UTglVDbVjK/LSR5zxuZdvy/wUATq5WRv73+038NTW100EquERxtZNrruX5ldd3/AI9VMEK+edu1dpb+Kl3ttVdu7+BVoAtQbS+4lOld9YnZZW0f96P5V3V51CV8wrt7bPvV6FZOI7WLdG25V2UAXTHlvmEW3/aoRMllzEzVTM7KNqqzLUkT7mwkO5t396gDSlJ+yXO4oN0bfKn8PBr7fh+++favhZp/9DuWKqq+Vt/Q190QMGLEcg4xQB8dftgoG+Jen4wW/sePjGcYlm7dq8IP935Gr3f9rwlfijYf9gWH/wBGz14WOqFidy/w/wBygGQ5ym47l2/7FGDudEPsq/3vnokVyrPhdu5vmpAUSSPKozf7X3aAJJELkylV3t8xXZ/D/eqDnPzM3yrt+7VkI/lIzFV3D5drL/u1WUA8Y/h3UAJtbCg7V/u0+NW3KULNupqqpKqvy/3t1S5JK8r93Z8tACNG8kyxLhix/iO35qrlSBubq3SrEzFSu5SzL/z0qNWUHH/s1ACmMEMRu/u7aI0IX5fm3UrNukx3b+L7tSMcRMMFW/h/3KAI40BZWXdsZvmWrEDebO0zLtK/Px/8TVdJPmXB+WNt1NWQ+WPL+Vg1AGreSwiNCsUkhVvlkP3d3+f4abaTf6Lfybooy23cu3/0Gm2Ni1wreY3kIv3mk+7U9w0Dafut9+1W2qn8Tf7VAGORkl23cNRs2hl+b/d2VY8vEm0/eWoeRvLZ+T5f71ADPvMqjcvy/dppT7pUfLVggksNrP8Aw/c+aiWIo3l/N838P92gBsYONpH3vu1GUPH8X+zVjZuMOVbcv3vkpAVXYF+Xd/Ey/wANAFVYyfuruqRImxlfldf4alaMsFBD7dny/JStHgMd/wAy/wDfNAG54Iw3i7T1Ur8zf+yV9JaWp8qLbt218tWFw9pcW9zB80kB3J/33X0f4X1RL/T4rmDeVlRWXLUAeh2KFolVlPzUzUI4ZrZ0b+7VfTJN1ooU/Ov96pTazyZIPSgDzPxLo+6WJYAm2RmXNZH/AAjNpbXcMke15wvleWy/xN/cr07W9GLWZgO3zG/1K/8AAKo+HfDDbvtN0c3oG5cfOqp/cRKAOVsdIuLJ5BfMsEUjfL5i1W8TeHrXVAqmUw7d7qQv3kr03U7aaeeQT29uC8O9kgi2LtT/AGK5a3tYLCOe0iVhEd08bM27b/fRKAPBfEfh6G1neLT5C6R7Nyt96sI2rxspkAWTb92voGz0S3uNXMk6qzSfJ8x/grD8V+DZNY1q0srGNIZGtpRGxj+VmRN+xn/g+RHoA8TaLJUgL8v95ajdOFx8rbf++a9kf4VPZ6TYX17H51vcMmXiu0/ds/8As/8AAK8x1m0j0/WL2zhyyW9wypn5G2//ABVAGcuTGp/iWumsdWhi01PMf5vufc+b/YrmoTsVvuf7336dyY9oH+xQB1CazbSSqimRf7vyVHr+py20NulnIS8i7pG2fw1zkbYcjC/K3y/JS3MwupWbjHXDUATy6pf3CiOW4cqcgoRt4r9KLIlolJJJKKSTX5kLyqJtVeV/ir9NrD/VL/uL/Kga2fy/U+QP2vgR8TdOYNkjR4wF9MSy8/r+leDSrt3FPMZtzL92vf8A9rlN/wAR9OXO3/iVR/N/21lrwl4mZmXLbPuNQIzl+VNjfdb5qBlGYZYBf/HauyRnawpGtstt3Nt20AV1AmGAuHYMxP8Atf5H/j1MO4zbmDbt38NaMkJUg+WsjMvyr/F/vVGsJDRsjbm+/QBSSPJX5Wy33lpzR4VSq52/3a1NO0ue/m2WdvK2W6eX/wCzV6BoHwl1S/tEur+RLS0+9uZt7UAeUTRcs6K22nxQeZKEgRnkP8KmvpLwf8IdImKzzQyTxRtw1w/yyf8AAK2dR8D6Hbb75rV4SG8m1e3h2L/45soA+a9H0W91q7aw03SppLsffG5vl/3q1fFvgTW/DNpZXWpW0SR3HyLsfdtZK+rvBHhfT9Ot2urW1EMk3fbspvjfw3Hr/h2fTNhFwC0lv/vLQB8UCFlJRwi7W+XdSeT5ahWG5t38PzV2fiDRF/eTQhlOwEq1cwsQIU/MzfwsrUAI1wvlfvFQkPgRL8u2tbVNCvdKt4hqCxxyyNsaFZN0sS/7SVmxRAzxAhi24Mx/ururs/iAtre+IF0/Rba8uhFIVeaQ7nnbP8H+zQByMqoYZBC8CBlX+L5qiNuzyx7/ALjHZtX/ANmq/q2iX2lXbWl5FtuB8h3H/wBmrvvAPwq1DxQpmvi+mafCfmkkXMsz/wBxUoA8ugBTf5a5ZU3bv7q1YlKGwWQomTJ8wavXPGvwzawhSLS2gtbKHJBAZprhv9pq30+HVpa/CvVYY4Fn1C4haaGVo8SlkXfsoA+d5GzK219q/wDoNNjZTIoA5b5du35ql8vcQqHqP4qd5bPLnb8yt/FQBAqY3EjbtSk27W2p8y/e+ZKnSM8of4m+VmpDEp7/ADfSgBq7WG3+KvUfhFrCQW72VwxQB2aEv8i/3tu6vMAu1TtG7HNa9lM2kXN3aTG3ubYsYpvLl3o6/wCy6UAfTnh3XNOdXljuIJ1H3vKb7tb51m2l2w2S77mT/Vxt8mf9pv8AYrhfDV3oDaLp03l3At/s7tD5FmkTSN/tP/c/v1oWriO5lnlfzrmbrN9zb/cX/gFAHb2ipFF5lxIs08n3pAn/AKD/AHKfI0KKroqq26sNr8ugCBtyr/eppumSL96Nv93ZQBuX7ypcQSRNEsZilhlU/wASts3f+gVy2oRW7Xdt9nXaqwSt/wAA+RK04b5JYEQhNy1m3G0NIw2Eum1dv8KUAZjosbKy7mNdfoEIsoJr6eBftLx+VDlfur/G3/A6h0jSILC1bUdUXL7UZIf9r+Dd/t1rqryjfdN5ZZd0cP8As0Acn4khU27y+WGCs33a8F8Y+Frye9u9Q0y3821ad0RFT97Jtwzsqf8AA/8AxyvpW+sRc/aIgfLg2fvGRt/yf/F1n3mjQ+WBCqoFX937UAfHMbDeUKgioXTopHzKtewfEPwEJbu4u9MjWOctlrcnarf/AGVeSSwtDJIk6mKUNtZSu2gCMN91vm3MtXrjUJn0+GwYJ9lt5ZZI08pQ29tu7LbdzfcX71UljDL13NtojHG7P3legB0Zy6rt+bO6v04sP9Uv+4v8q/MyFMgdhldvy/e4r9NLH/VD/dX+VA1s/l+p8j/tcYX4l2B3BSdIQcn/AKay14YwXcx8tNzf7Fe6ftbf8lK03p/yCo/vf9dZK8OMa5X5d3y0Eobt/un5ttJbSrGzN1Zf4fufx08rH5BIWMAf3f4q7Dw14OmuVhuLy3ZbcpuWEL80if7VAzF0jQrzXGig0y23M3zSSs+yJV/269V8K/CvTbPTm1PX2a+EcfmrCjOkdd3oWgPBZyCCAJNIqoy7diRLXV3lhHqNilndP5cAKuVj+XdQBxegaMmpT28Q0iQ6bueVUtJViiRVf/vtq67xdDGbG3tLWJ1O5VRY13/LVzTdO0myEbRR29v9nXZHI5zsXf8AN89TSeKdDtZNjavYLI3ZpiKANOBYrPQ41ddpjgbczrs+auStbq4ns4ojcNbx2nzKTBvVvn+Xd/nZXW22uaXeIsdpf2UzN3idXp97Y2t+0bXQC7f9W8X+fnoAW9hnt4JZsRqIVdplX7rVn3ccKg5O7B3Ky/3Wqze3q6bpMhuIxebQFLKn3v8AbZK4bwhrD3l7qdpcFmaOBGiVv4Yt9AHlPj21Sz8Q6nFsbyDI0q/7jfPXjzIpDK7IW3sitXu3xFjZr6KTam57b7qfPu2PXi+pQuL1/LidWYv/AAUAUIY2lYiPcz5O3anzV9S+DtG046ZZal5QN5JFGzsy/wASfwV4d4DsrA6oZtUkRHjTzPLZfuNXunh3VbFoDFbMWjV/u0AN8X+F7TWfsrWYCypMZCyH71dbFcsLOKPyxEFRSUX5V+5WfJdIgBiXc392uV8SG61CylgmvnsS6fLDD/F/vUAXPEdyNSZmIxZJzJJs+VkX+CuYk+NukNYSqNMuhMyssEKxIit/Cv8AHSaxpupXXh1Bb3c0UzxDMe7Zj5K8K1BpVgswxGfs4xuNAFAMzYJGU3gEr/DT3bJCr/e+T5NlOhgM10kaP8ztsX/Zrp5vCIdHNteopyu7zE/ioA5UqSiyBU2bvl3Mm7/vioiFZWxzt+b5q6iXwXqSo22a0bZ935qdH4L1CZWjeW1Tb6uwb/0CgCz4N8NW2sWU091NMqpNsWONU/u/xNXb6V4Z0e0VPL0+CUj7rTLu+b+9VXwppEmj6a1vJLFI0knm/u0+Va345Aqx87m/3KAOo8KLbPBLaXUUYt0DMke37rVWjlit3xGrTW4HzR7PutXEeMfEF/oWn27adIqTTTGF/MXd8uK1/iLqt5pXiLwzYwsix3OlaerbU2u0hdgzfL/F0oDpc7uzEcwzEm91707HmsEkH/AWrjrW9aDUXimnYZ/1bNJ8zVtzXhktg+PmX+JaAL0EZMhZvu1uaPpyFGvpnT93/qY9n/j1Zlo0biaaQ/6NGPNlb+98n3Kj/ty4jjht7Lm5eL5tyf6v5KAOonRJJIjOnmN5m7Kj739ytEW8rq0sku2Vl/eNs+6v9xazNGtRHGst2/mTtxtZv/ZP4K2bKQ3U7eZsWFaAKctvui8pVZd3zKn9xf77VV8pRIyJ0b5dgT7jVq3TmKQRKPMmkb5Y6Ze2Ul5aSQyy4kaPCqvyorUAcdrmli4MqbNzLXkfxJ8HtqNv9ttipvkKJnP+sX+61e/x2872cQul/wBIVcyH/brndZsYFt3Vx+6H+zQB8csjo5xujcHaVZfmoQFj8h+bbXofxS8JSaZetqNom60lbErKv3W/vV5zKo27doVqAJ4gVeIZ3bs1+mtj/qh/ur/KvzHUAuMqpz8y/wDfVfpxZYEagf3F/rQC6/L9T5J/a1z/AMLH09V2f8gyL73/AF1lrxCMBnGACQyFV/vV7d+1l8/xNsVU7Wj0qFs/WWYf0ri/h7oXmT/2reeWIoDuhjb+LZ/FQFrEPhTwzH/bkCaoUeSNfOkt13/L/sNXsekWMReKSZHRh+9ZWk+6/wDuVy/gHTLkyXmpXnlol6gYK33tv97/AMfqh4x8XGJ3sdLkSML+7nuS2/a/9xdlAHba7460bRvMtEka7uoV/wBTC33P9+uL1T4meIbuFIbGG00uORPl+TzW/wB6uP0jTx9pjMuwojblJHzH/erRuC0b20ihVbb91G/9noAq3rahrE+dX1C5viP4Xdiv/fFXbLTLNEjdbZQF+dWArLjaQSQRRjdH8zBnT5vn2VrRgsm1Xkb+CgC3HY2KoztAkUm77xUIzV1Hh7xZrXh3Js7s31lGi5tbqTd8v+y3365mKR/IXYVLP/Bu+7/sVaf95ExLLGG+T5aAPbtE8RaZ4jsHkgH2eaJf9Igkbe0X/wBhXKX0bab47tCsKJDfxy2Khf8Anr/rV/8AQK8703U7rTtWj1K0YLNCeE3f6xf7jV3fxKuk1DwlHeaYrQrLi+tg/wDyzZH3slAHO/EZViGmznczIrbvnrxm9tJJJmh2Fcy/8A3tXtHjy7ju9O0eVW2JdWjzgff/AOeP/wAXXl8luftMPlYDNdRIrP8AJ/Gj0Aben2otIQqRnb5a7v8AarZsLqW0naZE2yR1Q2Rthhu5/wBirIVGMm7cv/jlAHX6d4lkOxJbdmc/LtVq1Eh+eaWX5pn4+593/Yrj9Bg+03sJj3bRXZxvufNABnGCw3dFry19LtNQ1izS7t1aKPSYAq/c/jevUlfbETu+6BXjuvaxJpGu6Q0MfEmnwrLu+fYm7+CgDI8OadFMLmV0XyxOFtmzsZdv+3XVwooTaFXctQ21jHDa7YllVi3mfN8/3vnqy8ajefvLt+b+OgCVghDfKlTWynMZ/wBnZUQXLnarbdvzLVqGNFP3furQBYi45/ib+KpUBAX/AGahh2bN21mqRUVSq7G3UAcf8UWK6dpqh1X/AEmQ/Tit34qQRRfF3RrT5v8AR4bKLb97ZtjFYPxGKSS6FbldyyTN/wChJXRfFW5gPx/mYSBI4JYvvjpi1Q5/PNA+hk/EC9+y3umyoR+7Z5dprVtfFdtehbLTzJ9pm3qVki2eVXK+PbuOTUrUQmOXy4/+WbbvmqHwAFm8TxNMPM8xXdmYfe/v0CPUb+8v0VNMhkjRgvmuI/mX/vqtfwrZSy30bGUySR7dzMn3m/uVPpdtGrRw29tGit82UrqNJto7e3LKFKqv3l/vf36AL1srzSLEy7pHWr9xLHZWu5xtSL+7/E39xap2BSK3knccf+y0mmI2rX4nZQtpb/6mNvu7v71AFvS7aRY2mlA+0TcHH8P+xVi6iyq/u2Z1/u/JVyMIqbR+8P3N2ynzW8wwu1PM27lXdsZtlAGZBGy74grf3l3Vma5BiMNj/brZSQrNMXVtsa/NsqveywTSeVu8vavzbqAPPNZ05Lm1lt7iJZLeeERMrf8As9fOfjPw+3h/XGs1zJbsWaKbPO3+7/wGvqS+h8u8khdYmDruVtn8dcD440Ia9Z3WmxhDcTx+ZZu/8EsX8P8AwJPk/wCAUAfPCPtkXamOStfppZf6sf7q/wAq/NNYXjmKTB1dTtkjP3tyiv0tsxiMf7q/yoBdfl+p8xftD6RDqPxctJ7r/j1tdGiklXHUebNhc+/P5VzHhCK0uoLgRxQvK4TzPKT91t/uV6B8eriS38byPDG0zR6Kj+Uv8X7yWvP5biLw94cldJGkMZ+be29nkagbIvHvib7Cq6RpSr9rkXbK8af8ey/3Erz+GRJZvsduGNv0Lj+IVUuXXZO5ctLI7NJJ/Fuap9PiLr5Sp88jbP8AVUCNe6+aGK4iEW1U3tHh9yf7H+5/3xTb6eOSWJ41fcW/vfc/j/4BUcsENtdRyXPzRwS7PubP++q0bK6sZY7WCXr8jKqxfJ8n+3QBPomnvOrTJb/I33eEq/HZTxKuYU3BvlTdVGDVHQkRli/3dvlJVldSlaOJi/zKyMv7qgDUtdPaCKTcnyK3zbv4v9ukkiDFjtG9dn/AqF1YxWvlIrFgv975qvQ3iXFjjc+dv3W/hb7lAGWqb7gq0bbVG5m/uL/Hv/74rpbq8WXwjfWs+VitneUfN/yylT/7D/x+ueLwQJOZDtLN8sX/AD0Ss9lN1pmvXUpfYqLAo3fe+Te9AG5f3IuNH8ExNGjLLYXUa/N/sI6/+gVxs8gtvFNnYRlW8hnZvk2Nu2V0Xis3enaV8PfsiL9qit/3cf3txbyUx/4/XEXE1tN49t1tArRR/K8ind5knz7n/wC+noA7cDZ8rKjNT2X5f4fm/i/vVXYRl1LFt3+9UsEImdI4sNuZF3UAdT4Zg2W7ybV+b5K3FXuy1RsoUs7ZIV6KvzVaVtxZfvLQA5iuwqVyMNla8E8fNuudLS5URTrYQoYm+le8grkL8leJfGRiPEigZ3Lbr8rJQBt6DBLHpifb7gS3EzeYWaTdt3/w1qBFwy71+b+Gq9pDttoo027ERfm3VeSJVbHyMzL/ABNQAyThlVZP++aljVdylCnzf3KdsBdfu/dpSuPlYr/s0ASLt2ddtOwpj6VCx+X+D5f9qpFYsf4f92gDkvG6pP4i8MQj73n4/wDIqVS+K1vNq/xX8RQ2UfnXBvZFWNW2/djH/wARWpqjif4meEIOoNzbr09Z1FRXayP8afEjuGDx3t6CuP7rbKB30Z53e2FzY3ixXtu8L/LuX5K634WWtvd+IX3x3bXNrD5luV2eWv8AA27/AL7SqXjWVv8AhIrgMFQqqKoWu5+Etns0O4kVP3t3JsD5+by0/wDs99Aj1HS4lt7dAnDyL8vzfdroPuwx20Y+ZtqGsfSbfNq02WZopET/AIDWrakpuuPk4+WPd/eoAnuk86ZLG3G4Rrudq3UT7PaJb22zy9uw/wB6s/S7ZbVC852u/wC9Zm/uVatbgFSVWMMyeVtZvmSgDb0uJIoWumfcZF/d7k+6lTWmZZ7lz/rGXarbv4aqCYPFG4VPLjXYtTacykz/AN1vkWgCk8OyKWNj1+RaxdQhJ3b13I3yL81b7lmZS2zy1XdWXKiTW+0fwpuVv9qgDkdXnLSRx3Db7iOTfGzf3f40asfV0Mdm1wM+baOs6f7Wz73/AI5vroPE8ZVo71E3K37v50+7/tVjRR/LPbzjgwsg/j3fJQB458Y9BXT/ABLNqdrGn2K9nkI2r0avui0/1a/7i/1r5g1rSx4j8B6hZ+QHm0qArvZ/nM0Q+X/xzZ/33X1BbZEag9lH8qAXX5fqfO3x5neH4jR7drCTSYV/2v8AXSV5h4mja70PU4FKN5bLIqp/sPXon7QiFPiJHNJIy2o0iJXVPvbt8+2uLyJNO86JUkVoGfayb0ZNlA2eaSImzBeLcrbt332oN+bO4DhURmV12um7dVSb5I9+YjwPlqFA0kweP5Xb5vvUCNm4ljk2yyXMDuzNi3kRvu7fvBkTn5k2/wD7Wam0g+TKsu+KOZfk+ZKzHmDSGGNT5O50WZt+zY/360oWRVhZD8u35VoA0rNvK8h96sx+81XUYRqjyOvGxNuz+5WfbLl1djuVf4dn8VSy/vX2oUZz/dSgC7GFWGSbf8w+T/dq1bztbRFozuYrtX5KoNIWEaRbNrN93ZUqS7GKR7Fkj/vUAN0e8jNy0M07SRWuEj3fPt/v/wC9V4SlfB2oSb2zL9olXcn3mYJCtcvHdC1trlZP3jo9xuH/AAOvQNMi03U9M8N6HAbe5vZplur7Z/yzjT53/wC+32UAc98Z7oWFxoVopRWtdOX/AFTbPmY//YV554TZk1+zIY7g+3an3m+Suu+NR+1+Jbyd2Xy7eWKzjTPULFub5vq1cX4bdF1+0bcv+u4+X5qBHqRfarbvM2M2z72+tbw4hm1FfvMsfzLWE00eNyOnzN/drovC2Gnk2tuVY6BnWIeeV+b/AHKXcFVty/Mv3aS0hkuyVh3cfeP8K0+/t00+RY7h0Hmf8tP4aAEYseNvy14f8ZDjxc20/MLZRur17UdRs7GMNPNg/wB2vDPiJfDUPEss23ywsSJ5e7+7QB3ekt9q0m1keMlJEV9yt92tYLtLKVx8teR6Jqx0u7jdA/lrtLBm+XbXpH9rabFYrevPEsDL8o3fM3yUAa0SyZRDEquq9MVlazr2maUuy4kjMu3csMY3NurjNd8WXV7vh0/dbQbduC37xq5PYm5htAfsCaAO1vfHF1MoXTbKCGP1k+dqx38U63InN75f+6uysOZ4Ci+WN21qZJMCG8v5fm+ZWagDrPAt3Pf/ABK8KyTzNKf7QtipkP8AD5tZPjbUjP4w1q8hYfvb24fKnH35Grd+DEH2v4r+H41UnZPvAPJO0M1cVeO88kkrHPmFn+9/eIoH0/ryG+fNJna5ZnKkL95t1fTXhrRv7K0qwtZDiS2to0Y/7Tffryb4L6PFeazPq91EZU07a8SfwtNjduY+i7S34V7MEubi3vrxpV2QMvzH+P56BHS6VtTR7xI1Zm/iXZWxp1rE0VpCYWkWTfIPk+7XPaNK92iAH5m+/wDNXVWWq2ryOYwypCWEbfwt/BQBW1m4UtcbCnlxj0/z/crD8GLJcwjVrhI0nvDvVd33I/4Kq6pK39iXaKAszS/Zgrf366O0jSwjt7Ynb5CLCF/3E2UAdDcFVCW8YX5F+7WhpxQRRxCPcrfJ/wACrm4pkuhJ5W5XjXYrNV6yvbiCKa5u3WRYo8rtT+L+CgC3qcwDQWyBd8jfMv8As76xTIdgQruZU+7VqxiYyfaJDm4mYJCv92oYoBIyY+5soAdqGnxzaDDC/wArNE4Vtn8VcZrlkUhWSH5Jom3GvQp7dX02zUjbFEz7v++64jxlewW9m4T5N01vFIy/3GmRKAMzwvqMbweLXSNfKaAXUat/eeORGT/xxK+hYPvE+qg/zr5Vtbo6Hd+NHmKtappkV1ZxPnmUsyqpwPnG819VQksoJ6lQeKAPmv8AaOtJZvGSNaY84aWisv8Az0XzJfkrzPw7fgQi0ulaG2YNGuG3sv8AA6NXpnx41MWfxXs7aVM28+l2+7DquP3lx61wOpabbSXaTQQ290JI8SRK2xf7+6gbPMZLdjJLES4kg3IzbN33R/8AF1FarAkcrzwSTERbY1jb7rfwPt/jWp71guo3gQgt5zP5ez51WquQ0qqqq275cI2xv++KBGjZxeZIrrbIsR3SrI0G35dzotXIELFUZd21P4dj1Ws4jFt3uN4V0+9/cT+GrVryic/K33dyfeoAtGZbYQou5gWp0Rkj3BlG4t/sbap+aXmmYfwt8qtVhVWWONZJfmVt22gC7CSZFDD/AFfyKv39lTys2y4xu3L839yqtnCsjZbzP73y0tw6uZCm5iq76AKGj2q3viU2LmNLVZvtM7O3yiD+7/tV7F4NgjN1da66mOOdY4rVZV2stsq/+z//ABFeF3sEa+LNJiCssUrwKePvLur3Lx1qkeh+CdRmAeOS5H2e3TG1hIy/w0AeIeNb83OmWOdwlvrm61F0fsHYKn6IaxfC7Fde07I6TcD+7T7+ZrrVvN8tvKh2wLk8qqrt21rLDCXBUW5P3lb+KgSO08x8YYgnd/G1dd4LtjeXL2z/ALofP5h/9kriPBulfaNUjlFvI8aN8smz+L+CvXrPw7eW9gqRRBw8fzeWnzK1AzRuNNmgiIt9RZdn3Vjj/iqO4t7iGyuLa+Ec8QXzFfdsZdlYyeGZrS4QyPeyH7S25Wb+/TrQI2padpFy91HsRhcy3jMit/cVP770AcF4hMh1Zw8wZWbdGw3puX/cry/xQ7DWp0k25XYjbv4a9s+KTW7SWtyshjnl3LHGU2KkH8FeH65KLieeWJZS0hVSqr/DQBi8yuybtq7vlzV/c8kSxjLRq235t3y1VW0naT93aybN3HyN/F92rBfbIiTLJHtbaystADQfufLuSOmlVIB+Tcyf79MD7JWJLY2t8rVNE4V+ZV3N97alAEJ2Z2k/xf3KGUGPbjp975f4qV/vMsa/e+789PZJym1lU7f+AbKAO7+BEsdv8VNNnfgRR3kjH+JNttLj9cV59Km6UmX5VYj5mruvhBIbfxTqt3GgaS30fUJhn+Bhbvz+HWuIUJ5ybjhVGfk/ioC3U9e+Dlu1xoE8FrK0cs9y0asFQ/wJXbeCtRGnadfaZqtsJHmkkdo1+Zdz796bv46yPhJB9nsNDmKsyhZJztXf3d//AGSu5+G2jJH4OsIdUDLczwSXErp/C+5/noAsaBDHFbJtkB2Ls8uRam8Redb2EEMLCOFTlWT7oatdLUmOMoQ0qpurV1Ozh1zRZI4lXzkHyq6fcagDkblv7YjE8ASJpZo7maPZ/wAtf4v/AIurmsXDPfzeWreV5pVmrLsIprFEuIfMQ2Z8i6jR/wDVL/uf3Ktpunv1SL/WyN8mygDT0mIxyxrbuGz/AKxmrfvbY+Xa20atuT5j/vVHplqfIEcZ3Hb/AN9f7VbUEZKrK5XP3NzN9ygCsIxABbWw3SJ/rHT/ANAqe3sFghka42uqrjhqlWZSxKfKu3mRl+X/AIBXLeINUudQQWtqGjtt21v7zUAVPEviRnkNvp6sz7mOVrhvEMsraRcNGVe7Vo5k2cb/ACpUl2f+OV2E+npbWscKR8v80gSqBtYbadZ3RWKxv8n+xtoA8v8AEyPd+PLtLYhra2sAJFI3L5m6Tylb/a6P/wABr7Htx8i/7or4m+H032jwzqW9m2o5JLNvYs8Sbmr7Zt/uDjHFALY+dP2g9Ni1HxksMyh92mwLwPm/1svT3ryyGS58P3Mdk4MtjtTM8j7Ntek/tA3q2HxFW6WziubmHR4PLDbhtBnl5yEOPrXG2+raZqekrBJGImnj2yQyfw0DZ5z4vZJdcu5beSCWKVEZGX7n3Nn/ALJXPZ8xjEreWG2J9z71dJ4tsobDUwYl+Ro/3a1hafExm3oWEkfzKyts/wA/PQI2peI4mZkPkJtVVdNuz/df7lVomYCJlKbtife/iq6oG1pVj/eN8+37n/oFMt0Q3a7UZv4PLb/P+3QAkSndGrbPMffu+bf9yrbh1ik5VvKajyMXaloUjZvu7qtQRo2VK7mb7q7vlagB0cr2y7VKbhH95v71JKzsY4967lX+GplgKQyFoPu/3v4VrNv7gRQk7U+X+JqAG6VbJf8AjjQlkZY4Q3nO7D5FVfn/APZKn+InikeKNYi/s4ltLsiwgi8vcSf+ejfnXNqkmr3QZQIF2bP9tlrrdGt4bmZrae0XA3y4T/lp8lAHKae96kCx+Wslu+5G5311Xh/T47prVr6GKaOMb0+XYzL/ALTp9+rttYJIzNFaqLdfmVv73361rKAxRkFYlaNtytQB7P4X0qwgtbSWwRfJaNdrba6hIwFXrtrkvhxqJOjNYyy5uLWTcq7vm2vXVedEsyxjdlKAKeqFormIqIwW+6v+xXnHxT1p4/D93p8+jXBF2Ft0nRkkWJm+6zbH3Zr0q6jtZLxioO3b8v8AergvizBCfC124nljlhmiljjY70n2P9ygDyLxJaalrKwTS28zQ2kKxRtO2yWdET7zp/wCsW3TWmVY4nSO23bmWKREz/vNsr0/StIM1nMbu6aS4aBx9naTasHyfI7O/wB/+D5KzdOme7t47ItZFnPyC52eVtoA4a7udUijWK3e7hiSJbWSM3G75P8AvhPlqHxNpdnBNLax/a02RxyebPF8/mbN7/8Aj2+vQH/sx5Gjt7GW4lkTfMF3ov8A3xVfUbEW7Si1jvokgL74po9ypuTZ/wCgUAeLXMQimaF0KbV25/h+/wDeqO3iLOnyp81eh6p4bkvryygidPtd1/q5FX5WrpfhV8Ihr0Ooaj4ta6srG0fyBbwja0jEfeZv7vvQB5fY+HtWu7VLy10rUp7crsEsdozRN/wKrE2iT6fAlxqVpdWsBPBkhZFP/jlfYGtXFp4W0Dw/p9plNPDfZsK5bytsP/1qsaZ4k0G90grcbrsN+6ELQHbJ/wB90AfJ3w6vrO0uPFhubmCJX0O8ii3NtEkjoq7F3d+a4/TrV7zUobeKNJJHOyNF/vV9cePtM8GeI/DcdqmgQxT2rgqtvGsLxrx91l+9ux+NeY+FvAWg6fq+o3eoXmpW1uNi2X+jbpEVk+bf/wCgUCtY3/A0qeHH0qdv30FtD5Mpb5PkZPv12N9FdWGh38/mqlhLbW9hbRK3zL8/z7f+2O+uSjs7OPTLmO0uWvLQTeVHceVsDp/uVaTVbuHS9P0u6haa2t5vPty3+46bP/H3oGbFrJI7Q2/nmORl/dlm/wBZ/sf79aNh9vgnYPcyQyj5EurVt+z/AGJUf7yVhWz2t/a/ZkfBfgK3yMrVv+HtUW7A0/XraKe8h+UTbPvf71AFm8uLyLE81pbPfRfulvLRtnmJ/tRfxVVikhsY5Jrl4/Ok+9tTZtSrOuf8S8SPZ26BkO6OPduWKudsbQXdz9pvMyRt823d/nfQB0lt4ndpF+xWdxcSQrs3J8taljr97PPH9r0xIQv8Xm7/APxyq1tbR5jwd8f8Oa1rSJIkw5VV/wDQv9igCxeS+bazecUWEKm3/erEnudOsSI5plR2+6u7dUd9d3erXH2XRFEMEf8ArLpl/wDQalsfDUMNq00xYHazSSSNuaRqAMy/1W2ulX7IA23+4tZ7zNKjk2jAbD0/i+WujS2iW3keGFdy/wCrbb9xa4rx/qX9m6FrV3vb9xasFz/eb5E/9DoA8r+FCxTaLqEascDazYXnHl19xW/3B9K+Ovhhbf2P8O9W1uZHeaZmitV+5u2DZ/6G9fYsH3R0ztFALY+dP2hNNF54ykeCKNro6THEjv0wZJMr+NeQ6h4cMd0WhMcKxNudnTyl+Z/7/wDe+5Xt3xtuHtfiDBJKsBsxpke9n+8G3zdK46eO11XRfJCSrFdRI21Rsb7+/d/45QNnlni9PLs7FmuIJ3ZpX3RSIzKr7NiN/crC0HYtwHkOzzGZF3fJWr4+tFttXlhRvOO13+982zf8v/jlZ9jGkaEExHy06Ij0CLxZyZC/mKBIr527v49u1f8AgdR2qLJJI8VxllRP9ir12jwmPy51kjil+Vk/vff3p/sVFbxEwyEsnnM275VoAsxopnVQ3mD+FqkRJEk25Rtrbm2rTYkWQt5RXzNuxG2U8MYwmx9pVfkbd96gCa8ulS1kWLcwZfkXZXMasC6w4XzPMkXbGzfLW1HK+6MMcK0XzNWVfRCTV7e3yjBfu/7z0AT2MZOoaZbom13O4qvz+UtXrO6L3a3MFsfsiu7rI38Xyf8AoFRy5jtr26UlXm/0aHD7ti/cT/2etawYJJE8KyQxRrsTC/cSgDav4pYUIllnlZGxGpZNzf3/APgFUpZWjDJt2o1TT3ENrZrAqF75vm3eV93f/t/3Kx476KaOVJZ/JuWmSKP+7t/jZ6AO/wDBHiePTtQEsvy200fkSMifebf8n/j716AfFKyDy2tmZt25R93bXhlpIsV5bG2e5vJbceY8bf6pP9r/ANAevULZrXVY7e6t3SWKYb02t/32lAGuvxE06yufLubkpK3dU81v/HKxvHXjB9RsVsmtbqG2nCgzMqIyo6f3P9x/468213QpdP1K8PlPDHmWRBM3ztF992ra1y+hvNC05gLD7ZKy+dNbJskban/LVP4PnegCXxBci5muJJrtLaZipktJbVopZpf4dv8AB/c3/wC3VOG2tLSxk/tK3ErJMqEKz7tv3H+T/fetZZbPUbPThctJPbyrFE3mxfvFk37H/g+f+DZWZfDUdRvY9GeMKTeJACYtkg/gVXegCtbXllp2pyo8ZuijL5ZVk+aJk+4yV0epavYlA1g0SeTD+6jubeZmSTYiJ5X9xPk2bKbZQaLN4fubkWNoZYoJVEV2/wC8kZ/7v+2julZekX1hYBJJre3a4jb9y7Rbt3+3/v0AJ4c1BINb0eDUEQQPOJLaaZ9vlSf3dz/wPXe+Gb27kBt7y1+wpKGt5YUb/WbH+82yvNfF12+vGwhEJnhhtXiKF8srO3/jlew/C3S7a+0tdPuzPD4khjb7RPJNuMkeflfb+VAEHiHQoby2xFIUlXug+WpYrO5hhjitGMMSD92iLWxq+m3ekTsl6A0TN+7lH3WpWG9dp+bcaAOQnXUY7i3aGO3laWZInZk+ZV2P9ynLZSRz3NtKdyp8y/7NbsapbyI7/N5bbqp3cqSRzyqd0jf7FAHmvi6ZvDt5b38QC2TSKl5Gdw4YbVl2/wB9K3b+ORLNY7nY8aHAuIU/h2f3P4Kz/HPljRLszKrqgD7PubdjVvNHJaa1f2o8plSU7VdtjsufvrQBkeYSkd2sqb0+RmWr8esR3TRsz26Xcf3XaobnSJoZZJrMLA/z7go+9/vVItq8qKupaTGzK2zzoRt/8coA3rbU31qFYZ3iMkKqqyQfI1dFp9gY448Kd7L/AN9VyOkwWFvMiWTzLNMVQwTf+y10mpa7aW9w8G/ayvtb5KANuFUEq20O3/aar/2a1bbLOUKqr7V/uVhaVPBPtMG2QN9795XU2UaN5KhWi2ru2t92gAaZYmt7a3t1VGVuNtVpLeeVJZbs/L5Duse75Uq+IYInZiE2K3y7v4ay9a1EvFJBArZ27N1AGPqVwLWzQRHdK38K15z41tmvvDGsGQ7Y1t2ZV/vN/frtblvNnZz8237tcV8ULwweF78BljuJdka/8D+//wCOUAcj4Jun1LwzDoqfLHZtIzf7W8b9/wDwD56+z4BgAf7Ir45+GGlG18O6hezFlF24RG/vIgr7Gh+4PpQPofOHx1uXj+KdvBEjSCXS4c/7GJJ+g79a4iOyZbmS5sJR9paPasc7PtX/AG1rsf2gGjf4mRQzRb86VbshV9rBlkuD/WvP9MvXgsTK0A8uOTa1snzbV/3P8/coBnCeM4n/ALfYToPO8pHb5k/77qGwQGRVbyWUfe82tTVYX1O91G4jZHiX5o/k2Nt2fIiJVCwyQu1pIwrcfJQIlhh2wTLHMjKqfdb76r8laO2VbUfdVty7W/vLSzW0cCSN5siqjL8u773+5UZIJKMGyv3WoAtzxrHCXjVGCsjNtSqkqtcysyr8qr/v1ICqyMcySFm+7V6KKCCGQFeVXd96gCBLSOC0RpwsHlxs27Gysjw/bi81a51CT5beJtyszfef7lWLnGrBmZBb6bHu53bPM/2/9ypIbSfUkig02GZNNX70knKFqAFi2XtwlzKFi0mz3eSW+VG/2qddaqbixjNqjfZDJs85/kRv9itmPw7DMQL1RcOi8Rt91F/2EpY/CdqCojhMfzfd3UAUdNu0uolWadLdXV3a4ZHlaJUT+P8AuU270+OylvGkNqoVFa2bzHaW4V9mxtn9z+OtRvC8tvbsllPJ97csbfOv/AqXWLG+e2N3dDfcwqsXkxr8qQL8ibf9ygBuhouqFreKK1hVz+9naXY38f3E+/8A98f3K67weTYaxcaVLOZ4rqBJ7dom+62z/P8A3xXCaXqj6fI9xaW4bC5Hyv8AL/tfJWn4dsLia3nudNuIRfwFBb2rD55H+/8AI1AHrOvaUuqeFUtVkME8kreXLt+5/s143Da3i372Ihk+0QbvMiRN+K7P/haJW3Fnqvh2K2ktpHMyef0b/ZSuT8TeINOu76y1GEGJmDm4hVNm35/k+egCxaavcaZEsFs0UUkMjN+8g+ZW/wCB1seDXjuZtRmkiU3TKkkbEOmxvO370rF1OMHVdFLTl1v4ZUNyjI++VHfZ/wCyJ89QWun3FxqyWJkgt4pIPP33B+4v/AP4/v0Aa3iKcSakUMzIURP3Ct8sTP8AO6f+P1Qv7IwWqzpP5sa7W8xf+Wbf5+SteHTdOdYtPFzFLekNI93Fv/dN/Ankv/B/wOudsdcS20+aBDEUeKVVZE3LJv8A73/jlAGudJTWbOGdPK89UYNJbQvEibU+87/wVJ4U1fXNAurDU7aSSWOPax86P70Lj5vm/wBz/wAfrEh8RNHc2k13bWl6EAVPtG5Nv/fH36veEbK9eGwaaU/2cGaeWCNt29Pk2/J/t0AfWOhavBrunDzYw6OPmV1qrfeEonO7T7hrV/4Ub5lrK+H1lLZaFEbtALiSR5fLZvuq/wBz/wAcrtxMFcBl+X+9QB4z4q03UdLuR9oiHkM3yyq3ytWFcXSx2wix81e2eMv7PTw7ePqkfmW+OVT7zN/DtrwG5snljzb3EiPjhW2PuoA5nxrcGbRryKRzCskLJu/CvTfEFlqKzsf7LtLuHA5Pzt92vMtR8GeIfE1yLK2vLD7Oo/eOQ67U/vbP71en2Wm3ulaZCmpaykpiRY1OzYzfJQBg6bcWt3eCymsYLO4b/VpN8is39yr9zpckW0XNtpiHZ90xuzVZnsZbpPJeaTDf8s9rvUTaFdjaW1MRRf3Zt6f+gPQBQe4NvMqW1rJI8bblPlbF/wDH614Y7a8tY5ZobaC8b78dz/7JVGPQL25WVbiWe2iSPzW23z7tv9/Y6VmureG70alLBc3FlN5St5jf6v8Ag+b/AGKAOog0JgFltYxY3H3laBv3Tf8AAK6LQNXZpja6j+7uI12sB2pfD1/bahZ2yMpVQv7v/ZqXU9Jtr26SN42eRW2K6/LQBq31xbWdu09zIRGG9K5+41G3uYD9lRljHf8A2KVtL+1y22mxzB4oZHkuJGbd5S/3P9+rmoWtrHZymKJm2rtXYvy0AczeBBE24sqr8zNXjPxn1RRHo9rbxCLfJLdMzf8AfCf+z1674klhsSiz8APv8la8G+IR/t3x1Bp8JDskMdkxVPlV3G9v++N//jlAHpHhXTVsPA9rqesS5soLESxW6Dbu3D71fU8H+rH0r5T8Wzrd6bJZRjbYwwGOJcfwKD/8RX1VbDCD6UD6HzV8epzB8V4Qwj8ptKt1Vm/hbzLiuLZL6K3ANxBOvzI21fJZF/vb/wDYrp/2mIYZPiLDvikkkXSYQAj7eTLL/TdXIaE93cRb4JlNkF2tLcje1u38ats+9QDHaHpE1g3mJGpuHjCbg37rb9//AH91U38MrPKZxALWeTduj+R1/wB6uySwvo4S9xc2Frbt8kU0sW9blv8AZ+eoZtLvkmhtzeNBqsm9ktmjTy9u/wDvUCPNNS0u/tYJEu5Cm1twQn5dv9zfWWkVwwVZJ4vvbPmevWzbxebJB/ar28kPzS+e6BR/1y+Sqq21hj7d/atz9jZstHJMnn7v93+7QB57DI0KyLIylv8AdqeG01PUPJgtoXFruTzJJvkRv+AV6SkAhi2W+HA+ZSx/h/y9Jdxs80KIygqrtzQBy9r4ctzNHNdu100f/LNk2qrf7ldBFAuFADkR/dz/AAVOli0yr9mkWZe/yVZS2kjl2K0G0SbF3I+5EoAjiWGJfLwzA/eqdRCy7fMX5WVP9ypIbC9Ea7olbn5mYPtVf++Ksmyllv38wRx2ed3mbvvNQBEkcLyLHIU2/wCxUk9jG5HBy3yLSeU6W9w8kLRovywpuT5qdHbB7jy8D7v3kZNtAGFe6LDLuKIqySfe8t9m7/erJFhqWlxXY0qaIRTSeb9mZNiL/sf5/uV2EaqyyuiTxLG21V2feqtI8Udmk8iMiM21VZPmagDzLXYTDqcN09tcCJ5HadW3Ntb+8j/7dUbg/bDaw2Bt7eWDe0lyF2L8v3f+B16jKEWOIySqN7NtjY1mN4XttXjEdpYAsjfNNA+35v8A0CgDzC91C5u7xn1DdIZ/4hh+V+9trUv0OnTWd3ol3cT2zxlIpyNjL/eX/wAfr0TTvAOp2N19p0/WZrd/L2obhd21W+dquR/CzT5rcLc3Ii/2bSLZ/Hv/AI99AHnuq+JvNtr6axsPIN6VE8qybGVs79uz/P3qzNAvrO1a5a8SNdkabZXXds/4DXst38MdEu444p3vWjhb5VVki/8AHkT5vuVf0X4d+HNHmaeysmNy3/LSWR5WFAHjnhm11e7nu5NMs1trBt3+kXKJFBH/ABo29v8A0BK9P+Ft9pSzz3txdeeLJ2jWZY/lkm/if/cXjZXVTeE9FuwRe2Ed2o5Pmu7gVfs9IsrOzFpZwQ2sKfdjjjRERqAPQbLUbS7iU2s8JXy/mUNV8SI5X50b8a8wfSozhNpBb/WMR860+SxI37Fl+X3oA3vijM48O2yx4eJrrDPj/YevMDteLPm7mX/arpbrTEl8xZlaeI/NtEmxlb/ZrD1DR7mwTzIHF1a/3/uMv+9QBveGJrW20qTKtNOfm2qm9m+StcWQ/f6jqioj/wAMaf8ALJf7lc14Zura2vlbaftkkez7nz/7n+5W/cXLujRMn7stuj/+yoAvWAWWFnjTbHu2LuTZupm1I9YsLcBSzLLIp/uqiffrDh1ldO16O31CSRbaeLyvMbqv9x//AEOtyzmsYtSuby6vYjcP+4iVP+WUVAGdCZLvUNaeNUVQVtIyzf3fnf8A9DStOezK63Y2s8avYS2brKrL/EmzZ/7PVS0tnj124DMIZYrycbmb7jypC6/+OI9alk7pqEdhqh3XiptSXZsWaJ//AGZHoAzYPDA0ZXFjIG088ras3zQf9cn/APZK27P99YrIXaa2ZedjbGWtEJ5Yw/K7flrGulbTZJLq3A2f8tIdn3v/ALKgDQWWC0QQWFqox0jH8CVga1rMkdo6wO7yMu1mX+9/s1avjFfWI8t2Noy/JHH8g3f7VcheQNakfZkCRRr91EoAx7q3mDzX10x82MBkjT5/4P4nrxbwBIbzxhJf3bMZ1hnnVt3/AC1cf/ZvXrHinUBb+GNRnLMpS1n8s9cts2f+hvXj3w+lZPEyQWi+Y8sEqIn/AI//AOyUAej6liS1njZT5jJu/wBnbivr63+7+A7Yr5GubW6XS7uecxw28EbSyNJJv7GvrmAYUfQUD6Hy9+0nME+JlvExC50iB/mHy/66br+VeWWgSOZXdS6H5m2t97/eru/2r7hYPiXaCX7raXF+fmy15ZY6nJFtl/dTH/po1AjuLae0mgihnu7mVY22RxyTy7V/3a3I9O0kwiNkVyX3M053bv8AgT1wcOoo7fMZV/g+atvS7/zFjHmrIvyfLigDo/s9kkSJbWtvbxNvZU2Y2U9Le1lfzZIot275v3VU4JhuVQyptZN1W4m/dtkxbqALMSRpAqRrtj/h+T7tRX4K3kK71T923/odXrSF5kjJlKx/ek/3aydXlt4tRhQHYvkb/vf7dABbozKnkgLH/sipreMKIlQSfL833qqR3UA8pVNK18qFdqszf3dlAGqrMB8inH+01E16QwgXEm3+633aznuJZ0VXbZB/tUyXUYo4WWKNkH3Mb6ANuS5lU+Y77nXu38NVpb52GGHyr/BXO3GojcxaVmb7nytVKTU95VFDKv8A33QB1cmoYk3tErHb8vyJTW1VI15VR/dWuNkvpJVjVVf723bsqa3NzMI43jZV3fL8n8VAHb6FKNRlImRZI4/vfxru/uV2EMcaosaFUX+6q1zHh2Eafp8MbKnnH5m2/wB6uqikXYCzUAW441I+X/x6pIxhl3KlRJKW71Osg2/MaAHKv92nLneyj/gNNV0ZuqU5XVi275qAJAu1tv8AcpGXd/s/3ajEo3fMdrN/cpWfnaw+agDQgTz4lf5cL8rfJTvIXb91PkqtYXKo+GPysv8AFVw3MY2qxbcn3WoAjS2BPyrUUtvtdmAwW+8v96rjSRIi87tzfK1RzXMMa/MaAOX1bQy8ZlsG2zn5mhdv/Qao6XrkUXyalaGORflbDbPmrrZ2TYwP3a5zXLCK8iBfdHJ/DIv3l/8Ai0oAs6/a2er6UIYY1Gxc25VPmT/YrlU1B38PjZ/r432t8n92pLM6hpkqR2k+Z1+dbd/mWZf761Q128e4ie+t9kYb5LmLbs+b+9soA9H0+4/tuwj1S1Cia4tzBKu77s8Xzo1JrONVW5W1fbdW/l31o38Sb0315LoPiy60S7eTTmDQzP8AvLeT7rV6Ho2swalI9zabWmf904/u/wCxQB2FvqwuSkqoweUK4/2P9inyuhUr8u4L83+9XI6kZbCWPayLFcM+w/f2t/crMl18QSLHMIlt1+7t+83+21AHQea0V+8Ubo0U33o/9r+8tZd7IqEqwVlVqin8RWDgeddRr/tN/DWJ4u1WwR4ZbO+t52u3eVo423+U38f+5QBxXxb1AR6CYHdWmuW8pVVvuqnzv/7JXMfD2xs7TTrvWdXaGCIP9nhaQ7P4Pnqh8Sr6e6voY8MsMcT/AHhsZmb/AClYOqW1tb+HtJMauLmeR2cMPvL/AA7f8/x0Ab3jTxq+qWklho6m307OWlY4aU5OOe1ff9uMIOnTtX5kXBIik/Hb/uZNfpxD9wfSgD48/a5Uf8LMsy33V0mM/wDkWSvEopZEZdh3Db93d92vc/2trWSb4k2ckYwyaPCcDqf303WvB2RjgBUdv9ygDat9SilfG1Fb+JGrUsZwqKxjVWVvT5G/2K4zdtKxMrZ/2mq1A6ecpQO25dzMw+b/AG6AO6ju2th9+SKQM6L82z/cq3aazdhUkSXcu75t2yuG+0XEFhbs6PFvLY8zf8y/7FSWd8T/AK24iJ3fxI9AHfx6teklWvG2j7qsNm3/AL4pyXjuNzSqG2bPm/2K59F0UwDzfENurt96GKwf/vj79Z1/e2wZlsdQnmdf+ndEWgDtxeCWTKSBVVv7lIuoska+Q43f3tleYvqEr5/fn5t23bJVY3Upj2+aW2/9NKAPUXvftEv7zy5Nv98fPSC4nldtjNnbsXaK8rkkfY3lDYfpVmC3mX5590ahfuq7LQB6Qyv+8wG+7600vaxTKWKll+8tcTEu4xpHJubbsX5quR2l5H1uirMv96gDqJdRikRfJtyrYq7pzzvqCNKV8rd90iuCuILwsqm6kb5vvbq1PCFqyarM7Ph1gdhkM39z7tAHqsd55KfIW+981ddZT770oi/u8K0e5vlriLNo5nAQo0U0e9a6LRJipayuV+Vf9WaANt59idf4qlkuXeH9yfmWqVzbXMMimPdOjf3fvL/8XWX9saN2Nu4O3/WK33qAN+K/W4/dSr5Lr/A1T+e8TKGO5axhLHfx/JtJ/wBhqPOnt28tSxX+61AG6sodc4+9TPtGCvlCsL7UF+8jK3+zUyXCSt+8b7396gDWW8Vn27/Lb+H5qtpd/uvMmnaViz/u1asCTJG07GX+9UlteG2leJGby5PkZQ2ygDTi15Y2ULu8tf8Alm3z1oebbXKR+S20Dc3yVhPG10vlLHG7D+L+JapvHd2bMEMmF/iWgDePmWysYm8xVb7tVJp1dGWRPm/u1Xg1JJk23UW9v96pZoIWTdCGaIfe2NQBQuohIArjdEv3ZF+9G399GqmJH80JPIv2v7q3AT5blf7jJTrhkQSBYSp/3qjuFV4pVkj/AHXoyfxUAUkt7CLfby2dtCrszeRJF8u7+9E38H+5T1itLXVDNp6C1KxpuaNtnzU5YGaCWOWFrqyjb7zJ8y01tPZdhRkkhb7rfe20AbV1rMUmkXFlfxSgGPzEuIPmZG/vulcu2ppexlHtpJJAvzBF+Rq0IIEiIyrH5eFqrJFD5jPa7LU/3V+63/AKAMO4S+UhbTTJGwvys2zbWZc6f4hciaG309GX7qTT79v/AABK7DkjYWVW29G/9kqhqFzb2Qlg1K4hiVFA8xpNm5f71AHIW/hKOW9F5q9099dnqsieUP8AvmuT8fyW8+v28VjNHJHaW6xMIG2Krb3+Vf8Ax2l8VeJTqc6x2jvHbbs5PyeZXOIqoRk7k2/eoAinjJU/c+XKfM3ua/TaH7g+lfmdIu2Eldm5Nqfqa/TCD7v4UDPF/i98JNR8ceLIdW07VbK0SO0jtTFLGzNlXd/4T/t1wVx+zXq0+PM1/SgV+6Vtn/8Aiq+qaKBHyS37L2sbgV8S2Hyt/FbtTk/Zi1hQR/wkunFf4lMLgfzr60ooCx8nS/s063IjBvEels7bg0hgcO/ru59V/nVdv2X9a2/L4m0//Z/dNX1zRQB8kr+zBrIkZh4i0xt3/TFqRP2X9aQrt8RaZtHT9y1fW9FAWR8k/wDDMWtquF1/Sf8Avy1QP+zD4gKnGvaUvzbuIpT/AEr69ooA+SYP2Z9ehXamsaP/AMCSX/CrcH7OmvQ9dU0V/wDeE3+FfVdFAHzAn7P/AIgi2+Tf6Kv4zf4UjfAHxOVVf7U0X5W9Zv8ACvqCigD5dPwA8SsU/wCJlofy+83+FWND+BPibTrxLh9R0ORRuVvnm/wr6aooA8AsvhH4jtzCGu9HZYmb7rvu2/8Afur1r8NPE0TuJLzSZIP+Wfzvu/8ARde40UAeVP4H177AsMc+mLL/AM9N8n/xNZ83w4124YLdTaRPEO7vJu/9Br2WigDxKX4WayrrJDd6cZE7yNJ/6Ftp8Pw68Toqq8+jOq/L/rX/APjVe1UUAeNt8ONbypM+nK3/AF1P/wAapg+Gut4XbLpX/f2T/wCJr2eigDxuP4c6+h/1+l/9/ZP/AImppPh3rUkW2SbTs/w/vZPl/wDHa9eooA8h/wCFd6yUjy+l71+83myf/E1L/wAIDrvk+X9ssD/s7j/8TXrNFAHkEnw51UoSrab5v95pG/8AiKjT4d+IEC/6Rpvy/d/fyf8AxNex0UDueSL4B1qSSE3k+nOiNu2rIy7v/HKR/h/rMpGZdNHoVkb/AOIr1yigDyE/D/WwcxyaXu/66N/8RTU+Hutx5aCbTYnP3gsz7f8AvnZivYKKAPHT8OdZbgy6aCP7kjf/ABFUJvhh4iLI0MukjC7WDTy8/wDjle40UAfOl58JvF7BBFLoc20jAa8lVQPosQrkNR/Z78c6jKsl/qOgPsXEaLPIir/5Cr66ooEfHq/s2eMe97oX3cf6+T/41TW/Zv8AF+7/AI/dA3f9d5v/AIivsSigD47X9m3xhI4R7zw+E77Z5uOMf3K+wIhtGPQCpKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Nowak AJ, Warren JJ. Infant oral health and oral habits. Pediatr Clin North Am 2000; 47:1043.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7505=[""].join("\n");
var outline_f7_21_7505=null;
var title_f7_21_7506="Patient information: Prescription drug abuse (The Basics)";
var content_f7_21_7506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16997\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?7/14/7405\">",
"         Commonly abused prescription drugs",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/6/11363\">",
"         Patient information: Narcotic pain medicines (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Prescription drug abuse (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/prescription-drug-abuse-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10515739\">",
"      <span class=\"h1\">",
"       What is prescription drug abuse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Prescription drug abuse&rdquo; is another term for when people use prescription medicines in ways that are different from how they were meant to be taken.",
"     </p>",
"     <p>",
"      Doctors call this type of drug use &ldquo;abuse&rdquo; when it has a bad impact on other parts of a person&rsquo;s life. For example, when using the drug too much causes the person to miss work or school, or to have problems getting along with friends or family.",
"     </p>",
"     <p>",
"      People who abuse prescription drugs might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Take drugs that are not prescribed to them",
"       </li>",
"       <li>",
"        Take more of the drug than what the label says",
"       </li>",
"       <li>",
"        Crush pills and inhale them, or inject them into a vein instead of swallowing them as directed",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515753\">",
"      <span class=\"h1\">",
"       What are the most commonly abused prescription drugs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The types of prescription drugs that people abuse most often are (",
"      <a class=\"graphic graphic_table graphicRef80775 \" href=\"UTD.htm?7/14/7405\">",
"       table 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Certain drugs to treat severe pain (called &ldquo;opioids&rdquo;)",
"       </li>",
"       <li>",
"        Drugs that make you feel alert and focused (called &ldquo;stimulants&rdquo;)",
"       </li>",
"       <li>",
"        Drugs that make you feel calm, relaxed, or possibly sleepy (called &ldquo;anxiolytics&rdquo;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515770\">",
"      <span class=\"h1\">",
"       What are common signs that a person might be abusing prescription drugs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Warning signs of prescription drug abuse include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Sudden changes in mood or behavior",
"       </li>",
"       <li>",
"        Being more irritable than normal",
"       </li>",
"       <li>",
"        Being more sleepy than normal",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who abuse prescription drugs might tell their doctor they need more medicine than they actually do. That way, they can get more of the drug they are abusing. They might also try to get the same prescription medicine from more than 1 doctor. Some people order drugs on the internet, too.",
"     </p>",
"     <p>",
"      But most people who abuse prescription drugs get them from a friend or relative, not a doctor.",
"     </p>",
"     <p>",
"      Prescription drug abuse is common among teenagers. Often, teens take drugs from their parents&rsquo; medicine cabinet. Other times, they get the drugs from other teens.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515793\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are worried that you have a problem with drugs, talk to your doctor or nurse, or to a mental health counselor. They can recommend treatments to help you overcome your problem.",
"     </p>",
"     <p>",
"      If you think someone close to you is abusing prescription drugs, ask them if they are taking medicines differently from how they are meant to be taken. If they are, encourage them to speak to the doctor who prescribed the drugs. You can also ask your own doctor or counselor for advice.",
"     </p>",
"     <p>",
"      If you think your child is abusing prescription drugs, talk to his or her doctor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515808\">",
"      <span class=\"h1\">",
"       How is prescription drug abuse treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatment for prescription drug abuse is counseling. In counseling, you can talk with a doctor or other specialist about how to stop abusing drugs.",
"     </p>",
"     <p>",
"      Other treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Prescription medicines that make it easier to stop abusing drugs. Medicines like these are available only for some types of drug abuse.",
"       </li>",
"       <li>",
"        Support groups, such as Narcotics Anonymous. In support groups, people talk about their drug use and share advice on how to quit.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515823\">",
"      <span class=\"h1\">",
"       What is withdrawal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When people take drugs for a long time and suddenly stop, they often get symptoms. These symptoms are called &ldquo;withdrawal,&rdquo; and might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling anxious or restless",
"       </li>",
"       <li>",
"        Trouble sleeping",
"       </li>",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Diarrhea",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have any of these symptoms after stopping a drug, talk with your doctor or nurse. He or she can prescribe medicines to treat these symptoms or suggest ways to help you cope.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515840\">",
"      <span class=\"h1\">",
"       Can prescription drug abuse be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To reduce the chances that you will abuse drugs, you should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Tell your doctor about all the medicines you take, including over-the-counter medicines.",
"       </li>",
"       <li>",
"        Take medicine only as prescribed.",
"       </li>",
"       <li>",
"        Read the instructions from the pharmacist before taking your medicine.",
"       </li>",
"       <li>",
"        Ask your doctor or pharmacist about your medicine if you are unsure about how it will affect you.",
"       </li>",
"       <li>",
"        Once your health problem is better, throw away any left over pills that were prescribed to treat the problem.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1129541\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/6/11363?source=see_link\">",
"       Patient information: Narcotic pain medicines (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/21/7506?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16997 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7506=[""].join("\n");
var outline_f7_21_7506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515739\">",
"      What is prescription drug abuse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515753\">",
"      What are the most commonly abused prescription drugs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515770\">",
"      What are common signs that a person might be abusing prescription drugs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515793\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515808\">",
"      How is prescription drug abuse treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515823\">",
"      What is withdrawal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515840\">",
"      Can prescription drug abuse be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1129541\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16997\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/14/7405\">",
"      Commonly abused prescription drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/6/11363?source=related_link\">",
"      Patient information: Narcotic pain medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_21_7507="Gallstones";
var content_f7_21_7507=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Gallstones (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/21/7507/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/21/7507/contributors\" id=\"au4308\">",
"       Salam F Zakko, MD, FACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/21/7507/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/21/7507/contributors\" id=\"se6409\">",
"       Sanjiv Chopra, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/21/7507/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/21/7507/contributors\" id=\"de2797\">",
"       Anne C Travis, MD, MSc, FACG",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?7/21/7507?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      GALLSTONES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Gallstones are solid, pebble-like collections that form inside the gallbladder. The gallbladder is located in the upper right abdomen, under the liver (",
"     <a class=\"graphic graphic_figure graphicRef68129 \" href=\"UTD.htm?26/37/27220\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     More than one million Americans are diagnosed with gallstones (cholelithiasis) every year, joining about 25 million who already have the disorder. Fortunately, most people with gallstones do not have symptoms and do not require treatment. In some cases, however, gallstones cause pain or other complications and must be treated, usually by removing the stone(s) or the entire gallbladder.",
"    </p>",
"    <p>",
"     More detailed information about gallstones is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=see_link\">",
"      \"Approach to the patient with incidental gallstones\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link\">",
"      \"Uncomplicated gallstone disease in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"      \"Treatment of acute cholecystitis\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=see_link\">",
"      \"Dissolution therapy for the treatment of gallstones\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      THE GALLBLADDER",
"     </span>",
"    </p>",
"    <p>",
"     The gallbladder is a pear-shaped sac-like organ with a muscular wall that is 3 to 6 inches (7.5 to 15 cm) long, located in the right upper side of the abdomen, under the liver (",
"     <a class=\"graphic graphic_figure graphicRef64960 \" href=\"UTD.htm?39/54/40804\">",
"      figure 2",
"     </a>",
"     ). It is connected to the liver and intestine through small tubes called bile ducts (",
"     <a class=\"graphic graphic_figure graphicRef68129 \" href=\"UTD.htm?26/37/27220\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The primary purpose of the gallbladder is to store and concentrate bile, a greenish-brown fluid that is produced by the liver. Bile is needed to digest and absorb fatty foods, and to absorb important fat soluble vitamins.",
"    </p>",
"    <p>",
"     Between meals, the gallbladder is relaxed and bile flows into the gallbladder, where it is stored and concentrated (",
"     <a class=\"graphic graphic_figure graphicRef68129 \" href=\"UTD.htm?26/37/27220\">",
"      figure 1",
"     </a>",
"     ). With meals, fatty foods in the small intestine cause the gallbladder to contract (squeeze) and partially empty into the intestine. &nbsp;A few hours later, the gallbladder relaxes and begins to store bile again.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      WHAT ARE GALLSTONES?",
"     </span>",
"    </p>",
"    <p>",
"     Gallstones are collections of solid material that form inside the gallbladder. Gallstones may be as small as tiny specks or as large as the gallbladder itself. The vast majority, however, are smaller than 1 inch (2.5 cm) and are one of two major types, cholesterol or pigment. Gallstone type is important since cholesterol stones are more likely to respond to non-surgical treatments than pigment stones.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cholesterol gallstones account for approximately 80 percent of gallstones in developed countries, including the United States.",
"      </li>",
"      <li>",
"       Pigment stones account for about 20 percent of gallstones.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      GALLSTONES RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Experts do not know for sure why gallstones develop. However, many people have bile with an abnormally high concentration of cholesterol",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     calcium from which stones may develop. &nbsp;There are a number of factors that increase the risk of developing gallstones",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Sex &ndash; Gallstones are more common in women.",
"      </li>",
"      <li>",
"       Age &ndash; The risk of gallstones increases with age. The condition is extremely rare in children and becomes progressively more frequent over time, especially after age 40 years.",
"      </li>",
"      <li>",
"       Family history and genetics &ndash; Gallstones are more common in certain families, suggesting that genetics has a role in gallstone development.",
"      </li>",
"      <li>",
"       Other factors &ndash; Other conditions can increase the risk of developing gallstones, including:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Pregnancy",
"      </li>",
"      <li>",
"       Use of medicines that contain estrogen (such as birth control pills)",
"      </li>",
"      <li>",
"       Obesity",
"      </li>",
"      <li>",
"       Frequent fasting",
"      </li>",
"      <li>",
"       Rapid weight loss (including patients who have surgical weight loss treatments)",
"      </li>",
"      <li>",
"       Lack of physical activity",
"      </li>",
"      <li>",
"       Diabetes mellitus",
"      </li>",
"      <li>",
"       Sickle cell disease (and other conditions associated with rapid destruction of red blood cells, such as in patients with mechanical heart valves)",
"      </li>",
"      <li>",
"       Cirrhosis or severe scarring of the liver",
"      </li>",
"      <li>",
"       Certain medicines",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      GALLSTONE SYMPTOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Silent gallstones",
"     </span>",
"     &nbsp;&mdash;&nbsp;The majority of people who have gallstones do not have symptoms; their stones remain \"silent\". Silent gallstones are often found on an ultrasound or CT scan done for other reasons. Silent stones do not need to be treated since the first symptoms of gallstones are usually mild and there are risks involved in removing the gallbladder.",
"    </p>",
"    <p>",
"     If you have silent gallstones, you should be aware of the initial symptoms of gallstone disease because you may need treatment if you develop symptoms (see",
"     <a class=\"local\" href=\"#H7\">",
"      'Biliary colic'",
"     </a>",
"     below). (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=see_link\">",
"      \"Approach to the patient with incidental gallstones\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Biliary colic",
"     </span>",
"     &nbsp;&mdash;&nbsp;Biliary colic, also known as gallstone pain or biliary pain, is the most common symptom of gallstones. It causes attacks of abdominal pain, often located in the right upper belly just under the lower ribs. You may also feel nausea, and vomiting, and pain in the right shoulder or back.",
"    </p>",
"    <p>",
"     Biliary colic usually happens when the gallbladder contracts in response to a fatty meal. This compresses the stones, blocking the opening. As the gallbladder relaxes several hours after the meal, the pain subsides. In some people, the pain happens without having eaten anything.",
"    </p>",
"    <p>",
"     Once you have a first attack of biliary colic, there is a good chance you will have more symptoms in the future. Such recurrent symptoms are usually more severe and occasionally associated with complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H328060538\">",
"     <span class=\"h2\">",
"      Complications of gallstones",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Acute cholecystitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Acute cholecystitis refers to inflammation of the gallbladder. This happens when there is a complete blockage of the gallbladder, caused by a gallstone. Unlike biliary colic, which resolves within a few hours, pain is constant with acute cholecystitis and fever is common.",
"    </p>",
"    <p>",
"     Acute cholecystitis is a serious condition that requires immediate medical treatment in the hospital. Treatment includes IV fluids, pain medicine, and sometimes, antibiotics. Surgery to remove the gallbladder is usually recommended during the hospitalization or shortly thereafter. If not treated, acute cholecystitis can lead to gallbladder rupture, a life-threatening condition. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"      \"Treatment of acute cholecystitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H328060568\">",
"     <span class=\"h3\">",
"      Choledocholithiasis",
"     </span>",
"     &nbsp;&mdash;&nbsp;This",
"     <strong>",
"     </strong>",
"     complication can develop if one or more gallstones leave the gallbladder and block the area where bile exits. It may lead to:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Jaundice, which is a yellow discoloration of the skin and eyes.",
"      </li>",
"      <li>",
"       Acute cholangitis, which is an infection of the bile ducts that causes pain, chills, and fever. This requires prompt treatment, usually involving removal of the gallstone with a non-surgical procedure known as endoscopic retrograde cholangiopancreatography, or ERCP. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?30/9/30865?source=see_link\">",
"        \"Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Acute pancreatitis, which is sudden inflammation of the pancreas, leading to severe abdominal pain. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=see_link\">",
"        \"Patient information: Acute pancreatitis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      GALLSTONE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     There are two parts to diagnosing gallstones: determining if gallstones are present, and determining if gallstones are the cause of symptoms.",
"    </p>",
"    <p>",
"     Gallstones are usually found using ultrasound, a painless test that uses sound waves to create an image of the gallbladder. An ultrasound is the most sensitive test with which to find gallbladder stones, but gallstones can also be seen on other imaging tests.",
"    </p>",
"    <p>",
"     Having gallstones does not mean that the gallstones are the cause of your symptoms. Thus, other tests may be recommended if there is doubt about the relationship of the gallstones to your symptoms.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      GALLSTONE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There are three general options for people with gallstones; the best option depends upon your individual situation.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Expectant management: Do nothing, wait and watch.",
"      </li>",
"      <li>",
"       Surgical therapy: Remove the gallbladder and stones.",
"      </li>",
"      <li>",
"       Non-surgical therapy: Eliminate the stones while preserving the gallbladder",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Surgical treatment",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Cholecystectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cholecystectomy is a surgery that removes the gallbladder. It is one of the most commonly performed surgeries in the United States. The surgery is done in an operating room after you are given anesthesia.",
"    </p>",
"    <p>",
"     The gallbladder is an important organ, but you can live without it. Removing the gallbladder does not usually cause serious complications. However, about half of people who have their gallbladder removed develop loose stools, gas, and bloating; in most people these symptoms are mild, do not require treatment, and improve with time.",
"    </p>",
"    <p>",
"     Surgery may be done through an open incision (cut) in the skin. In most people, the surgery is done using small instruments and a video camera, which are inserted into the abdomen through several small puncture holes. This is called laparoscopic cholecystectomy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Non-surgical treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nonsurgical treatments are available for some people with gallstones, mainly those who cannot undergo cholecystectomy. These treatments get rid of the gallstones while preserving the gallbladder. The main disadvantage is that the stones can come back over time. &nbsp;(See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=see_link\">",
"      \"Dissolution therapy for the treatment of gallstones\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Bile acid pill",
"     </span>",
"     &nbsp;&mdash;&nbsp;A bile acid pill (ursodeoxycholic acid or ursodiol) is a medicine that can dissolve and break down the cholesterol type of gallstones. About two-thirds of people who take it become symptom free within two to three months after starting treatment. However, it may take several years for the stones to disappear completely. The treatment is safe and well tolerated. Some people develop mild, temporary diarrhea.",
"    </p>",
"    <p>",
"     Because of its slow action, bile acid treatment is not practical in people who are having recurrent gallstone symptoms. Bile acid treatments are most effective for people with small cholesterol stones and a functioning gallbladder, which may be determined by using imaging studies. Even then, it may fail to eliminate the stones in some patients.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Extracorporeal shock wave lithotripsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Extracorporeal shock wave lithotripsy (ESWL) is widely used for kidney stones but has fallen out of favor for the treatment of gallbladder stones. Only a few centers worldwide continue to offer it. It uses shock waves to break gallstones into smaller fragments and \"sand,\" which can then be dissolved more easily with an oral bile acid pill. It is most effective in people who have a normal body weight (not obese), fewer than three stones, and who have good gallbladder function.",
"    </p>",
"    <p>",
"     The procedure may be uncomfortable, but a sedative can be given to reduce discomfort, and occasionally it may cause attacks of biliary pain as broken stone fragments pass through the bile duct.",
"    </p>",
"    <p>",
"     Since bile acid therapy is needed to clear the fractured stones and residue, lithotripsy is mostly used to treat cholesterol stones. The success of lithotripsy for gallstones varies, with experienced centers successfully treating 90 to 100 percent of people with one stone and up to 67 percent of people with two or three stones.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Gallstone recurrence",
"     </span>",
"     &nbsp;&mdash;&nbsp;The main disadvantage of the non-surgical treatments is that gallstones can come back since the gallbladder is still in place. With bile acid treatment, stones come back in about 50 percent of people in the first five years. However, symptoms do not always come back and retreatment is not always needed. After cholecystectomy, gallstones may recur in the bile duct in a small percentage of patients. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"      \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Gallstone prevention",
"     </span>",
"     &nbsp;&mdash;&nbsp;To try to prevent gallstones from coming back it is recommended that you try to stay at a healthy body weight by eating an appropriate number of calories and exercising for at least 30 minutes five days per week. If you are planning a rapid weight-loss program, such as weight loss surgery, your doctor or nurse should monitor you. Bile acid pills may be recommended to prevent gallstones from developing as you lose weight.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498640123\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H254632\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=see_link\">",
"      Patient information: Gallstones (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=see_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/31/4595?source=see_link\">",
"      Patient information: Gallbladder cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/17/34066?source=see_link\">",
"      Patient information: Jaundice in adults (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H254639\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/9/30865?source=see_link\">",
"      Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=see_link\">",
"      Patient information: Acute pancreatitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=see_link\">",
"      Approach to the patient with incidental gallstones",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"      Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15082?source=see_link\">",
"      Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=see_link\">",
"      Dissolution therapy for the treatment of gallstones",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14582?source=see_link\">",
"      Patient selection for the nonsurgical treatment of gallstone disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"      Treatment of acute cholecystitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link\">",
"      Uncomplicated gallstone disease in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000273.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000273.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institutes Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/gallstones/\">",
"      file://digestive.niddk.nih.gov/ddiseases/pubs/gallstones/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Gastroenterological Association (AGA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gastro.org/patient-center/digestive-conditions/gallstones\">",
"      file://www.gastro.org/patient-center/digestive-conditions/gallstones",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?7/21/7507/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?7/21/7507?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7507/abstract/1\">",
"      Ahmed A, Cheung RC, Keeffe EB. Management of gallstones and their complications. Am Fam Physician 2000; 61:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7507/abstract/2\">",
"      Darzi A, Geraghty JG, Williams NN, et al. The pros and cons of laparoscopic cholecystectomy and extracorporeal shock wave lithotripsy in the management of gallstone disease. Ann R Coll Surg Engl 1994; 76:42.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f7_21_7507=[""].join("\n");
var outline_f7_21_7507=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           GALLSTONES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           THE GALLBLADDER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           WHAT ARE GALLSTONES?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           GALLSTONES RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           GALLSTONE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           GALLSTONE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           GALLSTONE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/37/27220\" title=\"figure 1\">",
"           Gallbladder anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\" title=\"figure 2\">",
"           Abdomen anatomy adult PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f7_21_7508="Electroanatomic atrial tachy I";
var content_f7_21_7508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electroanatomic mapping of atrial tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Activation sequence obtained from electroanatomic mapping of the right atrium (RA) during atrial tachycardia shows the focus of the arrhythmia (red) along the medial mitral annulus, near the coronary sinus (CS). The RA is activated in a retrograde direction and the last portion to be activated is the area near the sinus node (dark blue/purple).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Marchlinski F, Callans D, Gottleib C, et al. Pacing Clin Electrophysiol 1998; 21:1621.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7508=[""].join("\n");
var outline_f7_21_7508=null;
var title_f7_21_7509="Sodium phenylacetate and sodium benzoate: Drug information";
var content_f7_21_7509=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium phenylacetate and sodium benzoate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/33/33299?source=see_link\">",
"    see \"Sodium phenylacetate and sodium benzoate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/32/2565?source=see_link\">",
"    see \"Sodium phenylacetate and sodium benzoate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ammonul&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Urea Cycle Disorder (UCD) Treatment Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as a loading dose over 90-120 minutes, followed by an equivalent maintenance infusion given over 24 hours. Dosage based on weight and specific enzyme deficiency; therapy should continue until ammonia levels are in normal range. Repeat loading doses are not recommended due to the prolonged plasma levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;20 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      CPS and OTC deficiency:",
"     </b>",
"     Ammonul&reg; 55 mL/m",
"     <sup>",
"      2",
"     </sup>",
"     and arginine 10% 2 mL/kg (provides sodium phenylacetate 5.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     , sodium benzoate 5.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     , and arginine hydrochloride 200 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      ASS and ASL deficiency:",
"     </b>",
"     Ammonul&reg; 55 mL/m",
"     <sup>",
"      2",
"     </sup>",
"     and arginine 10% 6 mL/kg (provides sodium phenylacetate 5.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     , sodium benzoate 5.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     , and arginine hydrochloride 600 mg/kg)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F221929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/32/2565?source=see_link\">",
"      see \"Sodium phenylacetate and sodium benzoate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as a loading dose over 90-120 minutes, followed by an equivalent maintenance infusion given over 24 hours. Dosage based on weight and specific enzyme deficiency; therapy should continue until ammonia levels are in normal range. Repeat loading doses are not recommended due to the prolonged plasma levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &le;20 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      CPS and OTC deficiency:",
"     </b>",
"     Ammonul&reg; 2.5 mL/kg and arginine 10% 2 mL/kg (provides sodium phenylacetate 250 mg/kg, sodium benzoate 250 mg/kg, and arginine hydrochloride 200 mg/kg).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      ASS and ASL deficiency:",
"     </b>",
"     Ammonul&reg; 2.5 mL/kg and arginine 10% 6 mL/kg (provides sodium phenylacetate 250 mg/kg, sodium benzoate 250 mg/kg, and arginine hydrochloride 600 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Pending a specific diagnosis in infants, the bolus and maintenance dose of arginine should be 6 mL/kg. If ASS or ASL are excluded as diagnostic possibilities, reduce dose of arginine to 2 mL/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;20 kg: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F221924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Ammonia clearance is &sim;10 times greater with hemodialysis than by peritoneal dialysis or hemofiltration. Exchange transfusion is ineffective.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F221925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ammonul&reg;: Sodium phenylacetate 100 mg and sodium benzoate 100 mg per 1 mL (50 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F221908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be administered via central line; administration via peripheral line may cause burns. Must be diluted prior to administration. In case of extravasation, discontinue infusion and resume at new injection site. Antiemetics may be needed to decrease nausea during infusion. Infuse loading dose over 90-120 minutes; maintenance dose is a continuous infusion.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F221939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatible",
"     </b>",
"     with arginine 10%.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to treatment of acute hyperammonemia and encephalopathy in patients with urea cycle disorders involving partial or complete deficiencies of carbamyl-phosphate synthetase (CPS), ornithine transcarbamoylase (OTC), argininosuccinate lysase (ASL), or argininosuccinate synthetase (ASS); for use with hemodialysis in acute neonatal hyperammonemic coma, moderate-to-severe hyperammonemic encephalopathy and hyperammonemia which fails to respond to initial therapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Nonspecific adverse reactions include: Nervous system disorders (22%); metabolism and nutrition disorders (21%); respiratory, thoracic, and mediastinal disorders (15%); general disorders and injection site reactions (14%); gastrointestinal disorders (13%); blood and lymphatic system disorders (11%); cardiac disorders (9%); skin and subcutaneous tissue disorders (6%); vascular disorders (6%); psychiatric disorders (5%); injury, poisoning, and procedural complications (4%); renal and urinary disorders (4%)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     More blood and lymphatic system, and vascular disorders were reported for patients &le;30 days of age; more gastrointestinal disorders were reported for patients &gt;30 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%: Miscellaneous: Infections (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     3% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Mental impairment (6%), seizure (6%), brain edema (5%), fever (5%), agitation (3%), coma (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (7%), hypokalemia (7%), hyperammonemia (5%), metabolic acidosis (4%), acidosis (3%), hypocalcemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (9%), diarrhea (3%), nausea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (4%), disseminated intravascular coagulation (DIC) (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory distress (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;3% (Limited to important or life-threatening): Abdominal distention, acute psychosis, acute respiratory distress syndrome, aggression, alkalosis, alopecia, anuria, areflexia, ataxia, atrial rupture, blindness, blood carbon dioxide changes, blood glucose changes, blood pH increased, bradycardia, brain death, brain hemorrhage, brain herniation, brain infarction, cardiac arrest/failure, cardiac output decreased, cardiogenic shock, cardiomyopathy, cardiopulmonary arrest/failure, cerebral atrophy, chest pain, cholestasis, clonus, coagulopathy, confusion, consciousness depressed, dehydration, dyspnea, edema, encephalopathy, fluid overload/retention, flushing, gastrointestinal hemorrhage, hallucinations, hemangioma, hemorrhage, hepatic artery stenosis, hepatic failure, hepatotoxicity, hypercapnia, hyperkalemia, hypernatremia, hypertension, hyperventilation, injection site reaction (blistering, extravasation, hemorrhage), intracranial pressure increased, jaundice, Kussmaul respiration, maculopapular rash, multiorgan failure, nerve paralysis, pancytopenia, pCO2 changes, pericardial effusion, phlebothrombosis, pneumonia aspiration, pneumothorax, pruritus, pulmonary edema, pulmonary hemorrhage, rash, renal failure, respiratory alkalosis/acidosis, respiratory arrest/failure, respiratory rate increased, sepsis, septic shock, subdural hematoma, tetany, thrombocytopenia, thrombosis, tremor, urinary retention, urticaria, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F221911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sodium phenylacetate, sodium benzoate, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F221895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nausea/vomiting: May occur; premedication with antiemetics may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edema: Use with caution in patients with sodium retention associated with edema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in patients with heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment and/or severe renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Administer through a central line; peripheral administration may result in burning. Must be diluted prior to administration; avoid extravasation (may cause necrosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nonpharmacologic support: Severity of hyperammonemia may require hemodialysis, as well as nutritional management and medical support.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Sodium Phenylacetate. Specifically, probenecid may inhibit the renal transport of the phenylacetylglutamine metabolite of sodium phenylacetate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Sodium Benzoate. Specifically, probenecid may inhibit the renal transport of the hippuric acid metabolite of sodium benzoate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F221914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In animal studies, phenylacetate was shown to cause neurological toxicity. Reproduction studies have not been conducted with this combination.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F221927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F221915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Caloric supplementation and dietary protein restriction should be part of treatment. Caloric intake of &gt;80 cal/kg/day should be attempted.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ammonul Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-10% (50 mL): $11700.76",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F221903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neurologic status, plasma ammonia, plasma glutamine, clinical response, serum electrolytes (potassium or bicarbonate supplementation may be required), acid-base balance, infusion site",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F221906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term target levels (may not be appropriate for every patient):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma ammonia: &lt;40 micromole/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma glutamine: &lt;1000 micromole/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal plasma levels of alanine, glycine, lysine, arginine (except in arginase deficiency); normal urinary orotate excretion; normal plasma protein concentration",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F221894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium phenylacetate and sodium benzoate provide alternate pathways for the removal of ammonia through the formation of their metabolites. One mole of sodium phenylacetate removes two moles of nitrogen; one mole of sodium benzoate removes one mole of nitrogen.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F221910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and renal; sodium phenylacetate conjugates with glutamine, forming the active metabolite, phenylacetylglutamine (PAG); sodium benzoate combines with glycine to form the active metabolite hippuric acid (HIP)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Batshaw ML, MacArthur RB, and Tuchman M, &ldquo;Alternative Pathway Therapy for Urea Cycle Disorders: Twenty Years Later,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):46-54.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berry GT and Steiner RD, &ldquo;Long-Term Management of Patients With Urea Cycle Disorders,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):56-60.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brusilow SW, Danney M, Waber LJ, et al, &ldquo;Treatment of Episodic Hyperammonemia in Children With Inborn Errors of Urea Synthesis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1984, 310(25):1630-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/21/7509/abstract-text/6427608/pubmed\" id=\"6427608\" target=\"_blank\">",
"        6427608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gutteridge C and Kuhn RJ, &ldquo;Compatibility of 10% Sodium Benzoate Plus 10% Sodium Phenylacetate With Various Flavored Vehicles,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1994, 51(19):2508, 2510.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/21/7509/abstract-text/7847413/pubmed\" id=\"7847413\" target=\"_blank\">",
"        7847413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Consensus Statement From a Conference for the Management of Patients With Urea Cycle Disorders. Urea Cycle Disorders Conference Group,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):1-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/21/7509/abstract-text/11148503/pubmed\" id=\"11148503\" target=\"_blank\">",
"        11148503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10084 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A18C3F2596-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7509=[""].join("\n");
var outline_f7_21_7509=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221922\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221934\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221923\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221929\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062200\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221924\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221925\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221905\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221891\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221908\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221939\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221907\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221932\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221911\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221895\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300065\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223020\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221900\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221914\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221927\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221915\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323874\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221903\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221906\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221894\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221910\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10084\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10084|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/33/33299?source=related_link\">",
"      Sodium phenylacetate and sodium benzoate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/32/2565?source=related_link\">",
"      Sodium phenylacetate and sodium benzoate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_21_7510="Circummarginate placenta";
var content_f7_21_7510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circummarginate placenta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7510=[""].join("\n");
var outline_f7_21_7510=null;
var title_f7_21_7511="Pindolol and hydrochlorothiazide: Drug information";
var content_f7_21_7511=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pindolol and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/21/43349?source=see_link\">",
"    see \"Pindolol and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9609766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Viskazide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9609770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker With Intrinsic Sympathomimetic Activity;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9609836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Dosage should be determined by titration of the individual agents and the combination product substituted based upon the daily requirements.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Usual dose: Pindolol 10-20 mg and hydrochlorothiazide 25-100 mg once daily. Maximum daily dose: Pindolol: 20 mg/hydrochlorothiazide: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     When higher doses or dosage adjustments are needed, use individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9609837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9609838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. No specific dosage recommendations provided by manufacturer. Contraindicated with anuria.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9609839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. No specific dosage recommendations provided by manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F9609874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Viskazide&reg; 10/25: Pindolol 10 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Viskazide&reg; 10/50: Pindolol 10 mg and hydrochlorothiazide 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9609841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with food or milk. Take early in day to avoid nocturia.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9609771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; not for initial therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9609764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Viskazide&reg; may be confused with hydrochlorothiazide, Visken&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9609799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9609776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Hypersensitivity to pindolol, hydrochlorothiazide, any other component of the formulation, or sulfonamide-derived drugs; decompensated heart failure, right ventricular failure secondary to pulmonary hypertension, significant cardiomegaly, sinus bradycardia, second/third degree atrioventricular (AV) block; cardiogenic shock; bronchospasm (including bronchial asthma) or severe chronic obstructive pulmonary disease (COPD); anesthetic agents producing myocardial depression; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9609777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects. Hypersensitivity to thiazides may occur in individuals without prior history of bronchial asthma or allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, and hyponatremia can occur with hydrochlorothiazide. Use of potassium containing foods/supplements or potassium sparing agents may be used to avoid or treat hypokalemia. Hypercalcemia and hypophosphatemia have been observed with prolonged thiazide therapy; discontinue use prior to parathyroid testing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular: Conjunctival xerosis (dryness of eye surface) has been reported with use of beta blockers; therapy discontinuation may be indicated if severe. Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with allergy to sulfonamide-derived drugs is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart failure (HF):  Use with caution in patients with compensated HF and monitor for a worsening of the condition. If condition worsens, consider temporary discontinuation or dosage reduction of pindolol. Patients should be stabilized on heart failure regimen prior to initiation of beta-blocker. Beta-blocker therapy should be initiated at very low doses with gradual and very careful titration. Adjustment of other medications (ACE inhibitors and/or diuretics) may be required. Beta-blockers with intrinsic sympathomimetic activity (eg, pindolol) have not been demonstrated to be of value in HF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; pindolol levels may increase significantly with hepatic impairment. In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; beta-blockers may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; thiazides may precipitate azotemia. Discontinue use with worsening of renal function. Use is contraindicated with anuria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Systemic lupus erythematosus (SLE): Thiazides can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Calcium channel blockers (nondihydropyridines): Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered over 1-2 weeks to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9659667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9609805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Hydrochlorothiazide peak serum levels may be decreased if taken with food. This product may deplete potassium, sodium, and magnesium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, and licorice (may worsen hypertension). Avoid black cohosh, california poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse (may increase antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9609772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9609774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thiazides are excreted in human breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9609775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9609840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food or milk.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9609843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate; serum electrolytes, BUN, creatinine",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9609833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pindolol: Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors and has mild intrinsic sympathomimetic activity; has negative inotropic and chronotropic effects and can significantly slow AV nodal conduction. Augmentive action of antidepressants thought to be mediated via a serotonin 1A autoreceptor antagonism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrochlorothiazide: Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9609808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/21/7511/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khan NA, McAlister FA, Lewanczuk RZ, et al, &ldquo;The 2005 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Part II-Therapy,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2005, 21(8):657-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/21/7511/abstract-text/16003449/pubmed\" id=\"16003449\" target=\"_blank\">",
"        16003449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/21/7511/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9528 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B09A38F648-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7511=[""].join("\n");
var outline_f7_21_7511=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609766\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609770\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609836\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609837\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609838\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609839\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609874\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234245\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609841\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609771\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609764\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609799\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609776\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609777\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299882\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9659667\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609805\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609772\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609774\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609775\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609840\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609843\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609833\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609808\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9528\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9528|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/21/43349?source=related_link\">",
"      Pindolol and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_21_7512="Factitious disorder and Munchausen syndrome";
var content_f7_21_7512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Factitious disorder and Munchausen syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/21/7512/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/21/7512/contributors\">",
"     Don R Lipsitt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/21/7512/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/21/7512/contributors\">",
"     Joel Dimsdale, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/21/7512/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/21/7512/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/21/7512/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factitious disorder is one form of feigned illness that must be carefully distinguished from malingering and somatoform disorders, a distinction based upon intentionality and objective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In malingering, feigning illness has an external incentive (eg, avoiding work, obtaining money), while factitious disorder has no other incentive than to be a patient and experience the sick role.",
"     </li>",
"     <li>",
"      Malingering and factitious disorder both differ from somatoform disorders (eg, hypochondriasis, conversion disorder, pain syndrome) in that the former are voluntarily produced while the latter are not.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factitious disorder and malingering occasionally occur together, while concurrent factitia and somatoform disorders are rare. Recognizing the differences in these complex presentations and learning the management of factitia can reduce the risk of iatrogenic complication and avoid unnecessary costs and medicolegal repercussions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factitious illness may have a broad spectrum of presentations. In its milder forms there may be only a slight exaggeration of physical symptoms. The most extreme and dramatic form is called Munchausen syndrome; it can include extensive travel and the seeking of multiple invasive procedures and operations, sometimes with serious risk to life. Impersonation and fabrication often accompany Munchausen syndrome.",
"   </p>",
"   <p>",
"    Patients who intentionally mimic disease have been recognized since at least the second century A.D. The first distinction between malingering and factitious disease was made in 1843 by Gavin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/2\">",
"     2",
"    </a>",
"    ]. A paper by Asher in 1951 semi-humorously described individuals who traveled widely (\"peregrinating\") seeking hospitalization by fabricating sometimes bizarre and dramatic episodes of illness (\"pseudologia fantastica\") [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/3\">",
"     3",
"    </a>",
"    ]. This extreme form of factitious disorder was named after Baron Karl Friederich Heironymous Freiherr von Munchausen, a retired cavalryman who told fanciful tales only to entertain others. Asher subsequently identified and classified the major presenting profiles of most factitious patients: abdominal (\"laparotomophilia migrans\"); hemorrhagic (\"hemorrhagica histrionica\"); and neurologic (\"neurologica diabolica\"). Others, following his style, added dermatologic (\"dermatitis artefacta\") [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/4\">",
"     4",
"    </a>",
"    ], cardiac (\"cardiopathia fantastica\") [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/5\">",
"     5",
"    </a>",
"    ] and febrile (\"hyperpyrexia figmentatica\") [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other disease labels include \"hospital hoboes\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/7\">",
"     7",
"    </a>",
"    ], \"hospital addicts\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/8\">",
"     8",
"    </a>",
"    ], \"polysurgery addicts\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/9\">",
"     9",
"    </a>",
"    ], \"professional patients,\" \"pathomimes\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/10\">",
"     10",
"    </a>",
"    ], and \"hospital vagrants\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/6\">",
"     6",
"    </a>",
"    ]. One author described individuals who seek the patient role through multiple surgeries as engaging in \"partial suicide,\" a compromise behavior designed (unconsciously) to forestall total self-destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/9\">",
"     9",
"    </a>",
"    ]. Others see the behavior as a form of \"deliberate self-harm\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/11\">",
"     11",
"    </a>",
"    ] or as a silent conspiracy (\"mania operativa\") between patients who avidly seek surgical intervention and surgeons eager to practice their skill [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review describes factitious disorder as a broad spectrum of illness behaviors, with Munchausen syndrome the most chronic and extreme form [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/13\">",
"     13",
"    </a>",
"    ], accounting for only about ten percent of all factitious disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review factitious disorder in general. Specific cases of factitious disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18951?source=see_link\">",
"     \"Factitious hypoglycemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6246?source=see_link\">",
"     \"Factitious diarrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evolution of factitious illness as a psychiatric disorder is reflected in the several editions of the American Psychiatric Association's Diagnostic and Statistical Manual (DSM) of Mental Disorders. The formal diagnosis of factitious disorder was introduced in 1980. By 1994, factitious disorder was subclassified into three types:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      With predominantly psychological signs and symptoms",
"     </li>",
"     <li>",
"      With predominantly physical signs and symptoms",
"     </li>",
"     <li>",
"      With combined physical and psychological signs and symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Munchausen syndrome by proxy was not formally named until 1977 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/15\">",
"     15",
"    </a>",
"    ], and only included in the DSM IV in 1995, noted as \"factitious disorder by proxy.\" The dynamics and family interrelationships were first described in 1972 in five cases of factitious fever in pubertal and postpubertal children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/16\">",
"     16",
"    </a>",
"    ]. In this condition, classified under \"factitious disorder not otherwise specified,\" parents (mostly mothers) induce illness in their children for the sake of obtaining care and support for themselves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The defining characteristics of all forms of feigned illness are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intentional production of feigned physical or psychological signs or symptoms",
"     </li>",
"     <li>",
"      Presence of illness behavior reflecting a wish to assume the sick role",
"     </li>",
"     <li>",
"      Confronting physicians with self-induced symptoms or disease",
"     </li>",
"     <li>",
"      Absence of external incentives for the behavior (eg, economic gain, avoiding legal responsibility, or improving general wellbeing as in malingering).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some have expressed dissatisfaction with the diagnostic conceptualization of both Munchausen syndrome and factitious disorder by proxy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], and there is some interest to reclassify factitious disorders as a subtype of somatoform disorder in the updated DSM under development [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precise prevalence data on feigned illness is lacking. Individuals with the more chronic and severe forms adopt aliases and sometimes modify their stories to avoid tracking. Longterm follow-up is rarely reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/21\">",
"     21",
"    </a>",
"    ]. Fabricated histories are notoriously unreliable and defy checking against factual accounts. Furthermore, dissembling patients frequently sign out against medical advice when on the verge of detection.",
"   </p>",
"   <p>",
"    Patients who self-induce illness usually have serious personality problems that compromise the development of personal relationships necessary for cooperative investigation and research. It also is often difficult to distinguish between naturally occurring organic disease, disease secondary to factitious behavior, and organic illness resulting from iatrogenic complications.",
"   </p>",
"   <p>",
"    These impediments to accumulating data suggest that factitious disorder, although relatively rare, is underrecognized and underreported. Minor cases of feigned illness, such as those in adolescents or in adults who tamper with thermometers, may not be reported at all. On the other hand, some cases may be overreported in the literature when reports are of the same patient in different settings with different stories and aliases. Most reports are of single cases, although some series of specific types of cases, especially those involving serious organ damage, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/22\">",
"     22",
"    </a>",
"    ]. It is anticipated that legislation on privacy and confidentiality will increase the difficulty in obtaining reliable data for research and prevalence studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study in a general hospital setting identified 10 cases of factitious disorder (0.8 percent) among 1361 patients referred over a three-year period to a consultation-liaison service for psychiatric evaluation. In another report of 343 patients referred to the National Institute for Allergy and Infectious Disease with fever of unknown origin, 32 (9.3 percent) were diagnosed with factitious disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/24\">",
"     24",
"    </a>",
"    ]. Approximately two-thirds of patients with Munchausen syndrome are male; females predominate 3 to 1 in non-Munchausen types of factitia.",
"   </p>",
"   <p>",
"    The prevalence of Munchausen by proxy is thought to be quite low, although it appears to be on the rise with new attention and detection in recent years (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    ). The proxy form of factitious disorder has also been reported in caretakers of the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The costs of factitious disorder are considerable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/27\">",
"     27",
"    </a>",
"    ]. The costs of care are seldom recouped; the more extreme feigners of disease often falsify demographic data. The cost of medical care for these patients does not include lost wages from unemployment, nor the high toll in suffering and aggravation experienced by their families and professional staff [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of factitious disorder remains largely conjectural. Possible explanations are found largely in the psychiatric and psychoanalytic literature. Explanations tend to fall into three categories [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stress",
"     </li>",
"     <li>",
"      Personality disorder",
"     </li>",
"     <li>",
"      Psychodynamic factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stressful events such as early losses through death, sickness, or abandonment often trigger repetitive behavior related to illness, doctors, and hospitals. Thwarted ambition to be a clinician or other health professional also may lead to playing out disappointment in the medical setting. Many case histories reveal personal experience of illness and hospitalization (often experienced as pleasurable) as well as physical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sexual abuse, identifying with the aggressor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the idealized authoritarian figure.",
"   </p>",
"   <p>",
"    Individuals who simulate disease display many characteristics of the borderline character personality disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/30\">",
"     30",
"    </a>",
"    ]. These include a sense of emptiness and boredom, thinly disguised rage, a strong need to exercise control over the environment, a tendency to play people against each other (\"splitting\"), attributing to others many of the individual's own objectionable attributes (\"projective identification\"), profound flaws in the sense of self and identity, and exquisite sensitivity to rejection and abandonment. It is not uncommon for such individuals to engage in asocial and illegal behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/31\">",
"     31",
"    </a>",
"    ]. There is considerable interest in the forensics of factitious illness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/32\">",
"     32",
"    </a>",
"    ]. A special risk of malpractice litigation has been recognized, affecting plastic surgeons who operate on undetected factitious patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychodynamic theories propose that sickness impostors act out the \"doctor game\" of their childhood in attempts to resolve ambivalent conflicts over passivity and activity, playing alternately the submissive part of patient and the authoritarian part of clinician being at once both victim and victimizer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients in hospital have been noted to sexualize their experience, suggesting replication of the \"doctor game\" in which fantasies about parental lovemaking are played out. Fears of retribution and possible annihilation are mastered by surviving multiple \"close calls\" through repeated self-exposure to high-risk encounters in the medical setting. It is hypothesized that the patients' denial of falsification when presented with hard evidence of feigned illness is rooted in the intense fear of bodily and psychological disintegration.",
"   </p>",
"   <p>",
"    Fakers of illness engage health professionals (primarily doctors) in sadomasochistic encounters, inviting pain and trauma (through surgery and other potentially painful interventions) and expressing hostility towards parent figures through repetitious aggressive efforts intended to prove them wrong. The faking of disease is believed to be intentional and conscious, although the compulsive nature of illness simulation is considered unconscious.",
"   </p>",
"   <p>",
"    No specific psychopathology is associated with factitious illness. The disorder has been reported accompanying psychopathic, sociopathic, borderline, passive-dependent, and passive-aggressive personality disorder. Dissociation may have an important role in some patients with the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/35\">",
"     35",
"    </a>",
"    ]. Cases have been cited in hysterical conversion, hypochondriasis, schizophrenia, psychotic and nonpsychotic depression, adjustment reaction of adolescence, malingering, anorexia nervosa, reactive depression, anxiety neurosis, bereavement, and somatization.",
"   </p>",
"   <p>",
"    Although isolated cases continue to be reported in the literature, research into the pathogenesis and treatment of factitious disorder has been lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Feigned illness is in most instances very convincingly and cleverly presented. Patients who simulate disease often demonstrate familiarity with medical terminology, usually from extensive contact with the health professions as a patient or an employee. Even when deception is suspected, it is sometimes impossible to discover the means by which it is accomplished.",
"   </p>",
"   <p>",
"    Patients may fake illness in a variety of ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Confabulated history alone (eg, cancer, AIDS, pulmonary embolus)",
"     </li>",
"     <li>",
"      Faking symptoms only (eg, chest pain, dizziness, paralysis, blindness)",
"     </li>",
"     <li>",
"      Creating a \"real\" illness by artificial means (eg, ingestion of thyroid hormone, laxatives, and anticoagulants, or injection of contaminants such as feces, bacteria, sputum, milk, kerosene)",
"     </li>",
"     <li>",
"      Mimicking bleeding by swallowing, instilling, or letting blood",
"     </li>",
"     <li>",
"      Embellishing old real illness or genetic defects in the context of simulated disease (eg, complaining of head trauma when there is a congenitally constricted pupil)",
"     </li>",
"     <li>",
"      Tampering with instruments, thermometers, IVs, or laboratory specimens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More than one method may be utilized during an encounter. Protracted failure of wound healing may suggest self-contamination, intentional dehiscence, or self-administered trauma. Drug-seeking and addiction may be part of the profile. It has been suggested that the accessibility of the Internet has the potential for increasing the versatility of those who simulate illness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases of Munchausen by proxy, parents may physically hurt their children; administer laxatives, salt, or other toxic substances; or attempt to suffocate and then rescue them [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/38\">",
"     38",
"    </a>",
"    ]. When confronted with evidence of tampering or confabulation, the typical response is irate denial of misbehavior, usually followed by angry departure against medical advice (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients in the hospital often appear more comfortable than their \"disease\" warrants. They are initially pleasant and cooperative with and receptive to all recommendations for evaluation and procedural intervention, no matter how complicated or risky. When later questioned or doubted, they may become enraged, disruptive, or even physically threatening.",
"   </p>",
"   <p>",
"    A careful history will sometimes reveal gaps, contradictions, or marked evasiveness. Requests by physicians for consent to contact family members, other doctors, or other hospitals are frequently denied; when permission is granted, explanations are offered for why discrepancies may be discovered. Nursing staff commonly observe that factitious patients rarely have visitors or receive phone calls, suggesting asocial, isolated, or secretive behavior. Patients who feign disease frequently induce extreme disruption on the ward and considerable staff disagreement by \"splitting\" caretakers into \"good\" and \"bad\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific diagnostic test for factitious disorder. The diagnosis relies heavily upon the astuteness of the clinician using the usual clinical tools (eg, history, physical examination, laboratory studies). One finding that raises the index of suspicion is a history that seems almost unbelievable or \"too good to be true.\" Most dissemblers are quite intelligent and have the capacity to remember important details of their stories; early detection is therefore not the rule, except in extraordinarily bizarre or extravagant cases.",
"   </p>",
"   <p>",
"    The first clue to dissimulation may come from careful checking with other sources (eg, hospitals, doctors, family) when there are spurious or inexplicable gaps in a patient's history. It is necessary to ask the patient for consent for this exploration until there is fairly sound evidence of feigning; performing these measures without consent may debatably be warranted to decrease the risk of self-harm in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/40\">",
"     40",
"    </a>",
"    ]. However, legislative regulations and ethical considerations regarding medical privacy and confidentiality may create a barrier to gathering data in suspected cases of factitia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/23\">",
"     23",
"    </a>",
"    ]. Refusal of well-intentioned and important data gathering may be another clue to the diagnosis.",
"   </p>",
"   <p>",
"    The source of illness should be questioned when routine treatment of a self-induced illness does not result in improvement or the course is atypical. Laboratory findings that are atypical, impossible, or inconsistent with the history or physical findings should also be regarded with suspicion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a later phase of \"illness,\" a readiness to acquiesce to procedures, tests, or surgery that commonly provoke anxiety may generate doubts about the patient's veracity. Ultimately, failure of the patient to show improvement or mysterious worsening of the condition may strengthen the suspicion of factitious disorder.",
"   </p>",
"   <p>",
"    When suspicion arises that a patient may be self-medicating, injecting, or instilling foreign matter into skin, muscle, or orifices, the inclination to perform a room search when the patient is out of the room has raised salient ethical questions. Finding syringes or vials of injectables such as insulin and anticoagulants is usually evidence of dissembling. The temptation is to confront the patient angrily with the evidence, running the risk of having the patient leave against advice. However, thoughtful and nonjudgmental confrontation of the patient, with a plan for psychiatric consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    referral if the patient is receptive, may provide an opening for further assessment and appropriate treatment; controversy persists as to whether direct confrontation is advisable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/23,42\">",
"     23,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some attempts have been made to utilize neuropsychological testing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/43\">",
"     43",
"    </a>",
"    ], biological markers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/44\">",
"     44",
"    </a>",
"    ], EEGs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/45\">",
"     45",
"    </a>",
"    ], and other techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/46-48\">",
"     46-48",
"    </a>",
"    ] to identify malingering and factitious disorder. However, a careful history and physical examination yield the best results.",
"   </p>",
"   <p>",
"    Early diagnosis of Munchausen syndrome by proxy is of greater urgency since the life of the child may be at risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factitious disorder must be differentiated primarily from somatoform disorders and malingering (",
"    <a class=\"graphic graphic_table graphicRef74035 \" href=\"UTD.htm?5/61/6107\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef75973 \" href=\"UTD.htm?19/49/20241\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malingering patients are usually reluctant to accept suggestions for diagnosis or treatment while those with factitious illness readily accept such suggestions.",
"     </li>",
"     <li>",
"      Malingerers often reveal clear-cut goals (eg, to escape unpleasant circumstances, to avoid incarceration, to build a lawsuit) while those with factitious disorder appear to be goalless except to assume the role of the patient. Ganser's syndrome is a special form of malingering in which individuals fake psychosis, often to escape prosecution or incarceration [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Somatoform disorders such as hypochondriasis, conversion disorder, pain disorder, or somatization disorder are typically not involved with conscious manipulation of the health care system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One review suggested a three-dimensional model to configure intentionality, level of consciousness, and symptomatology in differentiating among malingering, somatoform, and factitious disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/50\">",
"     50",
"    </a>",
"    ]. Others have suggested that all three conditions are various degrees of somatization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with dementia, schizophrenia, other psychoses, or mental retardation may inflict illness upon themselves, but it is usually unintended and the result of poor comprehension or reality testing. Most illness simulators are not psychotic, have average or high intelligence, and are sufficiently good at reality testing to construct very believable stories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific therapy for factitious disorder has been established. However, some consensus exists that the core management should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment of self-induced medical or surgical conditions, as indicated",
"     </li>",
"     <li>",
"      Education of",
"      <span class=\"nowrap\">",
"       medical/surgical",
"      </span>",
"      staff regarding illness behavior and dynamics in factitia, to reduce the clinician's feelings of anger, frustration, and helplessness",
"     </li>",
"     <li>",
"      Protecting the patient from self-harm or harmful procedures",
"     </li>",
"     <li>",
"      Attempting to limit a patient's care to one primary clinician and hospital",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ethical controversy exists around the question of whether faked illness warrants the same kind of medical treatment administered to other \"legitimate\" patients. Nevertheless, it is the clinician's duty to properly administer care if a patient's symptoms pose any risk. It is also the clinician's responsibility to try to curb the patient's deception and potentially risky behavior.",
"   </p>",
"   <p>",
"    The intervention of confronting a patient with the evidence of factitia has met with considerable controversy. Some clinicians consider this step essential [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/14\">",
"     14",
"    </a>",
"    ], while others warn of the risk of provoking psychosis or suicidal behavior. The anticipated risks of confrontation were not realized in one review of 41 cases of factitious disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/14\">",
"     14",
"    </a>",
"    ]. None of the 33 cases confronted with evidence of illness fakery signed out against advice or became suicidal, while 13 acknowledged their deception, most showed some improvement, and 4 of the most chronic became asymptomatic. In contrast, a study of 93 patients with factitious disorder, 71 of whom were confronted with their diagnosis, found that confrontation did not appear to lead to patient acknowledgment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some suggest that confrontation is effective in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      When it is a collaborative intervention by the attending clinician and psychiatrist together",
"     </li>",
"     <li>",
"      When it allows the patient a way to \"save face\"",
"     </li>",
"     <li>",
"      When it is not retaliatory or punitive",
"     </li>",
"     <li>",
"      When it is combined with other behavioral approaches",
"     </li>",
"     <li>",
"      When it precedes an offer of follow-up treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The literature reports a few cases of successful long-term treatment of factitious disorder utilizing predominantly inpatient care and behavioral techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/55-61\">",
"     55-61",
"    </a>",
"    ]. Caution must be exercised in attributing long-term benefits to any form of intervention due to a paucity of follow-up reports and the heterogeneity of factitious disorder. Some reports of extended treatment suggest a resumption of compulsive dissembling following a course of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/10\">",
"     10",
"    </a>",
"    ]. Individuals whose simulations are accompanied by anxiety, depression, or psychotic disorder may respond to the usual kinds of treatment for these disorders, with or without psychopharmacologic management [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with factitious disorder are seen in the medical-surgical services of a general hospital. On an inpatient service, consulting psychiatrists help staff to focus on minimizing the disruption of the nursing unit, and help lessen iatrogenic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/63\">",
"     63",
"    </a>",
"    ]. The focus is almost always upon management rather than treatment. In doctors' offices and the emergency department, educational efforts are directed at helping physicians recognize factitious behavior early, developing techniques for verifying suspicious histories, and avoiding expensive and potentially dangerous interventions.",
"   </p>",
"   <p>",
"    Consultation-liaison psychiatrists can help professional staff deal with their own sometimes violent feelings toward patients who fabricate illness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7512/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients at the milder end of the spectrum of factitious behavior have a better prognosis than those with chronic, bizarre, or flamboyant forms. Patients with underlying personality disorders are more refractory than others. If any approach is to be therapeutic, it is more likely to occur in the context of a continuing patient-clinician relationship, preferably with a primary care clinician. Few reports exist of successful psychotherapeutic treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factitious disorder is distinguished from malingering and somatoform, based upon intentionality and objective. Symptoms related to malingering and factitious disorder are produced by conscious manipulation, while somatoform disorder symptoms are without intention. Whereas an external incentive (work avoidance, financial gain) drives malingering, the incentive for factitious disorder is to adopt the sick role. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factitious disorder is comprised of a broad spectrum of illness behaviors, with Munchausen syndrome the most extreme form in which patients often seek multiple invasive procedures that may pose serious risk to life. A subtype of Munchausen syndrome, Munchausen by proxy, involves a caretaker (often a mother) causing symptomatic illness in another person (often a child, but occasionally an elder). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Illness may be imitated in multiple ways: confabulation, faking symptoms, ingestion or injection of substances, tampering with specimens or instruments. The diagnosis of factitious disorder may be suspected when a patient who declines consent to obtain prior records, the medical history has gaps or inconsistencies, laboratory studies are atypical, or in a patient who appears more comfortable than is warranted by the disease or in whom invasive procedures do not provoke usual anxiety reactions. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with factitious disorder are seen in the medical-surgical services of a general hospital. The efficacy of patient confrontation with evidence of falsification is debatable. Maintaining an established relationship with one caregiver (usually a primary care clinician) is encouraged. Collaborative assistance by psychiatrists in patient management is recommended. Identified underlying psychological disorders (anxiety, depression) should be treated, but the effectiveness of specific treatment strategies for factitious disorder has not been rigorously determined. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/1\">",
"      Drob SL, Meehan KB, Waxman SE. Clinical and conceptual problems in the attribution of malingering in forensic evaluations. J Am Acad Psychiatry Law 2009; 37:98.",
"     </a>",
"    </li>",
"    <li>",
"     Gavin, H. On Feigned and Factitious Diseases, on the Means Used to Simulate or Produce Them, and on the Best Methods of Discovering Impostors. John Churchill, London 1843.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/3\">",
"      ASHER R. Munchausen's syndrome. Lancet 1951; 1:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/4\">",
"      Kwon EJ, Dans M, Koblenzer CS, et al. Dermatitis artefacta. J Cutan Med Surg 2006; 10:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/5\">",
"      Park TA, Borsch MA, Dyer AR, Peiris AN. Cardiopathia fantastica: the cardiac variant of Munchausen syndrome. South Med J 2004; 97:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/6\">",
"      CHAPMAN JS. Peregrinating problem patients; Munchausen's syndrome. J Am Med Assoc 1957; 165:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/7\">",
"      CLARKE E, MELNICK SC. The Munchausen syndrome or the problem of hospital hoboes. Am J Med 1958; 25:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/8\">",
"      Barker JC. Hospital and operation addiction. (Munchausen syndrome). Br J Clin Pract 1966; 20:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/9\">",
"      Menninger, K. Polysurgery and polysurgical addiction. Psychoanal Q 1934; 3:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/10\">",
"      Cramer B, Gershberg MR, Stern M. Munchausen syndrome. Its relationship to malingering, hysteria, and the physician-patient relationship. Arch Gen Psychiatry 1971; 24:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/11\">",
"      Fliege H, Scholler G, Rose M, et al. Factitious disorders and pathological self-harm in a hospital population: an interdisciplinary challenge. Gen Hosp Psychiatry 2002; 24:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/12\">",
"      Chertok L. Mania operativa: surgical addiction. Psychiatry Med 1972; 3:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/13\">",
"      Spiro HR. Chronic factitious illness. Munchausen's syndrome. Arch Gen Psychiatry 1968; 18:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/14\">",
"      Reich P, Gottfried LA. Factitious disorders in a teaching hospital. Ann Intern Med 1983; 99:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/15\">",
"      Meadow R. Munchausen syndrome by proxy. The hinterland of child abuse. Lancet 1977; 2:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/16\">",
"      Herzberg JH, Wolff SM. Chronic factitious fever in puberty and adolescence: a diagnostic challenge to the family physician. Psychiatry Med 1972; 3:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/17\">",
"      Rogers R. Diagnostic, expanatory, and detection models of Munchausen by proxy: extrapolations from malingering and deception. Child Abuse Negl 2004; 28:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/18\">",
"      Turner MA. Factitious disorders: reformulating the DSM-IV criteria. Psychosomatics 2006; 47:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/19\">",
"      Krahn LE, Bostwick JM, Stonnington CM. Looking toward DSM-V: should factitious disorder become a subtype of somatoform disorder? Psychosomatics 2008; 49:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/20\">",
"      Dimsdale J, Creed F, DSM-V Workgroup on Somatic Symptom Disorders. The proposed diagnosis of somatic symptom disorders in DSM-V to replace somatoform disorders in DSM-IV--a preliminary report. J Psychosom Res 2009; 66:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/21\">",
"      Fehnel CR, Brewer EJ. Munchausen's syndrome with 20-year follow-up. Am J Psychiatry 2006; 163:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/22\">",
"      Mehta NJ, Khan IA. Cardiac Munchausen syndrome. Chest 2002; 122:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/23\">",
"      Krahn LE, Li H, O'Connor MK. Patients who strive to be ill: factitious disorder with physical symptoms. Am J Psychiatry 2003; 160:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/24\">",
"      Aduan RP, Fauci AS, Dale DC, et al. Factitious fever and self-induced infection: a report of 32 cases and review of the literature. Ann Intern Med 1979; 90:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/25\">",
"      Ben-Chetrit E, Melmed RN. Recurrent hypoglycaemia in multiple myeloma: a case of Munchausen syndrome by proxy in an elderly patient. J Intern Med 1998; 244:175.",
"     </a>",
"    </li>",
"    <li>",
"     Feldman, MD, Ford, CV. Patient or Pretender: Inside the Strange World of Factitious Disorders. Wiley, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/27\">",
"      Powell R, Boast N. The million dollar man. Resource implications for chronic Munchausen's syndrome. Br J Psychiatry 1993; 162:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/28\">",
"      . The costs of factitious disorders. Psychosomatics 1994; 35:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/29\">",
"      Pilowsky I. Abnormal illness behaviour. Br J Med Psychol 1969; 42:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/30\">",
"      Nadelson T. The Munchausen spectrum: borderline character features. Gen Hosp Psychiatry 1979; 1:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/31\">",
"      Lipsitt DR. The factitious patient who sues. Am J Psychiatry 1986; 143:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/32\">",
"      Eisendrath SJ, McNiel DE. Factitious physical disorders, litigation, and mortality. Psychosomatics 2004; 45:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/33\">",
"      Eisendrath SJ, Telischak KS. Factitious disorders: potential litigation risks for plastic surgeons. Ann Plast Surg 2008; 60:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/34\">",
"      Simmel, E. The \"doctor-game,\" illness and the profession of medicine. Int J Psychoanal 1926; 7:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/35\">",
"      Toth EL, Baggaley A. Coexistence of Munchausen's syndrome and multiple personality disorder: detailed report of a case and theoretical discussion. Psychiatry 1991; 54:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/36\">",
"      Feldman MD. Munchausen by Internet: detecting factitious illness and crisis on the Internet. South Med J 2000; 93:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/37\">",
"      Levenson JL, Chafe W, Flanagan P. Factitious ovarian cancer: feigning via resources on the internet. Psychosomatics 2007; 48:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/38\">",
"      Schreier HA, Libow JA. Munchausen syndrome by proxy: diagnosis and prevalence. Am J Orthopsychiatry 1993; 63:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/39\">",
"      Groves JE. Management of the borderline patient on a medical or surgical ward: the psychiatric consultant's role. Int J Psychiatry Med 1975; 6:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/40\">",
"      Meropol NJ, Ford CV, Zaner RM. Factitious illness: an exploration in ethics. Perspect Biol Med 1985; 28:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/41\">",
"      Wallach J. Laboratory diagnosis of factitious disorders. Arch Intern Med 1994; 154:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/42\">",
"      van der Feltz-Cornelis CM. The impact of factitious disorder on the physician-patient relationship. An epistemological model. Med Health Care Philos 2002; 5:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/43\">",
"      Nies KJ, Sweet JJ. Neuropsychological assessment and malingering: a critical review of past and present strategies. Arch Clin Neuropsychol 1994; 9:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/44\">",
"      St&aring;lenheim EG, von Knorring L, Wide L. Serum levels of thyroid hormones as biological markers in a Swedish forensic psychiatric population. Biol Psychiatry 1998; 43:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/45\">",
"      Rosenfeld JP, Ellwanger J, Sweet J. Detecting simulated amnesia with event-related brain potentials. Int J Psychophysiol 1995; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/46\">",
"      Donnelly B, Boyd V. Use of the bispectral index (BIS) monitor to aid in the diagnosis of pseudoseizures. Br J Anaesth 2006; 96:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/47\">",
"      Stone J, Zeman A, Simonotto E, et al. FMRI in patients with motor conversion symptoms and controls with simulated weakness. Psychosom Med 2007; 69:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/48\">",
"      Shelton JH, Santa Ana CA, Thompson DR, et al. Factitious diarrhea induced by stimulant laxatives: accuracy of diagnosis by a clinical reference laboratory using thin layer chromatography. Clin Chem 2007; 53:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/49\">",
"      Dwyer J, Reid S. Ganser's syndrome. Lancet 2004; 364:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/50\">",
"      Taylor S, Hyler SE. Update on factitious disorders. Int J Psychiatry Med 1993; 23:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/51\">",
"      Folks DG. Munchausen's syndrome and other factitious disorders. Neurol Clin 1995; 13:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/52\">",
"      Eisendrath SJ. Factitious physical disorders: treatment without confrontation. Psychosomatics 1989; 30:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/53\">",
"      Wedel, KR. A therapeutic confrontation approach to treating patients with factitious illness. Soc Work 1971; 16:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/54\">",
"      Hollender MH, Hersh SP. Impossible consultation made possible. Arch Gen Psychiatry 1970; 23:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/55\">",
"      Plassmann R. Inpatient and outpatient long-term psychotherapy of patients suffering from factitious disorders. Psychother Psychosom 1994; 62:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/56\">",
"      Mayo JP Jr, Haggerty JJ Jr. Long-term psychotherapy of Munchausen syndrome. Am J Psychother 1984; 38:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/57\">",
"      Tucker LE, Hayes JR, Viteri AL, Liebermann TR. Factitial bleeding: successful management with psychotherapy. Dig Dis Sci 1979; 24:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/58\">",
"      Klonoff EA, Youngner SJ, Moore DJ, Hershey LA. Chronic factitious illness: a behavioral approach. Int J Psychiatry Med 1983; 13:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/59\">",
"      Solyom C, Solyom L. A treatment program for functional paraplegia/Munchausen syndrome. J Behav Ther Exp Psychiatry 1990; 21:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/60\">",
"      Yassa R. Munchausen's syndrome: a successfully treated case. Psychosomatics 1978; 19:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/61\">",
"      Spivak H, Rodin G, Sutherland A. The psychology of factitious disorders. A reconsideration. Psychosomatics 1994; 35:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/62\">",
"      Earle JR Jr, Folks DG. Factitious disorder and coexisting depression: a report of successful psychiatric consultation and case management. Gen Hosp Psychiatry 1986; 8:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/63\">",
"      Gregory RJ, Jindal S. Factitious disorder on an inpatient psychiatry ward. Am J Orthopsychiatry 2006; 76:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/64\">",
"      Groves JE. Taking care of the hateful patient. N Engl J Med 1978; 298:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7512/abstract/65\">",
"      Feldman MD, Feldman JM. Tangled in the web: countertransference in the therapy of factitious disorders. Int J Psychiatry Med 1995; 25:389.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7765 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7512=[""].join("\n");
var outline_f7_21_7512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7765\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7765|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?19/49/20241\" title=\"algorithm 1\">",
"      Diagnostic algorithm somatoform factitious malingering disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7765|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/61/6107\" title=\"table 1\">",
"      Differential Dx factitious somatoform and malingering disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6246?source=related_link\">",
"      Factitious diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18951?source=related_link\">",
"      Factitious hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=related_link\">",
"      Munchausen syndrome by proxy (medical child abuse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_21_7513="Complementary and alternative remedies in rheumatic disorders";
var content_f7_21_7513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complementary and alternative remedies in rheumatic disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/21/7513/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/21/7513/contributors\">",
"     Richard S Panush, MD, MACP, MACR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/21/7513/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/21/7513/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/21/7513/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/21/7513/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/21/7513/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 13, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"All who drink of this remedy are cured, except those who die. Thus, it is effective for all but the incurable.\" Galen.",
"   </p>",
"   <p>",
"    What is the role, if any, for \"complementary\" and \"alternative\" remedies in the routine therapy of patients with rheumatic diseases? Despite considerable interest in these therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/1-11\">",
"     1-11",
"    </a>",
"    ], I do not consider that anything truly clinically important has emerged in rheumatology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    \"Alternative\" or \"complementary\" therapies in medicine have gained public attention and implied endorsement by the United States government:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A survey of patients followed in private and university-based rheumatology practices found that roughly two-thirds had used some form of complementary or alternative therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent survey of 232 consecutive patients in both private and university rheumatology practices found that one-third were actively using one or more of these therapies during the course of one year [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 1992, Congress established an Office of Alternative Medicine, now renamed the National Center for Complementary and Alternative Medicine, at the National Institutes of Health (NIH), with an annual budget now in excess of $100 million.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It therefore behooves clinicians to be familiar with some of these \"complementary\" and \"alternative\" remedies available for rheumatological patients in order to be able to effectively communicate with patients and colleagues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Rheumatology (ACR) established a committee in 1993 to address pertinent issues originally surrounding the efficacy of these remedies. At that time, the committee deliberately selected the term \"questionable,\" following the approaches of other groups. This permitted the avoidance of other terms that euphemized questionable remedies. To conform to current trends, the ACR later adopted the terms \"complementary\" and \"alternative.\"",
"   </p>",
"   <p>",
"    There are three types of therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genuine, defined as those proven acceptably safe and effective",
"     </li>",
"     <li>",
"      Questionable",
"     </li>",
"     <li>",
"      Ineffective",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    I have come to prefer the terms \"mainstream\" and \"nonmainstream\" to best categorize how therapies are conceived. These names are preferable to other terms for possible remedies, such as \"unapproved\" (eg, by the Federal Drug Administration), \"false\" (disproven), \"unproven\" (experimental), \"dubious\" (very doubtful), \"non-standard\" (falling short of practice standards), \"irregular\" (not used by mainstream medicine), or even \"alternative\" or \"complementary\" (reflecting various questionable or conventional treatment options) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/1,3,10,11\">",
"     1,3,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     APPEAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with rheumatic disease suffer physically and emotionally. They must learn to cope with the illness, the constraints imposed by the limitations of medicine, and the considerable uncertainty concerning outcome. These adjustments are not always easy.",
"   </p>",
"   <p>",
"    Patients want hope for a cure or for relief. Nonmainstream approaches offer hope. Patients may therefore turn from science and seek understanding and relief (and empowerment) from questionable sources [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/1-11\">",
"     1-11",
"    </a>",
"    ]. We can understand this quest and sympathize since we have undoubtedly also sought and used questionable remedies (such as chicken soup for a cold or a rub for an ache). Increasingly, many seek \"complementary\" and \"alternative\" remedies as a lifestyle choice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/15\">",
"     15",
"    </a>",
"    ]. Recent observations suggest that many patients seeking \"complementary\" and \"alternative\" therapies do so in response to psychosocial distress, not necessarily because of severe or unresponsive illness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MEDICAL RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical response to \"complementary\" and \"alternative\" remedies therefore remains problematic. Our different options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We can inform ourselves, which is the intent of this section.",
"     </li>",
"     <li>",
"      We can dismiss them.",
"     </li>",
"     <li>",
"      We can establish repositories of information about them, which the American College of Rheumatology and Arthritis Foundation has done [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We can try to communicate with patients and the public through the media. However, \"Doctor's diet cures arthritis\" makes instant headlines in the lay press; by comparison, \"Doctor's diet doesn't cure arthritis\" takes years of research, writing, and revision before appearing in the rheumatology literature, and has limited impact upon physician and patient practices [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We can aggressively combat public perceptions in the press and in the courts, as does the National Council Against Health Fraud. Although this is a worthy effort, its success is also limited [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Education and communication must suffice until our science improves [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many physicians have a too frequent impulse to disdain and sometimes to ridicule \"complementary\" and \"alternative\" remedies. We have a traditional intellectual view of science and the idea that human problems can be understood and solved by the appropriate application of science. However, science is not immune to superstition, fraud, errors, conservatism, pigheadedness, fashion, and trends (eg, tonsillectomies, adenoidectomies, irradiation for acne or ankylosing spondylitis, and iced saline lavage for GI bleeds) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/3-11\">",
"     3-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several possible explanations for our dismissal of \"complementary\" and \"alternative\" remedies from legitimate study. Arguably, we no longer dismiss CAM. First, non-mainstream approaches evoke discomfort and prejudice, and seem to defy rational explanation. Second, quackery is purveyed by practitioners whom we sometimes consider unsavory and our intellectual inferiors since we do not share their belief system, are offended by their audacity, or may feel demeaned if we condescend to consider their notions.",
"   </p>",
"   <p>",
"    It may once have seemed absurd to propose that diet, antibiotics, or red peppers might sometimes help arthritis or that antibiotics would help peptic ulcer disease. However, the outright rejection of \"complementary\" and \"alternative\" remedies risks missing potentially beneficial therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HAZARDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some may argue that patients should be permitted to try \"complementary\" and \"alternative\" therapies because they are often at least innocuous, I argue that it is not responsible to use therapies generally not considered acceptably safe and effective. As examples, some \"complementary\" and \"alternative\" therapies are not innocuous and are occasionally harmful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are documented instances of patients who received therapies other than those promised and suffered from adverse results, including marrow aplasia, serious infections from contaminants, and death [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/3-5,10,19,20\">",
"       3-5,10,19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients seeking \"complementary\" and \"alternative\" remedies may inappropriately neglect their illness [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Expenditures on \"complementary\" and \"alternative\" remedies may divert scarce health-care resources from more appropriate areas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    I will next consider selective and representative examples of \"complementary\" and \"alternative\" remedies. A detailed discussion of these remedies is beyond the scope of this presentation, but has been reviewed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/1,2,5,11,21,22\">",
"     1,2,5,11,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SELECTED \"COMPLEMENTARY\" AND \"ALTERNATIVE\" REMEDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prominent \"complementary\" and \"alternative\" remedies for rheumatic disorders include (",
"    <a class=\"graphic graphic_table graphicRef71871 \" href=\"UTD.htm?12/19/12605\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diet",
"     </li>",
"     <li>",
"      Vitamins and minerals",
"     </li>",
"     <li>",
"      Nutritional supplements",
"     </li>",
"     <li>",
"      Fish oils",
"     </li>",
"     <li>",
"      Antimicrobials (nitroimidazole, rifamycin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      , tetracyclines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Biologic therapy (thymopoietin, transfer factor, placenta-derived factors, venoms, and herbal remedies)",
"     </li>",
"     <li>",
"      Other pharmacologic agents (cis-retinoic acid, isoprinoside, amiprolose,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Topical agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"       dimethyl sulfoxide",
"      </a>",
"      [DMSO])",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Mechanical/instrumental",
"      </span>",
"      therapies (hyperbaric oxygen, laser irradiation, acupuncture, photopheresis, electromagnetic radiation), chiropractic manipulation, homeopathy, biofeedback, exercise, yoga, and others (eg, sitting in abandoned uranium mines) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;A microbial etiology for rheumatoid arthritis (RA) has long been an attractive but unproven hypothesis. However, antimicrobials might be useful if this hypothesis were true. The following are instructive clinical experiences concerning therapy using antimicrobial agents for patients with rheumatic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the following reflect largely isolated and unconfirmed observations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nitroimidazole antimicrobial drugs have been tried for the treatment of RA because of the efficacy of levamisole, another imidazole derivative, and because of claims that RA was caused by Amoeba limax. Results, however, have not been impressive [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/1,21,22\">",
"       1,21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rifamycin, an antibiotic that blocks DNA-dependent RNA polymerase and inhibits cellular protein synthesis, was promising for the treatment of rheumatoid knee synovitis in preliminary observations [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      therapy has also been tried based upon a putative mycoplasma etiology for RA. Such therapy was considered ineffective for many years. This issue has been revisited, however, since later scientific work found that tetracyclines, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      , may have significant physiologic effects, including reduced collagenase activity, lessening of bone resorption, and perturbation of T-cell and neutrophil function. In addition, these drugs were found to be antiproliferative, antiinflammatory, and antiarthritic in animal and possibly human arthritis. Thus, tetracycline therapy is no longer considered \"complementary\" or \"alternative\". (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=see_link&amp;anchor=H3978675#H3978675\">",
"       \"Initial treatment of mildly active rheumatoid arthritis in adults\", section on 'Other therapies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with chronic inflammatory arthritis and antibody titers to Borrelia burgdorferi of 1:64 or greater have had encouraging responses to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       Ampicillin",
"      </a>",
"      was reported to be beneficial under certain conditions for patients with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       Amantadine",
"      </a>",
"      , an antiviral agent, was useful for a group of patients with teenage-onset juvenile idiopathic arthritis who had elevated antibody titers to influenza A and were born during an influenza epidemic [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If observations suggesting a benefit from antimicrobial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiviral therapy are consistently confirmed, either chronic arthritis in some patients results from bacterial, spirochete, or viral infection, or such therapy may be antirheumatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Foods, diet and nutritional supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;For years, special diets for patients with arthritis were relegated to quackery. It was not long ago that the Arthritis Foundation presented \"The Truth about Diet and Arthritis,\" stating \"if there was a relationship between diet and arthritis it would have been discovered long ago. The simple fact is that there is no scientific evidence that any food has anything to do with causing arthritis and no evidence that any food is effective in treating or 'curing' it [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/27\">",
"     27",
"    </a>",
"    ].\"",
"   </p>",
"   <p>",
"    We and others have now reexamined this notion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How might food affect arthritis? First, some patients with rheumatic disease may be allergic to certain foods and have symptoms that might be a manifestation of food allergy. Second, certain types of diets with particular amounts of calories, protein, and fatty acids may affect the immunologically-mediated inflammation that occurs with arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Is there a diet for arthritis? There is",
"      <strong>",
"       no",
"      </strong>",
"      compelling evidence at present that any diet other than a healthy, balanced one is consistently helpful to patients with arthritis. One study of a popular diet (the elimination of red meat, additives, preservatives, fruit, dairy products, herbs, spices, and alcohol) for patients with arthritis found no consistent salutary effect on disease activity [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Is arthritis caused by food hypersensitivity in some patients? Physicians and patients remain intrigued that arthritis may occasionally be the result of hypersensitivity to foods. As examples: palindromic rheumatism has been associated with sodium nitrate; Beh&ccedil;et&rsquo;s syndrome with black walnuts; systemic lupus erythematosus (SLE) with canavanine in alfalfa (which may cross-react with native DNA or activate B lymphocytes) and with hydrazine, and RA allegedly with many substances including house dust, tobacco, smoke, petrochemicals, tartrazine, dairy products, wheat, corn, and beef. In addition, rheumatoid-like synovitis in rabbits has been induced by dietary cows' milk [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/1-10,28\">",
"       1-10,28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Careful, prospective, placebo-controlled, double-blind studies confirmed (for selected patients) that inflammatory arthritis could be associated with foods. One patient, for example, had 30 minutes of morning stiffness, nine tender joints, and three swollen joints on her regular diet [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/8\">",
"       8",
"      </a>",
"      ]. Virtually all of these findings disappeared after a three day fast. They could then be reproduced by milk challenge but not with other foods.",
"     </li>",
"     <li>",
"      The role of fish or plant oils or diets? Nutritional status exerts a profound influence on immune responsiveness and disease expression. As an example, mice with SLE or rats with arthritis that are fed diets rich in eicosapentaenoic acid (a naturally occurring, substituted, polyunsaturated fatty acid analog) fared better than did control animals [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/28\">",
"       28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Clinical trials of fish oils and plant seed oils have suggested a modest decrease in certain symptoms with therapy in patients with RA but not SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. Beneficial effects of fish oil supplementation may be enhanced by limiting the dietary intake of polyunsaturated oils (eg, corn, soybean, safflower, sunflower) to 10 grams or less per day [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/30\">",
"       30",
"      </a>",
"      ]. Although capsules of fish oil are convenient, the amount of omega-3 contained in each capsule is equivalent to that found in one mL of cod liver oil; thus, a 20 mL dose of cod liver oil, which is the usual daily dose, provides roughly the same amount of such fatty acids as that found in 20 capsules of fish oil.",
"      <br/>",
"      <br/>",
"      In comparison to a typical \"Western\" diet, a Mediterranean diet generally derives fewer calories from animal fat and more from cereals and vegetable oils, particularly olive oil. Liberal intake of fresh fruits and beans as well as a moderate daily consumption of wine is also typical of this type of diet. The possible effects of a Mediterranean diet (MD) was the subject of a study in which 51 patients with RA were randomly assigned to a MD or to an omnivorous cuisine for 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/31\">",
"       31",
"      </a>",
"      ]. While those subjects who ate a MD had more improvement in some measures of disease activity, other indicators were unchanged. There was little change noted in patient global-assessments in the omnivorous subjects nor in their disease activity scores. Since the intervention and assessment were not \"blinded\" in any fashion, a significant placebo effect in the group assigned to the Mediterranean diet cannot be excluded.",
"      <br/>",
"      <br/>",
"      These observations suggest that dietary factors that modify arachidonic acid-derived prostaglandin or leukotriene generation affect inflammatory and immunologic responses and may therefore ameliorate symptoms of rheumatic diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/1,2,5,10,11,28\">",
"       1,2,5,10,11,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The role of nutritional supplements? A number of substances, including copper, zinc, and vitamin B, have been reported to be helpful for patients with arthritis. In general, however, the evidence in support of such claims is scant (",
"      <a class=\"graphic graphic_table graphicRef61494 \" href=\"UTD.htm?23/63/24572\">",
"       table 2",
"      </a>",
"      ). As an example, although copper salts have been antirheumatic in clinical trials, their use was associated with many adverse effects; as a result, copper salts have not evolved as an important therapeutic agent. In another study, some patients with RA benefited from oral zinc; however, the improvement was modest and inconsistent, and was not confirmed in other studies. In addition, although the administration of L-histidine has helped a small set of patients with RA, it has not emerged as an important agent. Evidence to support the efficacy of vitamin C for arthritis patients is also lacking [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/1,2,5,10,11,28\">",
"       1,2,5,10,11,28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      While concentrations of vitamin B6 are reduced in the serum of patients with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/32\">",
"       32",
"      </a>",
"      ] and levels of pyridoxal 5' phosphate, the active metabolite of B6, are inversely correlated with disease activity [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/33\">",
"       33",
"      </a>",
"      ]; there is at present no convincing evidence that supplementing the diet with vitamin B6 has any beneficial effect on disease activity or associated disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A general overview of dietary supplements is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Herbal remedies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various herbal preparations are undergoing investigation for possible benefit for arthritis. A good example is a Chinese herbal remedy (an alcohol extract of Tripterygium wilfordii Hook F, TwHF) for rheumatoid arthritis (RA), with suggestive immunosuppressive properties [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/34\">",
"     34",
"    </a>",
"    ]. A well designed study randomly assigned 35 patients with RA to placebo or one of two doses (180 or 360",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    of an",
"    <span class=\"nowrap\">",
"     alcohol/ethyl",
"    </span>",
"    acetate extract of the herb [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/35\">",
"     35",
"    </a>",
"    ]. A dose-response relation was noted with ACR 20 responses of 80, 40, and zero percent in the high-dose, low-dose, and placebo groups, respectively; ACR 50 responses were note in 50, 10, and zero percent. Self-limited diarrhea developed more often during active treatment than with placebo (in approximately one-third and none, respectively).",
"   </p>",
"   <p>",
"    Another randomized trial compared TwHF with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    in 121 patients with RA; only 62 and 41 percent of those receiving TwHF (60 mg three",
"    <span class=\"nowrap\">",
"     times/day)",
"    </span>",
"    and sulfasalazine (1 gm",
"    <span class=\"nowrap\">",
"     twice/day),",
"    </span>",
"    respectively, completed the study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/36\">",
"     36",
"    </a>",
"    ]. Among those who completed the study, an ACR20 response was achieved significantly more often after 24 weeks of treatment by patients receiving TwHF (68 versus 36 percent). HAQ scores and IL-6 levels improved more with TwHF, but there was no difference in ESR and CRP. There was a 2.4 point improvement in the DAS28 with TwHF. Adverse event rates were similar in the two groups. Additional clinical study and further investigation into the mechanism of the beneficial antiinflammatory effects of this herbal preparation will be valuable.",
"   </p>",
"   <p>",
"    Additional herbs and dietary supplements that have been studied in patients with RA include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those that showed some promising results: two Ayurvedic mixtures, borage, garlic, Phytodolor, Uncaria tomentosa, fish oil, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"     </li>",
"     <li>",
"      Others that were not associated with any clinical improvement, including blackcurrant (Ribes nigrum), Boswellia serrat, evening primrose (eg, from Oenothera biennis and Oenothera lamarckiana), feverfew (Tanacetum parthenium), and green-lipped mussels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, all the studies were small, the effects were modest at best, and need confirmation in standardized trials.",
"   </p>",
"   <p>",
"    Other herbal preparations have been promoted as treatments for osteoarthritis. One systematic review concluded that there was as yet no evidence of a significant benefit with Eazmov, Gitadyl, or ginger extract [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/38\">",
"     38",
"    </a>",
"    ]; by comparison, there was some evidence of efficacy (decreased pain) for Reumalex (a combination of willow bark, guaiacum resin, black cohosh, sarsaparilla, and poplar bark), willow bark alone, stinging nettle, Articulin F (a proprietary combination of Boswellia serrata [Indian frankincense], Withania somnifera [winter cherry], turmuric and zinc), devils claw, extract of soybean and avocado unsaponifiables (ASU), Phytodolor (a combination of poplar bark, ash bark, and goldenrod), and capsaicin cream. These will require rigorous well controlled randomized study to confirm putative salutary effects.",
"   </p>",
"   <p>",
"    A general overview of herbal medicine is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the newer biologic agents, such as monoclonal antibodies, interleukins, cytokines, and similar products, are exciting because of their potential, and for some, their established clinical value. Even those biologic agents whose therapeutic roles are still being evaluated, are not usually considered \"alternative\" remedies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional \"complementary\" and \"alternative\" remedies and their possible efficacy include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although venoms affect inflammatory and immune responses in vitro, they have no documented clinical utility. Indeed, a \"beekeepers\" arthritis has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      New pharmacologic approaches are of interest; some (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      ) may receive further attention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=see_link\">",
"       \"Investigational approaches to the pharmacologic therapy of osteoarthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"       Dimethyl sulfoxide",
"      </a>",
"      (DMSO) and hyperbaric oxygen are not of proven value [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/1,5,10,19,21,22\">",
"       1,5,10,19,21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Laser therapy, utilizing low power light sources, has been evaluated for both rheumatoid arthritis and osteoarthritis. A systematic review of reported clinical trials reported that laser treatment of the hands of patients with rheumatoid arthritis provided significant benefits [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/40\">",
"       40",
"      </a>",
"      ]. By comparison, consistent trends have not been observed in those with osteoarthritis. It is difficult to provide any specific recommendations regarding low level laser therapy because of variations in protocols, including laser intensity, duration, wavelength, and frequency of treatments.",
"     </li>",
"     <li>",
"      Homeopathy and biofeedback have shown varying degrees of benefit in certain situations; however, these studies have not been confirmed [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/1,5,6,21,22,41\">",
"       1,5,6,21,22,41",
"      </a>",
"      ]. The subject of homeopathy is reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26903?source=see_link\">",
"       \"Homeopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acupuncture has not been found effective in patients with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/42,43\">",
"       42,43",
"      </a>",
"      ], and is not a risk-free procedure. A review of reported complications included two deaths due to needle injuries to the heart and 90 pneumothoraces, of which two were fatal [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7607?source=see_link\">",
"       \"Acupuncture for rheumatic conditions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although popular, permanent magnets appear to be without benefit in patients with chronic low back pain as demonstrated in a pilot randomized trial of 20 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/45\">",
"       45",
"      </a>",
"      ]. They also appear to be no better than placebo in relieving wrist pain in patients with carpal tunnel syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/46\">",
"       46",
"      </a>",
"      ]. Improvement in pain and function have been reported in some studies of patients with osteoarthritis of the knee or hip [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. Blinding is a problem, as subjects can often discern the difference between magnetic devices and nonmagnetic or weakly magnetic (placebo) controls. Pulsed magnetic fields were not more effective than a sham treatment for patients with osteoarthritis of the knee [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reports have evaluated the possible efficacy for certain patients with rheumatoid or osteoarthritis of multiple different therapies, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/50\">",
"       50",
"      </a>",
"      ], manipulation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/51\">",
"       51",
"      </a>",
"      ], electromagnetic radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/52\">",
"       52",
"      </a>",
"      ], photo- (chemo-) pheresis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/53,54\">",
"       53,54",
"      </a>",
"      ], yoga [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/55\">",
"       55",
"      </a>",
"      ], mud [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/56\">",
"       56",
"      </a>",
"      ], prayer or distant healing [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/57,58\">",
"       57,58",
"      </a>",
"      ], Ayurvedic medicine [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/59\">",
"       59",
"      </a>",
"      ], and perhaps chicken soup [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/60\">",
"       60",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      As an example, glucosamine hydrochloride and chondroitin sulfate have undergone vigorous long-term evaluation in a study sponsored by the NIH. Although generally safe, these remedies should be considered questionable (or investigational) approaches.",
"     </li>",
"     <li>",
"      I am also not aware of appropriate evidence-based observations to support recommendations for the use of methonyl-sulfonyl-methane (MSM) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/61\">",
"       61",
"      </a>",
"      ], cetyl myristoleate [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/62\">",
"       62",
"      </a>",
"      ], ginger [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/63\">",
"       63",
"      </a>",
"      ], or zinaxin [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Suggestive observations are available for s-adenosylmethionine (SAM-E) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/65\">",
"       65",
"      </a>",
"      ]; however, its use should be considered with caution in patients with RA on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Pain relief from the application of leeches was reported in a study of 51 patients with osteoarthritis who were randomly assigned to have leeches (Hirudo medicinalis) or topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      applied to an affected knee [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/66\">",
"       66",
"      </a>",
"      ]. Significantly more pain relief was reported with leeching than with diclofenac when assessed at seven days. The benefit persisted for up to 28 days and was associated with improvements in stiffness and function. The lack of blinding of patients and assessors is a major potential source of bias and diminishes confidence in the results [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/67\">",
"       67",
"      </a>",
"      ]. Use of leeches also carries a risk of cellulitis and septicemia due to Aeromonas hydrophilia that colonize medicinal leeches. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23943?source=see_link\">",
"       \"Aeromonas infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A small beneficial effect of whole-body massage using a Swedish technique was suggested in a pilot study when compared to wait-listed controls [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted when reading reports of \"complementary\" and \"alternative\" remedies that the placebo effect can be quite powerful in patients with arthritis. In one preliminary report, for example, clinical improvement of as much as 50 percent occurred in up to 45 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, I do not consider that diet or other \"complementary\" or \"alternative\" therapies have a role in the routine management of rheumatic diseases. Nevertheless, examination of the role of diet and other questionable remedies in arthritis reminds us that it is occasionally salutary to critically reevaluate prevailing notions about therapies. For antimicrobials, diet, exercise, and perhaps others, this reexamination has led to new insights about the pathogenesis and therapy of rheumatic diseases. We therefore need to balance a healthy skepticism with a willingness to consider nontraditional concepts (",
"    <a class=\"graphic graphic_table graphicRef51906 \" href=\"UTD.htm?19/2/19499\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is important that we recognize the current limitations of science in enabling us to understand diseases and treat patients. We should therefore be cautious about being dogmatic in interpreting those notions not thoughtfully scrutinized; however, we should also be resolute against those ideas we are confident to be false and not questionable, and we should recognize that the ability to distinguish among these possibilities may be difficult. I believe that reason will ultimately triumph over superstition; as Bertrand Russell wrote, \"what science cannot tell us mankind cannot know.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ACR POSITION STATEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following position has been taken by the American College of Rheumatology (ACR) concerning \"complementary\" and \"alternative\" therapies (CAM) for rheumatic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &rdquo;The ACR recognizes the interest in CAM modalities. The ACR supports rigorous scientific evaluation of all modalities that improve the treatment of rheumatic diseases. The ACR understands that certain characteristics of some CAMs and some conventional medical interventions make it difficult or impossible to conduct standard randomized controlled trials. For these modalities, innovative methods of evaluation are needed, as are measures and standards for the generation and interpretation of evidence. The ACR supports the integration of those modalities proven to be safe and effective by scientifically rigorous clinical trials published in the biomedical peer review literature. The ACR advises caution for those not studied scientifically. The ACR believes healthcare providers should be informed about the more common CAM modalities, based upon appropriate scientific evaluation as described above, and should be able to discuss them knowledgeably with patients&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7513/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20123066\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians should be familiar with the common complementary and alternative remedies available for arthritis to facilitate effective communication with patients and colleagues. Therapies can be separated into those which are genuine (ie, those proven acceptably safe and effective), questionable, or ineffective. We distinguish between remedies that are mainstream and nonmainstream in the context of usual medical practice. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various factors contribute to the appeal of complementary and alternative remedies. These include seeking hope for understanding and a cure or relief from physical and emotional suffering due to the effects of the medical illness; as a response to psychosocial distress independent of illness severity; as a lifestyle choice; because of difficulty coping with the limitations of medicine, and uncertainty concerning outcome. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Appeal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinician&rsquo;s response to use of complementary and alternative remedies should include education of the patient and general public, and maintaining communication with the patient regarding these issues. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Medical response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that clinicians should not support the use of therapies that are generally not considered acceptably safe and effective. Potential harms of such therapies include adverse effects, failure to use accepted effective interventions, and financial cost. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hazards'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are a wide variety of complementary and alternative remedies for rheumatic disorders (",
"      <a class=\"graphic graphic_table graphicRef71871 \" href=\"UTD.htm?12/19/12605\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Selected \"complementary\" and \"alternative\" remedies'",
"      </a>",
"      above.) Among the more common are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antimicrobial agents (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Antimicrobials'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Special diets or dietary supplements (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Foods, diet and nutritional supplements'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Herbal remedies (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Herbal remedies'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Homeopathy, magnets, acupuncture, Ayurvedic medicine, and others (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Other'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Special diets or other \"complementary\" or \"alternative\" therapies do not have a role in the routine management of rheumatic diseases. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Perspective'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/1\">",
"      Panush RS. Is there a role for diet or other questionable therapies in managing rheumatic diseases? Bull Rheum Dis 1993; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     Panush RS.. Diet and rheumatic disease. In: Textbook of Rheumatology, Kelley WN, Harris ED, Ruddy S, et al (Eds), Saunders, Philadelphia 1994. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/3\">",
"      Panush RS. Alternative medicine: science or superstition? J Rheumatol 1994; 21:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/4\">",
"      Panush RS. Reflections on unproven remedies. Rheum Dis Clin North Am 1993; 19:201.",
"     </a>",
"    </li>",
"    <li>",
"     Panush RS. Diets, other \"Complementary\" and \"Alternative\" therapies, and the rheumatic diseases. In: Arthritis and Allied Conditions - A Textbook of Rheumatology, 14, Koopman WJ (Ed), Lippencott, Williams &amp; Wilkins, Baltimore 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/6\">",
"      Panush, RS. Food for thought, but not for arthritis. Primary Care Rheum 1992; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/7\">",
"      Panush RS, Carter RL, Katz P, et al. Diet therapy for rheumatoid arthritis. Arthritis Rheum 1983; 26:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/8\">",
"      Panush RS, Stroud RM, Webster EM. Food-induced (allergic) arthritis. Inflammatory arthritis exacerbated by milk. Arthritis Rheum 1986; 29:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/9\">",
"      Panush RS. Food induced (\"allergic\") arthritis: clinical and serologic studies. J Rheumatol 1990; 17:291.",
"     </a>",
"    </li>",
"    <li>",
"     Panush RS. Questionable remedies. In: The Primer on the Rheumatic Diseases, 11th Edition, Arthritis Foundation, Atlanta 1997. p.450.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/11\">",
"      Perlman AI, Eisenberg DM, Panush RS. Talking with patients about alternative and complementary medicine. Rheum Dis Clin North Am 1999; 25:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/12\">",
"      Panush RS. Shift happens: complementary and alternative medicine for rheumatologists. J Rheumatol 2002; 29:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/13\">",
"      Rao JK, Mihaliak K, Kroenke K, et al. Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med 1999; 131:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/14\">",
"      Rao JK, Kroenke K, Mihaliak KA, et al. Rheumatology patients' use of complementary therapies: results from a one-year longitudinal study. Arthritis Rheum 2003; 49:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/15\">",
"      Astin JA. Why patients use alternative medicine: results of a national study. JAMA 1998; 279:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/16\">",
"      Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999; 340:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/17\">",
"      Ernst E, Hung SK. Great expectations: what do patients using complementary and alternative medicine hope for? Patient 2011; 4:89.",
"     </a>",
"    </li>",
"    <li>",
"     The Arthritis Foundation guide to alternative therapies, Horstman J (Ed), Arthritis Foundation, Atlanta 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/19\">",
"      Dlesk A, Ettinger MP, Longley S, et al. Unconventional arthritis therapies. Arthritis Rheum 1982; 25:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/20\">",
"      Kraus A, Guerra-Bautista G, Alarc&oacute;n-Segovia D. Salmonella arizona arthritis and septicemia associated with rattlesnake ingestion by patients with connective tissue diseases. A dangerous complication of folk medicine. J Rheumatol 1991; 18:1328.",
"     </a>",
"    </li>",
"    <li>",
"     Panush RS, Katz P. Remedies of unlikely benefit. In: Rheumatoid Arthritis, Utsinger PD, Zvaifler NJ, Ehrlich GE (Eds), Lippincott, Philadelphia 1985. p.819.",
"    </li>",
"    <li>",
"     Panush RS, Longley S. Therapies of potential but unproven benefit. In: Rheumatoid Arthritis, Utsinger PD, Zvaifler NJ, Ehrlich GE (Eds), Lippincott, Philadelphia 1985. p.695.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/23\">",
"      Gabriel SE, Conn DL, Luthra H. Rifampin therapy in rheumatoid arthritis. J Rheumatol 1990; 17:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/24\">",
"      Caperton EM, Heim-Duthoy KL, Matzke GR, et al. Ceftriaxone therapy of chronic inflammatory arthritis. A double-blind placebo controlled trial. Arch Intern Med 1990; 150:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/25\">",
"      Wawrzynska-Pagowska J, Brzeziska B. [Treatment of rheumatoid arthritis with ampicillin: results of long-term observations indicating the possibility of inhibiting the progression of bone damage]. Reumatologia 1984; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/26\">",
"      Pritchard MH, Munro J. Successful treatment of juvenile chronic arthritis with a specific antiviral agent. Br J Rheumatol 1989; 28:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/27\">",
"      Panush RS, Lane NE. Exercise and the musculoskeletal system. Baillieres Clin Rheumatol 1994; 8:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/28\">",
"      Nutrition and rheumatic diseases. Rheum Dis Clin North Am 1991; 17:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/29\">",
"      Fortin PR, Lew RA, Liang MH, et al. Validation of a meta-analysis: the effects of fish oil in rheumatoid arthritis. J Clin Epidemiol 1995; 48:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/30\">",
"      Volker D, Fitzgerald P, Major G, Garg M. Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol 2000; 27:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/31\">",
"      Sk&ouml;ldstam L, Hagfors L, Johansson G. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/32\">",
"      Roubenoff R, Roubenoff RA, Selhub J, et al. Abnormal vitamin B6 status in rheumatoid cachexia. Association with spontaneous tumor necrosis factor alpha production and markers of inflammation. Arthritis Rheum 1995; 38:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/33\">",
"      Chiang EP, Bagley PJ, Selhub J, et al. Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. Am J Med 2003; 114:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/34\">",
"      Tao X, Davis LS, Lipsky PE. Effect of an extract of the Chinese herbal remedy Tripterygium wilfordii Hook F on human immune responsiveness. Arthritis Rheum 1991; 34:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/35\">",
"      Tao X, Younger J, Fan FZ, et al. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2002; 46:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/36\">",
"      Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med 2009; 151:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/37\">",
"      Ernst, E. Complementary and alternative therapies for rheumatoid arthritis. Int J Adv Rheumatol 2004; 2:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/38\">",
"      Long L, Soeken K, Ernst E. Herbal medicines for the treatment of osteoarthritis: a systematic review. Rheumatology (Oxford) 2001; 40:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/39\">",
"      Cuende E, Fraguas J, Pe&ntilde;a JE, et al. Beekeeper' arthropathy. J Rheumatol 1999; 26:2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/40\">",
"      Brosseau L, Welch V, Wells G, et al. Low level laser therapy for osteoarthritis and rheumatoid arthritis: a metaanalysis. J Rheumatol 2000; 27:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/41\">",
"      Bell IR, Lewis DA 2nd, Brooks AJ, et al. Improved clinical status in fibromyalgia patients treated with individualized homeopathic remedies versus placebo. Rheumatology (Oxford) 2004; 43:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/42\">",
"      Berman BM, Lao L, Greene M, et al. Efficacy of traditional Chinese acupuncture in the treatment of symptomatic knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1995; 3:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/43\">",
"      David J, Townsend S, Sathanathan R, et al. The effect of acupuncture on patients with rheumatoid arthritis: a randomized, placebo-controlled cross-over study. Rheumatology (Oxford) 1999; 38:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/44\">",
"      Peuker ET, White A, Ernst E, et al. Traumatic complications of acupuncture. Therapists need to know human anatomy. Arch Fam Med 1999; 8:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/45\">",
"      Collacott EA, Zimmerman JT, White DW, Rindone JP. Bipolar permanent magnets for the treatment of chronic low back pain: a pilot study. JAMA 2000; 283:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/46\">",
"      Carter R, Aspy CB, Mold J. The effectiveness of magnet therapy for treatment of wrist pain attributed to carpal tunnel syndrome. J Fam Pract 2002; 51:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/47\">",
"      Wolsko PM, Eisenberg DM, Simon LS, et al. Double-blind placebo-controlled trial of static magnets for the treatment of osteoarthritis of the knee: results of a pilot study. Altern Ther Health Med 2004; 10:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/48\">",
"      Harlow T, Greaves C, White A, et al. Randomised controlled trial of magnetic bracelets for relieving pain in osteoarthritis of the hip and knee. BMJ 2004; 329:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/49\">",
"      Thamsborg G, Florescu A, Oturai P, et al. Treatment of knee osteoarthritis with pulsed electromagnetic fields: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage 2005; 13:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/50\">",
"      Guti&eacute;rrez-Rodr&iacute;guez O. Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum 1984; 27:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/51\">",
"      Shekelle PG, Adams AH, Chassin MR, et al. Spinal manipulation for low-back pain. Ann Intern Med 1992; 117:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/52\">",
"      Trock DH, Bollet AJ, Markoll R. The effect of pulsed electromagnetic fields in the treatment of osteoarthritis of the knee and cervical spine. Report of randomized, double blind, placebo controlled trials. J Rheumatol 1994; 21:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/53\">",
"      Malawista SE, Trock DH, Edelson RL. Treatment of rheumatoid arthritis by extracorporeal photochemotherapy. A pilot study. Arthritis Rheum 1991; 34:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/54\">",
"      Laing TJ, Ike RW, Griffiths CE, et al. A pilot study of the effect of oral 8-methoxypsoralen and intraarticular ultraviolet light on rheumatoid synovitis. J Rheumatol 1995; 22:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/55\">",
"      Garfinkel MS, Schumacher HR Jr, Husain A, et al. Evaluation of a yoga based regimen for treatment of osteoarthritis of the hands. J Rheumatol 1994; 21:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/56\">",
"      Sukenik S, Giryes H, Halevy S, et al. Treatment of psoriatic arthritis at the Dead Sea. J Rheumatol 1994; 21:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/57\">",
"      Matthews DA. Prayer and spirituality. Rheum Dis Clin North Am 2000; 26:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/58\">",
"      Astin JA, Harkness E, Ernst E. The efficacy of \"distant healing\": a systematic review of randomized trials. Ann Intern Med 2000; 132:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/59\">",
"      Chopra A, Lavin P, Patwardhan B, Chitre D. Randomized double blind trial of an ayurvedic plant derived formulation for treatment of rheumatoid arthritis. J Rheumatol 2000; 27:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/60\">",
"      Panush, RS. Rx of the month: Chicken soup. ACR News 1994; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     Lawrence, RM. Methyl-sulfonyl-methane (MSM): A double-blind study of its use in degenerative arthritis: A preliminary correspondance. Personal communication, Tina Pavune, UC Berkeley Wellness letter. May 19, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/62\">",
"      Diehl HW, May EL. Cetyl myristoleate isolated from Swiss albino mice: an apparent protective agent against adjuvant arthritis in rats. J Pharm Sci 1994; 83:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/63\">",
"      Srivastava KC, Mustafa T. Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. Med Hypotheses 1992; 39:342.",
"     </a>",
"    </li>",
"    <li>",
"     Cush, JJ, Spiera, RF. Zinaxin (Ginger root): Physician information. ACR Hotline. American College of Rheumatology. Atlanta 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/65\">",
"      Schumacher HR Jr. Osteoarthritis: the clinical picture, pathogenesis, and management with studies on a new therapeutic agent, S-adenosylmethionine. Am J Med 1987; 83:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/66\">",
"      Michalsen A, Klotz S, L&uuml;dtke R, et al. Effectiveness of leech therapy in osteoarthritis of the knee: a randomized, controlled trial. Ann Intern Med 2003; 139:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/67\">",
"      Hochberg MC. Multidisciplinary integrative approach to treating knee pain in patients with osteoarthritis. Ann Intern Med 2003; 139:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/68\">",
"      Perlman AI, Sabina A, Williams AL, et al. Massage therapy for osteoarthritis of the knee: a randomized controlled trial. Arch Intern Med 2006; 166:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7513/abstract/69\">",
"      Weinblatt, ME, Maier, AL, Emery, P. Substantial placebo response in active rheumatoid arthritis (RA). Arthritis Rheum 1990; 33:S152.",
"     </a>",
"    </li>",
"    <li>",
"     Position statement on \"complementary\" and \"alternative\" therapies for rheumatic diseases. American College of Rheumatology, Atlanta 1998.",
"    </li>",
"    <li>",
"     American College of Rheumatology Position Statement: Complementary and alternative medicine for rheumatic diseases. August, 2008. www.rheumatology.org/practice/clinical/position/complementary.pdf (Accessed on August 24, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7979 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-DE299E3F9D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7513=[""].join("\n");
var outline_f7_21_7513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20123066\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      APPEAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MEDICAL RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HAZARDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SELECTED \"COMPLEMENTARY\" AND \"ALTERNATIVE\" REMEDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Foods, diet and nutritional supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Herbal remedies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ACR POSITION STATEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20123066\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7979\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7979|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/19/12605\" title=\"table 1\">",
"      Questionable arthritis remedies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/63/24572\" title=\"table 2\">",
"      Summary table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/2/19499\" title=\"table 3\">",
"      Principles of alternative remed",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7607?source=related_link\">",
"      Acupuncture for rheumatic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23943?source=related_link\">",
"      Aeromonas infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26903?source=related_link\">",
"      Homeopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=related_link\">",
"      Initial treatment of mildly active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=related_link\">",
"      Investigational approaches to the pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_21_7514="Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy";
var content_f7_21_7514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/21/7514/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/21/7514/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/21/7514/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/21/7514/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/21/7514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/21/7514/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/21/7514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease most often (60 to 70 percent) caused by mutations in one of several sarcomere genes which encode components of the contractile apparatus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCM is characterized by left ventricular hypertrophy of various morphologies, with a wide array clinical manifestations and hemodynamic abnormalities (",
"    <a class=\"graphic graphic_figure graphicRef58156 \" href=\"UTD.htm?11/9/11411\">",
"     figure 1",
"    </a>",
"    ). Depending in part upon the site and extent of cardiac hypertrophy, HCM patients can develop one or more of the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LV outflow obstruction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"       \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diastolic dysfunction",
"     </li>",
"     <li>",
"      Myocardial ischemia",
"     </li>",
"     <li>",
"      Mitral regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These structural and functional abnormalities can produce a variety of symptoms, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Presyncope or syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In broad terms, the symptoms related to HCM can be categorized as those related to heart failure (HF), chest pain, or arrhythmias. Patients with HCM have an increased incidence of both supraventricular and ventricular arrhythmias and are at an increased risk for sudden cardiac death (SCD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A resting or exercise provoked left ventricular outflow tract (LVOT) gradient is present in most patients with HCM (70 percent). Significant LVOT obstruction at rest, present in 20-30 percent, is an independent predictor of poor prognosis in patients with HCM. Four major approaches are available for treatment of LVOT obstruction in patients with HCM (",
"    <a class=\"graphic graphic_algorithm graphicRef86793 \" href=\"UTD.htm?29/22/30048\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pharmacologic therapy",
"     </li>",
"     <li>",
"      Septal myectomy",
"     </li>",
"     <li>",
"      Nonsurgical septal reduction with alcohol (ethanol) ablation",
"     </li>",
"     <li>",
"      Dual chamber pacing (which has only a limited role)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The non-pharmacologic treatment of patients with HCM will be reviewed here. Other issues such as the clinical manifestations, natural history, management of arrhythmias, and medical therapy of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link\">",
"     \"Natural history of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of therapy depends upon the clinical presentation. Most asymptomatic patients do not require therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef86793 \" href=\"UTD.htm?29/22/30048\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cardiac arrest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of sudden cardiac death (SCD) are at high risk for recurrence and should receive prophylactic treatment with an implantable cardioverter-defibrillator (ICD). These patients should also undergo investigations to determine the potential mechanism such as myocardial ischemia, LV outflow obstruction, supraventricular or ventricular tachycardia, or bradycardia. More than one mechanism is often identified; these factors should be treated aggressively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Syncope or presyncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;LV outflow obstruction is an important cause of syncope or presyncope. Arrhythmias (both brady- and tachycardias) and myocardial ischemia are other causes of syncope in HCM. Syncope can also be due to causes that are unrelated to HCM (eg, neurocardiogenic syncope) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/1\">",
"     1",
"    </a>",
"    ]. Unexplained syncope is considered a risk factor for SCD and warrants consideration of an ICD, particularly if a treatable mechanism has not been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chest pain or dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with chest pain or dyspnea are initially treated with negative inotropic agents, such as beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    . The medical management of HCM is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If symptoms persist despite maximal medical therapy or drugs are not tolerated, the subsequent approach depends upon whether the patient has obstructive or nonobstructive HCM. The nonpharmacologic therapies described below are appropriate only for patients with persistent symptoms and severe resting or provocable outflow tract obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Relief of outflow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy of outflow obstruction in HCM is to reverse or reduce the pathophysiologic factors responsible for the obstruction; these include septal hypertrophy and inward movement and bulging of the interventricular septum during systole and anterior displacement of the mitral valve during systole (SAM) due to high LV outflow tract blood velocities that pull the mitral valve leaflet toward the interventricular septum (Venturi effect). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Sequential approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;LV outflow obstruction can be reduced or eliminated by maneuvers that increase LV chamber size or decrease cardiac inotropy, thereby diminishing SAM. This can be achieved with pharmacologic or nonpharmacologic therapy.",
"   </p>",
"   <p>",
"    Pharmacologic therapy is the first-line approach in symptomatic obstructive HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If significant symptoms are refractory to medical therapy, the next step is surgery or septal ablation. It has been estimated that these approaches are required in approximately 5 percent of all patients with HCM and up to 30 percent in tertiary referral populations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/2\">",
"     2",
"    </a>",
"    ]. Dual chamber pacing can be tried in some patients, but this is now primarily performed in patients undergoing ICD implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CARDIAC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with obstructive HCM who are severely symptomatic (New York Heart Association [NYHA] functional class III or IV) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ), or have recurrent syncope despite pharmacologic therapy are candidates for cardiac surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Septal myectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;With septal myectomy, the proximal septum is approached through the aortic valve via an aortotomy and 3 to 15 g of septal muscle is removed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/3-10\">",
"     3-10",
"    </a>",
"    ]. The procedure is effective only if the myectomy is sufficiently extensive, involves the area of septum adjacent to mitral-septal contact (due to SAM), and eliminates or significantly reduces the left ventricular outflow tract (LVOT) gradient. Intraoperative echocardiography is vital in guiding the surgeon during this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extended septal myectomy and surgical repair of mitral subvalvular anomalies have been developed to more effectively reduce outflow and midventricular obstruction as well as mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Perioperative mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of septal myectomy performed through the mid-1990s described in-hospital mortality rates of 4 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/9,10,13\">",
"     9,10,13",
"    </a>",
"    ], with higher rates in patients over 65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/10\">",
"     10",
"    </a>",
"    ]. However, more recent series from experienced centers have described very low perioperative mortality rates as illustrated by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from the Cleveland Clinic, there were two deaths among 194 patients (1 percent) who underwent surgical myectomy between 1994 and 1999 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/15\">",
"       15",
"      </a>",
"      ]. However, there was no mortality between 1997 and 1999.",
"     </li>",
"     <li>",
"      In a series of 338 patients from Toronto General Hospital between 1978 and 1992, the mortality rate fell after surgical myectomy from 2.1 percent in the first 193 patients to 0.7 percent (one death) in the last 145 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In review of 289 consecutive patients who underwent surgical myectomy at the Mayo Clinic, there were two operative deaths (perioperative mortality 0.8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/18\">",
"       18",
"      </a>",
"      ]. Patients in whom mitral valve surgery or coronary artery bypass graft surgery were performed at the time of myectomy were excluded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients undergoing more complicated surgery (eg, concurrent valve replacement or coronary artery bypass graft surgery) have a higher mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. In the series from Toronto General Hospital, the 30-day mortality rate was 3.4 percent in the 89 patients who had any concomitant surgical procedure compared to 0.8 percent in 249 patients who underwent myectomy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of myectomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excessive removal of muscle can cause a ventricular septal defect, a serious complication that may be more common in patients with a mildly hypertrophied relatively thin septum [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/7,14,19\">",
"       7,14,19",
"      </a>",
"      ]. In the review of 338 patients from Toronto General Hospital, ventricular septal defect occurred in 2 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/14\">",
"       14",
"      </a>",
"      ]. Intraoperative echocardiography helps to avoid this complication and should be used for monitoring in all cases [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inadequate intraoperative protection of the hypertrophied muscle against ischemia may result in LV dysfunction at a later date.",
"     </li>",
"     <li>",
"      Traction on the aortic valve to improve visualization of and access to the interventricular septum may cause aortic regurgitation that may necessitate subsequent aortic valve replacement [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Development of left bundle branch block (LBBB) or complete heart block (CHB) requiring a permanent pacemaker occurs postoperatively in approximately 5 to 10 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/7,16,21,22\">",
"       7,16,21,22",
"      </a>",
"      ]. Injury to the left bundle branch is more common with myectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/15,22\">",
"       15,22",
"      </a>",
"      ]. Thus, patients with right bundle branch block at baseline are at increased risk for CHB [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/22\">",
"       22",
"      </a>",
"      ]. The risk is much lower (1 in 102 patients at the Mayo Clinic) in patients with a normal QRS interval at baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Long-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;LV myectomy results in resolution of the LVOT gradient and improvement in symptoms in almost all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In the series of 338 patients from Toronto General Hospital, 72 percent of patients had NYHA class III or IV symptoms (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) at baseline; after myectomy, 83 percent of patients improved to NYHA class I or II and 98 percent had no resting LVOT gradient (mean preoperative value 66 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were noted in studies from the Cleveland Clinic and the Mayo Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. The mean LVOT gradient fell from 62 to 67 mmHg to 3 to 7 mmHg and the NYHA class improved from 2.9 to 3.3 before surgery to 1.5.",
"   </p>",
"   <p>",
"    In addition, myectomy may reduce mitral regurgitation in patients without independent mitral valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/23\">",
"     23",
"    </a>",
"    ], improve myocardial perfusion, reduce LV end-diastolic pressure and left atrial size [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], and regress hypertrophy of other myocardial segments [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term survival is excellent after surgical myectomy at experienced centers. In the Mayo Clinic series, survival after myectomy was 98, 96, and 83 percent at one, five, and ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/18\">",
"     18",
"    </a>",
"    ]. These values did not differ from those in patients with nonobstructive HCM or matched controls in the general population but were significantly higher than in a group of 228 patients with obstructive HCM who were managed medically in whom the survival rate at these times was 90, 79, and 61 percent. The mortality benefit compared to nonoperated obstructive HCM included reductions in both HCM-related mortality and sudden cardiac death.",
"   </p>",
"   <p>",
"    Virtually identical values (98, 95, and 83 percent at one, five, and ten years) were noted at the Toronto General Hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/16\">",
"     16",
"    </a>",
"    ]. There were five independent predictors of overall mortality: concomitant CABG, preoperative history of atrial fibrillation, preoperative left atrial diameter &ge;46 mm, age &ge;50 years, and female gender.",
"   </p>",
"   <p>",
"    A retrospective analysis from a single center found that HCM patients who had undergone septal myectomy had a lower rate of appropriate ICD discharges as compared to a non-myectomy HCM group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mitral valve repair/replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral valve repair at the time of myectomy may be required in selected patients with elongated leaflets or mitral regurgitation caused by primary valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Extended septal myectomy and surgical repair of mitral subvalvular anomalies have been developed to more effectively reduce outflow and midventricular obstruction as well as mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mitral valve replacement, with or without myectomy, is usually limited to patients with primary mitral valve pathology and is now infrequently performed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Mitral valve replacement should not be performed for relief of LVOT obstruction if septal reduction therapy is an option [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/1\">",
"     1",
"    </a>",
"    ]. In the Mayo Clinic experience, less than 1 percent of obstructive HCM patients underwent mitral valve replacement without myectomy between 1972 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DUAL CHAMBER PACING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early 1990s, dual chamber pacing was presented as an alternative to myectomy to improve symptoms and reduce left ventricular outflow tract obstruction. Observational studies and small randomized trials suggested symptomatic and functional benefit from pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. However, subsequent data from single and multicenter randomized trials, particularly M-PATHY, demonstrated average LVOT gradient reductions of only 50 percent without improvement in exercise capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/14,39,40\">",
"     14,39,40",
"    </a>",
"    ]. The perceived symptomatic improvement was largely explained as a placebo effect [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines that recommended use of a pacemaker in patients with HCM for sinus node dysfunction or AV block [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/42\">",
"     42",
"    </a>",
"    ]. Permanent pacing may be considered (evidence is not well established) in medically refractory symptomatic patients with HCM and significant resting or provoked left ventricular outflow tract obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Patient selection and programming",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pacing is not a primary treatment of HCM, a small subset of predominantly older patients with localized mild septal hypertrophy may benefit from dual chamber pacemaker treatment. In such patients, this option should be considered when there are relative or absolute contraindications to surgery or alcohol ablation, usually because of",
"    <span class=\"nowrap\">",
"     septum/mitral",
"    </span>",
"    valve anatomy or comorbidities.",
"   </p>",
"   <p>",
"    Success of dual chamber pacing is dependent upon patient selection and appropriate programming of the pacemaker with adequate ventricular preexcitation. The RV pacing lead positioned at the apex must activate most of the LV myocardium before native conduction does.",
"   </p>",
"   <p>",
"    If the programmed AV delay is equal to or greater than the intrinsic AV conduction, significant preexcitation will not be induced and the patient is less likely to have clinical improvement. This is most likely to occur in patients with rapid AV nodal conduction, which is present in about 10 percent of patients with HCM, or during exercise.",
"   </p>",
"   <p>",
"    However, programming of AV intervals that are very short in order to ensure ventricular capture may lead to simultaneous contraction of the LV and left atrial chambers. Left atrial contraction in the presence of a closed mitral valve will result in pulmonary congestion and diminished LV diastolic filling, thereby reducing cardiac output. In some patients, the proper sequence of atrial and ventricular contraction can only be ensured by delaying AV node conduction with a beta blocker,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , or radiofrequency ablation of the AV node [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ALCOHOL (ETHANOL) SEPTAL ABLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous transluminal septal myocardial ablation, also called alcohol (ethanol) septal ablation, transcoronary ablation of septal hypertrophy, and nonsurgical septal reduction therapy, consists of infarction and thinning of the proximal interventricular septum via infusion of ethanol into the first septal perforating branch of the left anterior descending coronary artery through an angioplasty catheter (",
"    <a class=\"graphic graphic_figure graphicRef78141 \" href=\"UTD.htm?27/43/28342\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef81905 \" href=\"UTD.htm?43/46/44776\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58311 \" href=\"UTD.htm?3/36/3651\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alcohol ablation is being used more frequently as more interventional cardiologists are being trained in this procedure. There is a steep learning curve [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol septal ablation reduces LV outflow tract (LVOT) obstruction, improves symptoms, and increases exercise capacity. The benefit of septal ablation is comparable in younger and older (age &ge;60 years) patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proposed mechanisms of acute benefit are an improvement in LV relaxation and compliance via a reduction in regional asynchrony [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/50,51\">",
"     50,51",
"    </a>",
"    ], resulting in an increase in LV passive filling volume and a reduction in left atrial size and LV ejection force [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term benefit results from the creation of localized septal infarction and scarring, which increase the LV outflow diameter via septal thinning and \"therapeutic remodeling\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. The net effect is an increase in LV size and a decrease in LV mass and the extent of LV hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/48,55,56\">",
"     48,55,56",
"    </a>",
"    ], and alteration of septal activation, resulting in incoordination of contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reduction in nonseptal mass over time after ethanol septal ablation may indicate that myocardial hypertrophy in HCM is in part afterload-dependent and is not entirely due to the genetic defect [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Alternatively, infused alcohol may have damaged non-target areas of the myocardium.",
"   </p>",
"   <p>",
"    A meta-analysis of 42 observational studies (2959 patients, mean age 54) with mean follow-up of 13 months illustrated the range of results [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The resting and provoked left ventricular outflow tract gradients decreased from 65 and 125 mmHg to 15 and 31 mmHg at one year. There was also a significant reduction in mean basal septal thickness (20.9 to 13.9 mm at one year).",
"     </li>",
"     <li>",
"      The NYHA class improved from a mean of 2.9 to 1.2 (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ), peak oxygen consumption increased from 18 to 24",
"      <span class=\"nowrap\">",
"       mL/kg/min,",
"      </span>",
"      and mean exercise capacity increased from 325 to 438 seconds.",
"     </li>",
"     <li>",
"      Repeat alcohol septal ablation was performed in 6.6 percent of patients and surgical myectomy in 1.9 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individual observational studies suggested benefit in certain subsets of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among markedly symptomatic patients, alcohol ablation may be beneficial in patients with no resting LVOT gradient but a provocable gradient of &ge;30 mmHg. In a report of 45 such patients, the provocable gradient fell from 111 to 24 mmHg and NYHA class improved from 3.1 to 1.7; these changes were similar to those in patients with a resting gradient [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients who do not show initial benefit can have later improvement. This was illustrated in a series of 47 patients with a mean baseline LVOT gradient of 98 mmHg who underwent septal ablation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/60\">",
"       60",
"      </a>",
"      ]. All patients were followed with serial echocardiograms at three days, three months, and one year after the procedure. Among 22 patients who had no significant reduction in the LVOT gradient three days after the procedure, 16 had a significant improvement at three months. These late responders had a similar LVOT gradient at one year compared to those who improved immediately after the procedure (27 versus 13 mmHg, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Myocardial contrast echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial contrast echocardiography (MCE) can accurately delineate the size of the septal vascular territory and can predict the infarct size that will result from ethanol infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/61\">",
"     61",
"    </a>",
"    ]. In one series of patients treated with alcohol ablation, the use of MCE was associated with a higher rate of acute (92 versus 70 percent) and mid-term (94 versus 64 percent) procedural success than patients in whom MCE was not used [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/46\">",
"     46",
"    </a>",
"    ]. MCE also may lower the rate of complete heart block requiring pacemaker implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H20\">",
"     'Complete heart block'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of MCE for assessment of the myocardial infarct zone during alcohol ablation was given a class I recommendation by a 2003 task force of the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Society of Echocardiography",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ASE)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of alcohol septal ablation in patients with HCM include complete heart block, ventricular tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/63\">",
"     63",
"    </a>",
"    ], arrhythmic death, coronary dissection, pericardial effusion, and, although rare with experienced operators, large myocardial infarction resulting from escape of ethanol from the target vessel. ECG changes include transient QT prolongation, Q waves, right bundle branch block. An additional concern has been that subsequent scarring might increase the long-term incidence of ventricular arrhythmias, bradyarrhythmias, and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of short to intermediate term complications was evaluated in the meta-analysis of 42 studies of 2959 patients undergoing alcohol septal ablation at a mean follow-up of 13 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/58\">",
"     58",
"    </a>",
"    ]. The mean 30 day mortality rate was 1.5 percent (range 0.0 to 5.0 percent) and mean mortality beyond 30 days was 0.5 percent (range 0 to 9.3 percent). Complications included ventricular fibrillation (2.2 percent), left anterior descending artery dissection (1.8 percent), pericardial effusion (0.6 percent) and complete heart block (10.5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Complete heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete heart block (CHB) requiring a pacemaker occurs in 14 to 25 percent of patients after alcohol ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/15,17,21,65-67\">",
"     15,17,21,65-67",
"    </a>",
"    ]. In a report of 261 consecutive patients, significant predictors for this complication on multivariate analysis included LBBB or first degree AV block prior to the procedure, injection of ethanol by bolus rather than infusion, lack of use of MCE, injection of more than one septal artery, and female sex [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/65\">",
"     65",
"    </a>",
"    ]. The incidence of CHB fell from 33 percent initially to 10 percent in the last 191 patients in whom ethanol was given by infusion and MCE guidance was used.",
"   </p>",
"   <p>",
"    Injury to the right bundle branch is much more common than injury to the left bundle branch with alcohol ablation (54 versus 6 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/66\">",
"     66",
"    </a>",
"    ], probably because the right bundle branch and the left anterior fascicle are usually supplied by septal branches of the left anterior descending artery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/15,22,66\">",
"     15,22,66",
"    </a>",
"    ]. The predilection for involvement of the right bundle branch probably explains why LBBB at baseline is a risk factor for CHB [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of CHB and its relation to other conduction abnormalities was addressed in smaller series of patients undergoing alcohol ablation in single centers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Among 52 procedures in 48 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/66\">",
"     66",
"    </a>",
"    ] and 172 procedures in 172 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/67\">",
"     67",
"    </a>",
"    ], the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of transient CHB during the procedure was substantially different in the two studies (62 and 21 percent, respectively). Atrioventricular conduction returned to baseline within one to three hours.",
"     </li>",
"     <li>",
"      The mean time to development of delayed CHB was 36 and 75 hours after the procedure.",
"     </li>",
"     <li>",
"      In the report of 52 procedures, delayed CHB developed in 13 (25 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/66\">",
"       66",
"      </a>",
"      ]. Twelve of these patients had prior transient CHB and 10 also had new conduction abnormalities, predominantly RBBB. Delayed CHB developed in only 1 of the 20 who did not have transient CHB during the procedure. This patient had new bifascicular block after the procedure.",
"     </li>",
"     <li>",
"      In the series of 172 procedures, delayed CHB developed in 15 patients (9 percent), all of whom lacked retrograde atrioventricular nodal conduction after alcohol ablation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/67\">",
"       67",
"      </a>",
"      ]. Patients with retrograde atrioventricular block after alcohol ablation and at least one additional risk factor (intraprocedural complete heart block, age &gt;58 years, QRS &gt;120 msec) had a 26 percent risk of delayed CHB.",
"     </li>",
"     <li>",
"      In the latter study, permanent pacemakers were implanted in 20 of 172 patients (12 percent), 15 with delayed CHB and 5 with intraprocedural CHB lasting more than two hours [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/67\">",
"       67",
"      </a>",
"      ]. At six-month follow-up, permanent CHB was present in three of these patients (15 percent). Thus 3 of 172 (1.7 percent) of patients undergoing alcohol septal reduction were rendered pacemaker dependent. The long-term rates of temporary pacemaker dependency were not reported in either study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transient conduction abnormalities were presumed to be due to the acute effects of alcohol on the myocardium and conduction system (eg, ischemia, edema, and inflammation), while permanent conduction abnormalities were probably due to necrosis, scarring, and possibly remodeling.",
"   </p>",
"   <p>",
"    Based upon the above observations, some have suggested continuing temporary pacing for &ge;48 hours after alcohol ablation or for &ge;48 hours after the resolution of transient CHB [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/66\">",
"     66",
"    </a>",
"    ]. Continuation of temporary pacing up to six days after alcohol ablation has been suggested for patients with retrograde atrioventricular block and at least one additional risk factor as defined above [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit from alcohol ablation does not appear to be less in patients who develop CHB compared to those who do not. With the exception of the requirement for pacemaker insertion, the clinical and echocardiographic outcomes for patients who developed CHB in the above series of 261 patients were not different from those without CHB, with comparable improvements in NYHA class and exercise time and comparable reductions in septal thickness and the LVOT gradient [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COMPARISON OF SEPTAL MYECTOMY AND SEPTAL ABLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septal myectomy and septal ablation (nonsurgical septal reduction therapy with alcohol (ethanol) ablation, NSRT or alcohol ablation) are both performed in clinical practice. Randomized trials comparing the two approaches have not been performed, but several observational studies have compared the relative safety and efficacy of these procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Anatomic results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute morphological changes from septal myectomy and septal ablation were compared in a prospective study of 48 patients using serial cardiac magnetic resonance (CMR) imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/68\">",
"     68",
"    </a>",
"    ]. Patients with LV outflow gradients &ge;50 mmHg and NYHA class III to IV symptoms were offered surgical myectomy as primary treatment, with ethanol ablation offered as an alternative: 24 patients underwent each procedure. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated with septal ablation were older than those treated with myectomy (62 versus 50 years), but otherwise there were no significant differences in baseline characteristics between the two groups.",
"     </li>",
"     <li>",
"      Surgical septal myectomy consistently resulted in resection of the obstructing portion of the anterior basal septum. There was no evidence of myocardial necrosis.",
"     </li>",
"     <li>",
"      The results were more variable in patients treated with septal ablation. In 75 percent of patients, there was transmural necrosis of the inferior basal septum. In 25 percent of patients, there was sparing of the proximal basal septum with nontransmural necrosis in the distal basal septum and residual gradients at follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Clinical outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both septal myectomy and septal ablation reduce LV outflow tract obstruction and improve NYHA class in HCM although complications and some outcomes differ. Similarities and differences in results were illustrated by nonrandomized studies, five of which were included in a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/69\">",
"     69",
"    </a>",
"    ]. Of 351 symptomatic HCM patients included in the meta-analysis, 183 underwent alcohol septal ablation and 168 underwent septal myectomy. Baseline left ventricular outflow gradients were similar in the septal ablation and myectomy groups (81 versus 77 mmHg). Patients undergoing septal ablation were significantly older (mean age 54 versus 45 years).",
"   </p>",
"   <p>",
"    The following findings were noted at a mean follow-up was approximately two years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In-hospital mortality was not significantly different between the groups (0.6 percent for septal myectomy versus 1.6 percent for septal ablation).",
"     </li>",
"     <li>",
"      The improvement in NYHA class was similar in the two treatment groups (1.3 versus 1.5) (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Septal myectomy was associated with the following benefits: a lower rate of permanent pacemaker implantation for complete heart block (3.3 versus 18.4 percent), a lower left ventricular outflow gradient (mean difference 6.6 mmHg), and a lower rate of a repeat or follow-up procedure (septal ablation or myectomy) for recurrent left ventricular outflow tract obstruction (0.6 versus 5.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, since this meta-analysis included studies performed while alcohol septal ablation technique evolved, the reported rate of permanent pacemaker implantation with septal ablation may be higher than expected using current techniques. One of the studies reported that use of myocardial contrast echocardiography and slow ethanol injection was associated with a lower rate of complete heart block (8 versus 22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Advantages of each procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the medium-term outcome with these two approaches are similar, there are advantages to each [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/1,15,70-74\">",
"     1,15,70-74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advantages of surgical septal myectomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher success rate for septal myectomy (about 90 to 95 percent) than for septal ablation (about 80 to 90 percent) in relieving resting and provoked obstruction.",
"     </li>",
"     <li>",
"      Immediate sustained relief of obstruction and concomitant mitral regurgitation as compared to septal ablation in which improvement in obstruction may be delayed by up to three months.",
"     </li>",
"     <li>",
"      Lower incidence of CHB requiring pacemaker insertion (about 3 percent with septal myectomy versus 10 to 15 percent for septal ablation guided by myocardial contrast echocardiography).",
"     </li>",
"     <li>",
"      Better symptom resolution has been observed with myectomy than with septal ablation in patients &le;65 years old.",
"     </li>",
"     <li>",
"      Proven long-term (&gt;20 years) efficacy; similar data with septal ablation are not yet available. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Long-term outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No risk of coronary dissection and minimal risk of myocardial damage remote from the septum",
"     </li>",
"     <li>",
"      The ability to treat concomitant problems, such as mid-ventricular obstruction, constricting muscle bridges, coronary disease requiring CABG, right ventricular outflow obstruction, and mitral valve disease",
"     </li>",
"     <li>",
"      Evidence suggests that myectomy may reduce the risk of SCD and appropriate ICD discharges [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/18,28\">",
"       18,28",
"      </a>",
"      ], while septal ablation has not been demonstrated to reduce SCD or ICD discharge rates.",
"     </li>",
"     <li>",
"      Although both septal myectomy after failed septal ablation and septal ablation after failed septal myectomy have been successfully performed, the former is more common. Since septal ablation often causes right bundle-branch block and septal myectomy often causes left bundle branch block, patients undergoing both procedures incur a high risk of complete heart block and permanent pacemaker dependence [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/75\">",
"       75",
"      </a>",
"      ]. Therefore, a strategy of primary septal myectomy may help avoid permanent pacemaker dependence [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantages of septal ablation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of sternotomy, cardiopulmonary bypass and their associated risks; this is of particular importance in elderly patients and those with comorbidities",
"     </li>",
"     <li>",
"      Shorter hospital stay and recovery time",
"     </li>",
"     <li>",
"      Among older patients, the risk of stroke is lower with septal ablation than with septal myectomy.",
"     </li>",
"     <li>",
"      The ability to treat CAD which requires percutaneous intervention",
"     </li>",
"     <li>",
"      Less expense",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of issues remain unresolved in comparing the two procedures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conclusive evidence on the comparative impact on clinical outcomes and survival is not available. The long-term survival benefits noted with surgical myectomy have not yet been demonstrated with septal ablation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The potential impact of ethanol induced myocardial necrosis on future arrhythmic risk is unknown. As noted above, retrospective data suggests that septal myectomy may be associated with reduction in risk of sudden death and ICD discharges. However no comparison of the impact of the two procedures on subsequent arrhythmic events is available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary indication for intervention in obstructive HCM is persistent moderate to severe symptoms or exercise limitation despite adequate tolerated drug therapy. In the series of LV myectomy cited above from Toronto General Hospital, the Cleveland Clinic, and the Mayo Clinic, NYHA class III to IV symptoms (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) were present in 72 to 89 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/15,16,18\">",
"     15,16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Septal myectomy and septal ablation should be performed in centers with large HCM treatment experience and demonstrable low procedural mortality rates, since patient selection, procedural expertise, periprocedural echocardiography, and management are important components of a successful outcome.",
"   </p>",
"   <p>",
"    Given the unknown long-term risk of serious cardiac arrhythmia after alcohol ablation, surgery may be the preferred option in young patients, particularly those with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/72,76\">",
"     72,76",
"    </a>",
"    ], and in patients with additional structural abnormalities affecting the mitral valve [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/31,76\">",
"     31,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most appropriate candidates for alcohol ablation should meet all of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/44,77\">",
"     44,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HCM with severe symptoms of heart failure (NYHA class III to IV) (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) despite adequate tolerated drug therapy",
"     </li>",
"     <li>",
"      An LVOT gradient that has been variably defined as &ge;50 mmHg at rest or after exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/44\">",
"       44",
"      </a>",
"      ] or &gt;30 mmHg at rest or &ge;60 mmHg after exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/77\">",
"       77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Basal septal thickness &ge;18 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another proposed criterion is NYHA class II heart failure with a resting LVOT gradient &gt;50 mmHg or &gt;30 mmHg at rest and &ge;100 mmHg with stress [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consideration of alcohol ablation in such patients is particularly appropriate if they are elderly or have comorbidities that may increase the risk of surgical correction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/21/7514/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/1\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/2\">",
"      Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/3\">",
"      Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975; 52:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/4\">",
"      Maron BJ, Epstein SE, Morrow AG. Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy. Eur Heart J 1983; 4 Suppl F:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/5\">",
"      Beahrs MM, Tajik AJ, Seward JB, et al. Hypertrophic obstructive cardiomyopathy: ten- to 21-year follow-up after partial septal myectomy. Am J Cardiol 1983; 51:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/6\">",
"      Schulte HD, Bircks WH, Loesse B, et al. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy. Late results up to twenty-five years. J Thorac Cardiovasc Surg 1993; 106:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/7\">",
"      ten Berg JM, Suttorp MJ, Knaepen PJ, et al. Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow-up after Morrow septal myectomy. Circulation 1994; 90:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/8\">",
"      Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 1996; 111:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/9\">",
"      Heric B, Lytle BW, Miller DP, et al. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg 1995; 110:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/10\">",
"      Mohr R, Schaff HV, Danielson GK, et al. The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy. Experience over 15 years. J Thorac Cardiovasc Surg 1989; 97:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/11\">",
"      Marwick TH, Stewart WJ, Lever HM, et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 20:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/12\">",
"      Minakata K, Dearani JA, Nishimura RA, et al. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. J Thorac Cardiovasc Surg 2004; 127:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/13\">",
"      Sch&ouml;nbeck MH, Brunner-La Rocca HP, Vogt PR, et al. Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy. Ann Thorac Surg 1998; 65:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/14\">",
"      Maron BJ, Dearani JA, Ommen SR, et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/15\">",
"      Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001; 38:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/16\">",
"      Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005; 111:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/17\">",
"      Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/18\">",
"      Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/19\">",
"      Siegman IL, Maron BJ, Permut LC, et al. Results of operation for coexistent obstructive hypertrophic cardiomyopathy and coronary artery disease. J Am Coll Cardiol 1989; 13:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/20\">",
"      Brown PS Jr, Roberts CS, McIntosh CL, Clark RE. Aortic regurgitation after left ventricular myotomy and myectomy. Ann Thorac Surg 1991; 51:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/21\">",
"      Qin JX, Shiota T, Lever HM, et al. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol 2004; 93:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/22\">",
"      Talreja DR, Nishimura RA, Edwards WD, et al. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol 2004; 44:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/23\">",
"      Yu EH, Omran AS, Wigle ED, et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000; 36:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/24\">",
"      Bonow RO. Left ventricular structure and function in aortic valve disease. Circulation 1989; 79:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/25\">",
"      Cannon RO 3rd, Dilsizian V, O'Gara PT, et al. Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation 1992; 85:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/26\">",
"      J&ouml;rg-Ciopor M, Namdar M, Turina J, et al. Regional myocardial ischemia in hypertrophic cardiomyopathy: impact of myectomy. J Thorac Cardiovasc Surg 2004; 128:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/27\">",
"      Deb SJ, Schaff HV, Dearani JA, et al. Septal myectomy results in regression of left ventricular hypertrophy in patients with hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 2004; 78:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/28\">",
"      McLeod CJ, Ommen SR, Ackerman MJ, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 2007; 28:2583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/29\">",
"      Maron BJ. Surgery for hypertrophic obstructive cardiomyopathy: alive and quite well. Circulation 2005; 111:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/30\">",
"      Kofflard MJ, van Herwerden LA, Waldstein DJ, et al. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 1996; 28:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/31\">",
"      van der Lee C, ten Cate FJ, Geleijnse ML, et al. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation 2005; 112:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/32\">",
"      Cooley DA, Wukasch DC, Leachman RD. Mitral valve replacement for idiopathic hypertrophic subaortic stenosis. Results in 27 patients. J Cardiovasc Surg (Torino) 1976; 17:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/33\">",
"      Walker WS, Reid KG, Cameron EW, et al. Comparison of ventricular septal surgery and mitral valve replacement for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 1989; 48:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/34\">",
"      McIntosh CL, Greenberg GJ, Maron BJ, et al. Clinical and hemodynamic results after mitral valve replacement in patients with obstructive hypertrophic cardiomyopathy. Ann Thorac Surg 1989; 47:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/35\">",
"      Dearani JA, Ommen SR, Gersh BJ, et al. Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy--the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med 2007; 4:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/36\">",
"      Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J 1997; 18:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/37\">",
"      Gadler F, Linde C, Daubert C, et al. Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. PIC study group. Pacing In Cardiomyopathy. Eur Heart J 1999; 20:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/38\">",
"      Gadler F, Linde C, Juhlin-Dannfelt A, et al. Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest. Eur Heart J 1997; 18:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/39\">",
"      Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999; 99:2927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/40\">",
"      Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 1997; 29:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/41\">",
"      Linde C, Gadler F, Kappenberger L, Ryd&eacute;n L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. Am J Cardiol 1999; 83:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/42\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/43\">",
"      Jeanrenaud X, Schl&auml;pfer J, Fromer M, et al. Dual chamber pacing in hypertrophic obstructive cardiomyopathy: beneficial effect of atrioventricular junction ablation for optimal left ventricular capture and filling. Pacing Clin Electrophysiol 1997; 20:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/44\">",
"      Kimmelstiel CD, Maron BJ. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2004; 109:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/45\">",
"      Knight C, Kurbaan AS, Seggewiss H, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997; 95:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/46\">",
"      Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998; 98:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/47\">",
"      Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999; 20:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/48\">",
"      Lakkis NM, Nagueh SF, Kleiman NS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998; 98:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/49\">",
"      Gietzen FH, Leuner CJ, Obergassel L, et al. Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients. Heart 2004; 90:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/50\">",
"      Nagueh SF, Lakkis NM, Middleton KJ, et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999; 99:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/51\">",
"      Park TH, Lakkis NM, Middleton KJ, et al. Acute effect of nonsurgical septal reduction therapy on regional left ventricular asynchrony in patients with hypertrophic obstructive cardiomyopathy. Circulation 2002; 106:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/52\">",
"      Nagueh SF, Lakkis NM, Middleton KJ, et al. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999; 34:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/53\">",
"      Flores-Ramirez R, Lakkis NM, Middleton KJ, et al. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 37:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/54\">",
"      Kuhn H, Gietzen FH, Sch&auml;fers M, et al. Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. Eur Heart J 1999; 20:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/55\">",
"      Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001; 103:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/56\">",
"      van Dockum WG, Beek AM, ten Cate FJ, et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2005; 111:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/57\">",
"      Henein MY, O'Sullivan CA, Ramzy IS, et al. Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999; 34:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/58\">",
"      Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interv Cardiol 2006; 19:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/59\">",
"      Gietzen FH, Leuner CJ, Obergassel L, et al. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation 2002; 106:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/60\">",
"      Yoerger DM, Picard MH, Palacios IF, et al. Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2006; 97:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/61\">",
"      Nagueh SF, Lakkis NM, He ZX, et al. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1998; 32:225.",
"     </a>",
"    </li>",
"    <li>",
"     Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline for the clinical application of echocardiography www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/63\">",
"      Boltwood CM Jr, Chien W, Ports T. Ventricular tachycardia complicating alcohol septal ablation. N Engl J Med 2004; 351:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/64\">",
"      Fananapazir L, McAreavey D. Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol 1998; 31:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/65\">",
"      Chang SM, Nagueh SF, Spencer WH 3rd, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 2003; 42:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/66\">",
"      Chen AA, Palacios IF, Mela T, et al. Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2006; 97:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/67\">",
"      Lawrenz T, Lieder F, Bartelsmeier M, et al. Predictors of complete heart block after transcoronary ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172 patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007; 49:2356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/68\">",
"      Valeti US, Nishimura RA, Holmes DR, et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007; 49:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/69\">",
"      Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. Eur Heart J 2009; 30:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/70\">",
"      Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008; 118:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/71\">",
"      Wigle ED, Schwartz L, Woo A, Rakowski H. To ablate or operate? that is the question! J Am Coll Cardiol 2001; 38:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/72\">",
"      Watkins H, McKenna WJ. The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/73\">",
"      Maron BJ. Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 2007; 116:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/74\">",
"      Fifer MA. Controversies in cardiovascular medicine. Most fully informed patients choose septal ablation over septal myectomy. Circulation 2007; 116:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/75\">",
"      ElBardissi AW, Dearani JA, Nishimura RA, et al. Septal myectomy after previous septal artery ablation in hypertrophic cardiomyopathy. Mayo Clin Proc 2007; 82:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/76\">",
"      Yacoub MH. Surgical versus alcohol septal ablation for hypertrophic obstructive cardiomyopathy: the pendulum swings. Circulation 2005; 112:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/21/7514/abstract/77\">",
"      Roberts R, Sigwart U. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy. Circulation 2005; 112:293.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4920 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-217.117.136.88-59DAAF2E3B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7514=[""].join("\n");
var outline_f7_21_7514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Syncope or presyncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chest pain or dyspnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Relief of outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Sequential approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CARDIAC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Septal myectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Perioperative mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Long-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mitral valve repair/replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DUAL CHAMBER PACING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Patient selection and programming",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ALCOHOL (ETHANOL) SEPTAL ABLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Myocardial contrast echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Complete heart block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COMPARISON OF SEPTAL MYECTOMY AND SEPTAL ABLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Anatomic results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Clinical outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Advantages of each procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4920\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4920|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/22/30048\" title=\"algorithm 1\">",
"      HCM treatment algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4920|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/36/3651\" title=\"diagnostic image 1\">",
"      Angiography during septal ablation for HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4920|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/9/11411\" title=\"figure 1\">",
"      Morphologic variants HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/43/28342\" title=\"figure 2\">",
"      Ethanol ablation HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4920|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4920|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/46/44776\" title=\"waveform 1\">",
"      Hemodynamics during septal ablation for HCM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_21_7515="Opts poor resp opioid";
var content_f7_21_7515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Options when a patient is poorly responsive to an opioid",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Approach",
"      </td>",
"      <td class=\"subtitle1\">",
"       Options",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Try to find a more effective opioid",
"      </td>",
"      <td>",
"       Opioid rotation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Try to open the \"therapeutic window\"",
"      </td>",
"      <td>",
"       More aggressive side effect management",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Try adding a systemic or spinal co-analgesic to reduce the opioid requirement",
"      </td>",
"      <td>",
"       Add a systemic NSAID or an adjuvant analgesic, or trial of neuraxial (intrathecal, intraspinal) analgesia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Try adding a nonpharmacologic approach to redue the opioid requirement",
"      </td>",
"      <td>",
"       Consider neural blockade, a neurostimulatory approach, or a psychological or rehabilitative therapy",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NSAID: Non steroidal anti-inflammatory drug.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7515=[""].join("\n");
var outline_f7_21_7515=null;
var title_f7_21_7516="Focal transient neuro sx";
var content_f7_21_7516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=15\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=15\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Focal or nonfocal symptoms of transient neurologic attacks",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Focal symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nonfocal symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Common disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Seizures",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TIAs",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        occasionally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Migraine",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Syncope",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Less common disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vestibulopathy",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metabolic",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        \"Tumor attacks\"",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple sclerosis",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psychiatric",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nerves and nerve root",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transient global amnesia",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7516=[""].join("\n");
var outline_f7_21_7516=null;
var title_f7_21_7517="Empiric therapy gram negatives and anaerobes";
var content_f7_21_7517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric antibiotic therapy for gram-negative and anaerobic pathogens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose (adult)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        First choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Monotherapy with a beta-lactam/beta-lactamase inhibitor:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Piperacillin-tazobactam",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.375 or 4.5 g IV every six hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ticarcillin-clavulanate",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.1 g IV every four hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Combination third generation cephalosporin",
"        <strong>",
"         PLUS",
"        </strong>",
"        metronidazole:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ceftriaxone",
"        <strong>",
"         plus",
"        </strong>",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 g IV every 24 hours or 2 g IV every 12 hours for CNS infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Metronidazole",
"       </td>",
"       <td class=\"sublist_other\">",
"        500 mg IV every eight hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Alternative empiric regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Combination fluoroquinolone",
"        <sup>",
"         &Delta;",
"        </sup>",
"        <strong>",
"         PLUS",
"        </strong>",
"        metronidazole:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ciprofloxacin",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"       <td class=\"sublist_other\">",
"        400 mg IV every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Levofloxacin",
"        <strong>",
"         plus",
"        </strong>",
"       </td>",
"       <td class=\"sublist_other\">",
"        500 or 750 mg IV once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Metronidazole",
"       </td>",
"       <td class=\"sublist_other\">",
"        500 mg IV every eight hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Monotherapy with a carbapenem",
"        <sup>",
"         &loz;",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Imipenem-cilastatin",
"       </td>",
"       <td class=\"sublist_other\">",
"        500 mg IV every six hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Meropenem",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 g IV every eight hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Doripenem",
"       </td>",
"       <td class=\"sublist_other\">",
"        500 mg IV every eight hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ertapenem",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 g once daily",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Antibiotic doses should be adjusted appropriately for patients with renal insufficiency or other dose-related consideration.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Some clinicians use 4.5 g every eight hours for empiric therapy since the percent time above the MIC is similar between the regimens for most pathogens; however, this regimen is NOT recommended for nosocomial pneumonia or",
"     <em>",
"      Pseudomonas",
"     </em>",
"     coverage. Please refer to UpToDate topics on the \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\" and \"Treatment of",
"     <em>",
"      Pseudomonas aeruginosa",
"     </em>",
"     infections\".",
"     <br/>",
"     &Delta; Fluoroquinolones are generally avoided in pregnant women due to potential fetal toxicity.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Use carbapenems cautiously in patients with immediate-type hypersensitivity to beta-lactams.",
"     <br/>",
"     &sect; Ertapenem lacks activity against acinetobacter and pseudomonas and is not a recommended choice for a severe or nosocomial infection.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7517=[""].join("\n");
var outline_f7_21_7517=null;
var title_f7_21_7518="Drug Rx in silent ischemia";
var content_f7_21_7518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Efficacy of nifedipine and atenolol on silent ischemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 243px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Crossover trial of the effect of therapy on 24 patients with silent ischemia. Compared with placebo, both atenolol and nifedipine significantly decreased the number (left) and duration (right) of silent ischemic events during the monitoring period. However, atenolol was significantly more effective than nifedipine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Deedwania PC, Carbajal EV, Nelson JR, et al. J Am Coll Cardiol 1991; 17:963.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7518=[""].join("\n");
var outline_f7_21_7518=null;
var title_f7_21_7519="Tracheal bronchus II";
var content_f7_21_7519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheal bronchus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan shows a thin accessory right bronchus, originating from the right lateral aspect of the lower trachea at or below the level of the azygous vein arch. This is an incidental finding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_21_7519=[""].join("\n");
var outline_f7_21_7519=null;
